data_2lzp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lzp _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.873 0.368 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.07 0 CA-C-O 120.588 0.232 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t . . . . . 0 N--CA 1.498 1.932 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG11 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.409 HG11 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 N--CA 1.499 1.993 0 CA-C-O 120.925 0.393 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.65 0.262 . . . . 0.0 110.891 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.739 0.304 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 120.702 0.286 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 120.649 0.261 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.5 2.066 0 CA-C-O 120.884 0.373 . . . . 0.0 110.443 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.5 2.051 0 CA-C-O 120.796 0.332 . . . . 0.0 110.623 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.5 2.059 0 CA-C-O 120.575 0.226 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 15' ' ' ALA . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.425 ' N ' HG23 ' A' ' 14' ' ' VAL . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t . . . . . 0 N--CA 1.498 1.929 0 CA-C-O 120.991 0.424 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t . . . . . 0 N--CA 1.499 2.012 0 CA-C-O 120.716 0.294 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.501 2.084 0 CA-C-O 120.547 0.213 . . . . 0.0 111.369 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 N--CA 1.5 2.033 0 CA-C-O 120.852 0.358 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.545 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.545 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t . . . . . 0 N--CA 1.499 1.99 0 CA-C-O 120.822 0.344 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.932 0.396 . . . . 0.0 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.0 t . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 121.036 0.446 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' MET . . . . . 0.415 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.415 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 N--CA 1.5 2.032 0 CA-C-O 120.807 0.336 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.4 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.531 0.205 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t . . . . . 0 N--CA 1.498 1.955 0 CA-C-O 120.773 0.32 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.672 0.273 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.499 1.976 0 CA-C-O 120.749 0.309 . . . . 0.0 110.396 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t . . . . . 0 N--CA 1.503 2.175 0 CA-C-O 120.742 0.306 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t . . . . . 0 N--CA 1.5 2.067 0 CA-C-O 120.602 0.239 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 120.902 0.382 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 120.906 0.384 . . . . 0.0 110.287 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 N--CA 1.5 2.055 0 CA-C-O 120.78 0.324 . . . . 0.0 110.664 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.073 0 CA-C-O 120.541 0.21 . . . . 0.0 110.691 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.424 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' MET . . . . . 0.424 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t . . . . . 0 N--CA 1.497 1.904 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t . . . . . 0 N--CA 1.501 2.09 0 CA-C-O 120.581 0.229 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t . . . . . 0 N--CA 1.499 2.011 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.5 2.047 0 CA-C-O 120.638 0.256 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.505 2.282 0 CA-C-O 120.823 0.344 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.499 1.988 0 CA-C-O 120.559 0.218 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 120.508 0.194 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 120.975 0.417 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 120.709 0.29 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 87.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 . . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 . . . . . 0 N--CA 1.496 1.834 0 CA-C-O 121.247 0.546 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -148.16 87.76 1.62 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.451 -0.781 . . . . 0.0 110.17 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -87.04 -48.95 7.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.396 -0.815 . . . . 0.0 110.082 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.0 mt -108.48 -42.04 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.764 -0.585 . . . . 0.0 109.959 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.8 mp -88.5 125.2 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.374 -0.829 . . . . 0.0 109.894 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -106.88 -68.42 0.68 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.799 -1.321 . . . . 0.0 109.799 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.26 78.59 0.16 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -92.91 11.94 25.52 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.497 -1.002 . . . . 0.0 111.078 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.5 m -95.17 64.33 2.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.213 -0.93 . . . . 0.0 109.694 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.485 HG12 ' HD2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -121.4 158.94 52.16 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.367 -0.833 . . . . 0.0 109.957 -179.871 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' HG12 ' A' ' 10' ' ' ILE . 45.7 Cg_endo -78.03 166.43 24.9 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.942 1.496 . . . . 0.0 110.854 -179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.4 -28.7 38.86 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.853 1.449 . . . . 0.0 111.031 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p -67.44 -36.83 77.61 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.362 -0.836 . . . . 0.0 110.103 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.69 -40.93 98.03 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -82.34 -42.01 19.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.58 -0.7 . . . . 0.0 110.418 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.467 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 3.4 mm? -67.36 -46.23 73.96 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.467 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER 61.7 169.96 0.08 OUTLIER Pre-proline 0 N--CA 1.501 2.089 0 O-C-N 122.068 -0.395 . . . . 0.0 110.924 -179.92 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.446 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 46.0 Cg_endo -73.72 75.32 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.655 1.344 . . . . 0.0 110.152 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.228 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 . . . . . 0 N--CA 1.498 1.969 0 CA-C-O 120.705 0.288 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 m -120.51 139.94 52.16 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.035 -1.041 . . . . 0.0 110.131 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 53.57 75.2 0.27 Allowed 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 121.372 0.606 . . . . 0.0 110.48 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.2 tt -148.77 155.64 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.361 -0.837 . . . . 0.0 110.074 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 mt -92.55 -87.08 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.278 -0.889 . . . . 0.0 109.926 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -111.66 -61.62 0.47 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.26 -72.04 0.27 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.49 74.84 0.43 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.901 -0.764 . . . . 0.0 110.296 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.6 p -82.72 57.82 3.97 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.451 -0.78 . . . . 0.0 110.207 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 tp -76.82 135.32 67.78 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.341 -0.849 . . . . 0.0 110.364 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.428 ' O ' HG11 ' A' ' 14' ' ' VAL . 51.0 Cg_endo -81.53 131.19 7.28 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.836 1.44 . . . . 0.0 110.81 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.97 -21.75 18.03 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.761 1.4 . . . . 0.0 111.219 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -62.11 -46.33 96.71 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.241 -0.912 . . . . 0.0 110.867 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.428 HG11 ' O ' ' A' ' 11' ' ' PRO . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.411 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.07 -31.0 66.64 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -106.28 22.1 16.3 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.511 -0.743 . . . . 0.0 110.582 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.477 ' HB3' HD13 ' A' ' 29' ' ' LEU . 0.6 OUTLIER -95.8 -33.79 12.13 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.305 -0.872 . . . . 0.0 110.208 179.656 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' N ' ' CD1' ' A' ' 29' ' ' LEU . 0.0 OUTLIER -133.22 158.81 74.82 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.423 -0.798 . . . . 0.0 110.421 179.198 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.424 ' O ' ' HB2' ' A' ' 31' ' ' ARG . 51.3 Cg_endo -86.34 19.0 1.46 Allowed 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.827 1.436 . . . . 0.0 111.553 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' A' ' 30' ' ' PRO . 15.2 mtt85 . . . . . 0 N--CA 1.504 2.263 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.749 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 120.941 0.4 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 m 56.4 54.63 7.37 Favored 'General case' 0 N--CA 1.501 2.085 0 CA-C-O 121.423 0.63 . . . . 0.0 110.138 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -88.65 116.67 27.06 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.3 -0.875 . . . . 0.0 110.236 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 pt -89.83 64.1 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.51 -0.744 . . . . 0.0 110.447 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.2 pp -87.56 129.71 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.331 -0.855 . . . . 0.0 110.331 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.84 111.5 4.01 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.8 -95.55 1.08 Allowed Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.09 27.79 9.03 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.527 -0.984 . . . . 0.0 110.794 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.2 m -127.02 56.37 1.52 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.24 -0.913 . . . . 0.0 109.853 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.405 HG13 ' HD2' ' A' ' 11' ' ' PRO . 8.1 tt -143.64 134.01 12.13 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.408 -0.807 . . . . 0.0 110.163 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.405 ' HD2' HG13 ' A' ' 10' ' ' ILE . 51.0 Cg_endo -81.81 114.95 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 O-C-N 123.848 1.446 . . . . 0.0 111.019 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.09 -38.83 1.95 Allowed 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.804 1.423 . . . . 0.0 110.754 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t -66.23 -42.8 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.41 -0.806 . . . . 0.0 110.21 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG11 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.409 HG11 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.426 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.14 -34.13 69.92 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.2 m-70 -129.2 30.97 4.94 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.311 -0.868 . . . . 0.0 110.573 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.426 ' HB2' ' O ' ' A' ' 24' ' ' PHE . 5.0 tp -101.55 -34.8 9.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.29 -0.881 . . . . 0.0 110.647 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -120.05 80.23 26.6 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.286 -0.884 . . . . 0.0 110.752 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.94 59.05 6.32 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.775 1.408 . . . . 0.0 110.454 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.494 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.121 0.486 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -136.46 107.25 6.61 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.425 -0.797 . . . . 0.0 110.319 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -122.38 24.62 9.26 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.537 -0.727 . . . . 0.0 110.781 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.434 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 30.3 mt -110.74 77.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.109 -0.994 . . . . 0.0 109.369 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 32.7 mt 65.19 161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 CA-C-O 121.28 0.562 . . . . 0.0 110.429 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -66.55 -69.54 1.33 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.51 38.64 2.82 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt 51.67 37.77 20.97 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.79 -0.829 . . . . 0.0 110.71 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.2 m 56.96 86.17 0.07 Allowed 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.481 0.658 . . . . 0.0 110.438 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.2 pt -70.54 158.84 86.87 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.4 -0.812 . . . . 0.0 110.581 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.32 122.05 8.33 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.857 1.451 . . . . 0.0 110.772 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.32 -34.74 12.2 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.881 1.464 . . . . 0.0 110.762 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p -62.77 -34.24 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.389 -0.82 . . . . 0.0 110.422 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -85.14 -36.79 20.86 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 17.2 m-70 -72.34 -35.31 68.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.436 -0.79 . . . . 0.0 110.857 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.11 33.52 2.14 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.309 -0.869 . . . . 0.0 110.738 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.3 tt -89.74 134.79 31.51 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.141 -0.975 . . . . 0.0 110.267 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.29 84.43 1.36 Allowed 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.887 1.467 . . . . 0.0 110.355 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mtt-85 . . . . . 0 N--CA 1.502 2.129 0 CA-C-O 117.669 -1.158 . . . . 0.0 110.617 -179.738 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.121 0.486 . . . . 0.0 110.143 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.3 t -155.3 162.88 40.76 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.361 -0.837 . . . . 0.0 110.672 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.645 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 0.8 OUTLIER -125.93 42.75 3.23 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.505 -0.747 . . . . 0.0 110.525 179.89 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.7 mm -98.72 -43.74 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.238 -0.914 . . . . 0.0 110.162 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 mt -101.12 64.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.375 -0.828 . . . . 0.0 110.036 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.12 66.66 1.93 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.645 ' HA3' ' HA ' ' A' ' 3' ' ' GLU . . . -101.74 -79.93 1.44 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 7' ' ' GLY . 0.6 OUTLIER 32.28 60.23 0.36 Allowed 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.511 0.672 . . . . 0.0 112.122 179.911 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 t -92.71 16.27 12.64 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.263 -0.898 . . . . 0.0 110.98 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.413 ' HB ' ' HD2' ' A' ' 12' ' ' PRO . 0.0 OUTLIER -132.58 128.25 20.9 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.23 -0.919 . . . . 0.0 109.803 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.742 ' HG2' ' HD3' ' A' ' 12' ' ' PRO . 37.0 Cg_endo -66.72 -34.34 31.97 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.849 1.447 . . . . 0.0 113.157 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.742 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 55.8 Cg_endo -81.1 57.18 6.39 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 122.422 0.696 . . . . 0.0 110.382 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.6 p -67.48 -39.87 83.35 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.335 -0.853 . . . . 0.0 110.891 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.459 ' HB2' ' O ' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -84.64 -30.92 24.5 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -76.78 -43.09 38.29 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.351 -0.843 . . . . 0.0 110.507 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.83 -46.44 21.48 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.417 -0.802 . . . . 0.0 110.436 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.0 mt -113.3 134.05 21.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.244 -0.91 . . . . 0.0 110.273 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.77 102.93 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.984 1.518 . . . . 0.0 110.653 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.919 0 CA-C-O 117.914 -1.041 . . . . 0.0 110.741 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 . . . . . 0 N--CA 1.496 1.843 0 CA-C-O 120.904 0.383 . . . . 0.0 110.138 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 m -126.5 59.77 1.35 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.568 -0.707 . . . . 0.0 110.189 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -155.66 73.63 0.84 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.365 -0.834 . . . . 0.0 110.347 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.42 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 2.7 tt -171.11 145.99 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.512 -0.743 . . . . 0.0 110.248 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.42 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 19.1 mt 63.07 163.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.28 0 CA-C-O 121.497 0.665 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.88 -31.57 3.33 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.59 -45.86 1.34 Allowed Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 12.1 mt -99.52 30.46 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.483 -1.01 . . . . 0.0 110.712 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 p -129.98 34.71 4.22 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.186 -0.946 . . . . 0.0 110.019 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.9 142.91 21.26 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.418 -0.801 . . . . 0.0 110.149 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -75.73 115.7 4.26 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.85 1.447 . . . . 0.0 110.689 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.17 -39.76 2.84 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 123.769 1.405 . . . . 0.0 110.737 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m -64.62 -35.8 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.376 -0.827 . . . . 0.0 110.503 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.63 -37.53 70.85 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.56 29.54 7.92 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.348 -0.845 . . . . 0.0 110.499 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.9 tp -146.69 -51.69 0.22 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.281 -0.887 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 64.86 159.21 0.12 Allowed Pre-proline 0 N--CA 1.502 2.152 0 O-C-N 121.991 -0.443 . . . . 0.0 110.994 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.25 114.41 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.738 1.389 . . . . 0.0 110.487 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 117.867 -1.063 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.936 0.398 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.8 p -67.12 126.5 29.4 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 110.146 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 56.13 81.89 0.12 Allowed 'General case' 0 N--CA 1.5 2.045 0 CA-C-O 121.429 0.633 . . . . 0.0 110.565 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.8 pt -83.79 55.54 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.361 -0.837 . . . . 0.0 110.445 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.4 tt -163.45 133.01 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.318 -0.863 . . . . 0.0 109.957 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.35 97.94 0.16 Allowed Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.45 -62.49 1.15 Allowed Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.12 46.54 2.65 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.218 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.5 p -95.27 63.33 2.57 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.347 -0.846 . . . . 0.0 110.154 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.442 HG13 ' HD2' ' A' ' 11' ' ' PRO . 21.0 tt -80.44 141.52 53.02 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.442 ' HD2' HG13 ' A' ' 10' ' ' ILE . 50.4 Cg_endo -79.13 113.29 3.18 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.852 1.448 . . . . 0.0 110.668 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.95 -38.99 3.53 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.727 1.383 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p -62.2 -36.8 76.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.449 -0.782 . . . . 0.0 110.596 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.81 -37.03 73.21 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 12.4 m-70 -72.98 -33.89 66.11 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.496 -0.753 . . . . 0.0 110.645 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -80.3 -46.03 16.86 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.395 -0.815 . . . . 0.0 110.43 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.52 92.93 0.06 OUTLIER Pre-proline 0 N--CA 1.5 2.041 0 O-C-N 121.801 -0.562 . . . . 0.0 110.482 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.95 158.07 56.37 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.819 1.431 . . . . 0.0 110.4 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mmp_? . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 118.209 -0.901 . . . . 0.0 110.244 -179.912 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.062 0.458 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 m -96.7 56.14 1.46 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.372 -0.83 . . . . 0.0 109.855 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -132.47 40.16 3.31 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.482 -0.761 . . . . 0.0 110.576 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.599 HG21 HG12 ' A' ' 5' ' ' ILE . 2.4 mp -124.66 159.0 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.308 -0.87 . . . . 0.0 109.495 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.599 HG12 HG21 ' A' ' 4' ' ' ILE . 38.8 mm 59.93 83.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 CA-C-O 121.412 0.625 . . . . 0.0 110.406 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -110.26 -95.5 2.34 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.93 -94.15 2.33 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -155.21 72.52 0.83 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.519 -0.989 . . . . 0.0 110.051 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.6 t -125.23 18.69 8.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.422 -0.799 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.468 HG13 ' HD2' ' A' ' 11' ' ' PRO . 19.2 tt -150.33 137.84 11.79 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.153 -0.967 . . . . 0.0 110.314 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.477 ' HB2' HG23 ' A' ' 13' ' ' VAL . 47.7 Cg_endo -76.67 151.93 32.71 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.85 1.448 . . . . 0.0 110.536 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.99 -24.27 24.24 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.843 1.444 . . . . 0.0 111.239 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.477 HG23 ' HB2' ' A' ' 11' ' ' PRO . 33.5 m -60.25 -36.13 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 121.366 -0.834 . . . . 0.0 110.868 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.06 -22.62 66.98 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 8.4 m-70 -97.53 -20.09 17.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.335 -0.853 . . . . 0.0 110.785 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.9 mt -107.88 34.83 3.36 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.112 -0.992 . . . . 0.0 111.064 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -143.39 140.16 17.31 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.086 -1.009 . . . . 0.0 110.42 179.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.462 ' C ' ' HG2' ' A' ' 31' ' ' ARG . 51.2 Cg_endo -77.76 172.78 15.13 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 124.118 1.589 . . . . 0.0 110.536 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.462 ' HG2' ' C ' ' A' ' 30' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.494 0 CA-C-O 117.658 -1.163 . . . . 0.0 111.946 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.5 t70 . . . . . 0 N--CA 1.495 1.794 0 CA-C-O 120.976 0.417 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 p -145.48 101.95 3.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.536 -0.727 . . . . 0.0 110.41 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -115.38 109.74 18.34 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 56.5 mt 57.49 88.44 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 CA-C-O 121.569 0.699 . . . . 0.0 110.735 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.7 tt -109.41 18.73 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.341 -0.849 . . . . 0.0 110.738 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.29 -110.3 3.44 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -66.79 0.39 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -152.37 32.7 0.52 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.439 -1.036 . . . . 0.0 110.875 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 39.1 p -120.13 58.5 0.91 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.083 -1.011 . . . . 0.0 110.043 179.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.1 pt -87.31 148.03 43.67 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.337 -0.852 . . . . 0.0 110.294 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.31 142.89 30.83 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.811 1.427 . . . . 0.0 110.321 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.35 64.71 8.87 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.918 1.483 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -77.38 -41.05 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.307 -0.87 . . . . 0.0 110.443 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.96 -27.04 67.86 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -103.83 24.14 11.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.265 -0.897 . . . . 0.0 110.853 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -154.1 40.35 0.48 Allowed 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.077 -1.014 . . . . 0.0 110.578 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.9 tp -135.74 126.86 17.13 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.217 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.36 141.37 31.77 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.868 1.457 . . . . 0.0 110.439 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.337 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 121.191 0.52 . . . . 0.0 110.563 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -82.34 144.4 30.59 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.456 -0.778 . . . . 0.0 110.586 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -160.56 41.8 0.18 Allowed 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.533 -0.729 . . . . 0.0 110.392 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.3 tt -164.93 -41.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.209 -0.932 . . . . 0.0 110.715 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.2 pt -114.26 119.04 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.308 -0.87 . . . . 0.0 110.12 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.27 -98.11 0.15 Allowed Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -111.46 46.69 1.13 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 mp 50.41 58.71 5.2 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.697 -0.884 . . . . 0.0 110.761 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 p -87.84 56.44 3.89 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.28 -0.888 . . . . 0.0 110.165 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -74.03 155.13 88.6 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.455 -0.778 . . . . 0.0 110.458 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.451 ' HB2' HG11 ' A' ' 13' ' ' VAL . 45.7 Cg_endo -72.28 149.37 51.13 Favored 'Trans proline' 0 C--N 1.313 -1.297 0 O-C-N 123.769 1.405 . . . . 0.0 110.451 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.2 -28.36 23.23 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.848 1.447 . . . . 0.0 111.391 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.451 HG11 ' HB2' ' A' ' 11' ' ' PRO . 11.4 p -62.26 -37.04 77.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.268 -0.895 . . . . 0.0 110.623 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.18 -38.55 91.47 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 15.3 t-80 -109.11 55.97 0.63 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.356 -0.84 . . . . 0.0 110.151 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.54 -54.89 1.65 Allowed 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.33 -0.856 . . . . 0.0 110.457 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.47 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 6.0 tt -141.2 132.22 13.45 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.414 -0.804 . . . . 0.0 110.04 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.47 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.5 Cg_endo -74.44 126.18 10.14 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.885 1.466 . . . . 0.0 110.476 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 . . . . . 0 N--CA 1.5 2.056 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.515 179.942 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.16 0.505 . . . . 0.0 110.508 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.1 m -101.35 105.75 16.84 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.529 -0.732 . . . . 0.0 110.022 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -101.33 74.36 1.55 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.463 -0.773 . . . . 0.0 110.028 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.0 mp 52.12 63.67 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.708 -0.62 . . . . 0.0 110.348 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 48.2 mm -111.86 1.12 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.382 -0.824 . . . . 0.0 110.721 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -94.88 62.4 1.58 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.97 -48.16 1.51 Allowed Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.17 51.65 0.77 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.423 -1.045 . . . . 0.0 110.243 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.4 p 36.03 77.62 0.04 OUTLIER 'General case' 0 N--CA 1.507 2.389 0 CA-C-O 121.181 0.515 . . . . 0.0 111.699 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.1 pt -60.21 144.19 87.75 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.368 -0.832 . . . . 0.0 110.569 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -71.42 162.49 42.16 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.919 1.484 . . . . 0.0 111.053 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.45 -17.87 23.41 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 O-C-N 123.848 1.446 . . . . 0.0 111.17 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 p -62.91 -39.89 86.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.276 -0.89 . . . . 0.0 111.015 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 15' ' ' ALA . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.425 ' N ' HG23 ' A' ' 14' ' ' VAL . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.88 36.66 0.81 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -172.63 -41.88 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.188 -0.945 . . . . 0.0 111.059 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -54.31 -37.05 64.38 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.454 -0.779 . . . . 0.0 111.824 -179.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.15 121.43 26.2 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.2 -0.938 . . . . 0.0 110.369 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.85 97.91 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.829 1.437 . . . . 0.0 110.383 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.933 0 CA-C-O 117.845 -1.074 . . . . 0.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.9 0.381 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.3 m 53.63 72.07 0.46 Allowed 'General case' 0 N--CA 1.499 2.023 0 CA-C-O 121.427 0.632 . . . . 0.0 109.811 -179.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -78.71 67.56 4.48 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.346 -0.846 . . . . 0.0 110.129 -179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 49.3 mm -112.04 -46.46 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.416 -0.802 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.57 149.12 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.399 -0.813 . . . . 0.0 110.185 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -68.02 -49.0 50.63 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.84 44.93 1.7 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.57 ' HB3' ' CG1' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -108.42 14.48 24.71 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.343 -1.092 . . . . 0.0 110.745 179.677 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 m 56.6 31.52 19.29 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.512 -0.742 . . . . 0.0 110.924 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.57 ' CG1' ' HB3' ' A' ' 8' ' ' LEU . 1.1 pt -146.64 106.79 4.03 Favored Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.106 -0.996 . . . . 0.0 110.168 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -81.27 138.56 11.2 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.811 1.427 . . . . 0.0 110.69 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -77.76 66.65 8.09 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.911 1.48 . . . . 0.0 110.489 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t -81.53 -49.61 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.383 -0.823 . . . . 0.0 110.2 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.09 -26.8 68.49 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -102.98 -36.64 8.11 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.391 -0.818 . . . . 0.0 110.424 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 0.2 OUTLIER -78.41 -43.28 27.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.32 -0.862 . . . . 0.0 110.615 -179.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.6 OUTLIER 62.92 165.99 0.11 Allowed Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 121.989 -0.444 . . . . 0.0 110.995 -179.824 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.426 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 47.9 Cg_endo -75.2 82.49 2.03 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.676 1.356 . . . . 0.0 110.184 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 . . . . . 0 N--CA 1.495 1.799 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.477 -179.659 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 N--CA 1.495 1.802 0 CA-C-O 121.214 0.53 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 t -158.06 152.46 24.57 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.406 -0.809 . . . . 0.0 110.335 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -112.74 30.45 7.13 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.447 -0.783 . . . . 0.0 110.648 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt 52.58 54.28 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.222 0 O-C-N 121.538 -0.726 . . . . 0.0 110.506 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp 58.51 -89.69 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.7 -0.625 . . . . 0.0 110.668 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 49.22 6.42 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.19 -85.34 0.77 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 79.1 mt -115.49 38.98 3.09 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.59 -0.947 . . . . 0.0 109.787 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -144.65 54.58 1.25 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.479 -0.763 . . . . 0.0 109.941 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.4 tt -73.76 135.46 77.81 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.289 -0.882 . . . . 0.0 110.656 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -82.62 120.35 3.14 Favored 'Trans proline' 0 C--N 1.316 -1.152 0 O-C-N 123.847 1.446 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.92 -40.19 1.95 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.805 1.424 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t -62.68 -44.56 99.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.398 -0.814 . . . . 0.0 110.325 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.5 -40.68 79.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -111.27 35.22 3.67 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.444 -0.785 . . . . 0.0 110.064 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.514 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 7.1 tp -148.85 -50.41 0.16 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.401 -0.812 . . . . 0.0 110.323 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.514 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 24.1 mt 64.74 157.69 0.12 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 122.111 -0.368 . . . . 0.0 111.115 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -75.51 84.58 1.71 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.738 1.388 . . . . 0.0 110.622 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 9.0 ttm-85 . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.803 -179.924 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.901 0.382 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -74.93 83.77 2.22 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.43 -0.794 . . . . 0.0 110.193 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -90.06 63.95 6.05 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.345 -0.847 . . . . 0.0 110.411 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.476 HG23 HG22 ' A' ' 5' ' ' ILE . 3.3 mt -82.04 -43.47 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.347 -0.845 . . . . 0.0 109.755 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.476 HG22 HG23 ' A' ' 4' ' ' ILE . 5.8 pt -139.58 65.36 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.521 -0.737 . . . . 0.0 109.69 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.62 -113.69 0.59 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.92 -56.48 0.49 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.1 14.16 4.7 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.524 -0.986 . . . . 0.0 110.502 179.507 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 t -168.6 100.42 0.41 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.339 -0.851 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.4 128.31 67.58 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.435 -0.79 . . . . 0.0 110.885 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -80.35 112.34 2.75 Favored 'Trans proline' 0 C--N 1.317 -1.121 0 O-C-N 123.797 1.419 . . . . 0.0 110.65 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -76.23 -29.62 6.2 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 O-C-N 123.739 1.389 . . . . 0.0 111.451 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 p -62.31 -42.53 95.76 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.305 -0.872 . . . . 0.0 111.369 -179.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.39 -38.17 84.26 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 29.8 t-80 -103.35 51.76 0.79 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.52 -0.738 . . . . 0.0 110.046 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -109.46 -50.45 2.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.351 -0.843 . . . . 0.0 110.381 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.7 tp 58.12 87.87 0.13 Allowed Pre-proline 0 N--CA 1.502 2.14 0 O-C-N 121.742 -0.598 . . . . 0.0 111.027 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.4 77.47 2.1 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 124.022 1.538 . . . . 0.0 110.519 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.9 mtp85 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.149 -0.929 . . . . 0.0 110.257 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.028 0.442 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.84 161.29 19.54 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.538 -0.726 . . . . 0.0 110.214 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 58.14 74.09 0.44 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-O 121.511 0.672 . . . . 0.0 110.601 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.6 tt -90.91 -27.05 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.403 -0.81 . . . . 0.0 110.691 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.0 tt -147.09 157.18 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.288 -0.883 . . . . 0.0 110.294 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.27 -67.08 0.23 Allowed Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.46 50.42 3.18 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mt 51.59 47.2 25.27 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.709 -0.877 . . . . 0.0 110.806 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -90.51 60.89 4.76 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.266 -0.896 . . . . 0.0 109.965 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -73.67 139.63 77.68 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.565 -0.709 . . . . 0.0 110.525 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -74.84 147.61 34.89 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.837 1.44 . . . . 0.0 110.737 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.52 -21.54 25.77 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.89 1.468 . . . . 0.0 111.03 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.91 -36.61 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.419 -0.8 . . . . 0.0 110.227 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.545 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.545 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.5 -41.33 85.12 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.2 t-80 -105.35 22.46 15.37 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.406 -0.809 . . . . 0.0 110.475 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -154.28 43.22 0.52 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.329 -0.857 . . . . 0.0 110.345 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -85.99 135.99 36.79 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.49 69.4 5.93 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.876 1.461 . . . . 0.0 110.714 -179.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.192 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.498 1.927 0 CA-C-O 121.126 0.489 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.7 t -76.92 150.27 35.97 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.424 -0.797 . . . . 0.0 110.433 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.4 ' HB3' HD13 ' A' ' 4' ' ' ILE . 19.8 mt-10 -105.81 -77.98 0.58 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.486 -0.759 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' A' ' 3' ' ' GLU . 2.6 mp -133.92 -60.09 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.437 -0.789 . . . . 0.0 109.761 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.1 pt -117.93 -175.33 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.479 -0.763 . . . . 0.0 110.413 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -178.31 145.53 6.96 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.33 64.41 0.39 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.2 39.46 2.92 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.441 -1.034 . . . . 0.0 110.407 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.1 t -72.17 -20.97 61.51 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.329 -0.857 . . . . 0.0 110.741 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.427 ' CG1' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -144.68 160.44 47.44 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.356 -0.84 . . . . 0.0 109.749 179.784 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.427 ' HD2' ' CG1' ' A' ' 10' ' ' ILE . 49.2 Cg_endo -80.53 120.35 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.922 1.485 . . . . 0.0 110.706 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.73 -36.19 5.07 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.865 1.455 . . . . 0.0 110.933 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t -63.66 -44.12 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.404 -0.81 . . . . 0.0 110.394 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.404 ' CZ ' ' HD3' ' A' ' 30' ' ' PRO . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.56 -30.08 68.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 41.3 t60 -93.4 -39.16 11.07 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.47 -0.769 . . . . 0.0 110.281 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -80.29 -57.79 3.44 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.366 -0.834 . . . . 0.0 110.438 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 64.57 166.98 0.11 Allowed Pre-proline 0 N--CA 1.502 2.172 0 O-C-N 121.845 -0.534 . . . . 0.0 110.793 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.404 ' HD3' ' CZ ' ' A' ' 25' ' ' PHE . 49.9 Cg_endo -77.62 172.05 16.45 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.625 1.329 . . . . 0.0 110.826 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.367 179.839 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.978 0.418 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.0 p -143.72 84.47 1.79 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.504 -0.747 . . . . 0.0 110.403 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -98.96 64.18 1.4 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.204 -0.935 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.0 mt -91.8 -42.91 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.235 -0.916 . . . . 0.0 109.683 179.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 35.1 mm -119.21 61.35 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.547 -0.721 . . . . 0.0 109.484 179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.21 -80.44 1.82 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.83 -49.52 2.01 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.43 60.47 0.88 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.499 -1.0 . . . . 0.0 109.923 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 68.2 p -102.66 28.5 6.02 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.462 -0.774 . . . . 0.0 110.794 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.4 pp -121.49 155.98 58.71 Favored Pre-proline 0 N--CA 1.497 1.881 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.4 Cg_endo -73.64 122.19 7.64 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.809 1.426 . . . . 0.0 110.508 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.7 -44.28 1.51 Allowed 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.827 1.435 . . . . 0.0 110.893 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.8 m -60.83 -34.52 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.381 -0.824 . . . . 0.0 110.17 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.48 ' HB ' ' HG2' ' A' ' 11' ' ' PRO . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.81 -32.18 71.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -110.97 54.99 0.66 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 109.679 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.16 -66.09 1.01 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.384 -0.822 . . . . 0.0 110.767 -179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.403 HD13 ' HD2' ' A' ' 30' ' ' PRO . 0.2 OUTLIER -157.52 114.4 1.88 Allowed Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 -179.727 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.403 ' HD2' HD13 ' A' ' 29' ' ' LEU . 46.9 Cg_endo -72.55 86.91 0.98 Allowed 'Trans proline' 0 C--N 1.313 -1.32 0 O-C-N 123.997 1.525 . . . . 0.0 110.419 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 13.6 mtt-85 . . . . . 0 N--CA 1.502 2.13 0 CA-C-O 117.663 -1.16 . . . . 0.0 110.713 -179.903 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 N--CA 1.498 1.947 0 CA-C-O 121.072 0.463 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -106.58 96.87 6.76 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.249 -0.907 . . . . 0.0 110.107 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.82 110.75 1.72 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.557 -0.714 . . . . 0.0 110.161 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.2 pt -128.76 167.33 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.447 -0.783 . . . . 0.0 110.066 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 23.6 mt 57.24 83.17 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 CA-C-O 121.361 0.6 . . . . 0.0 110.393 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.04 79.16 1.93 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.89 -57.99 4.63 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 tp -122.43 55.1 1.16 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.36 -1.082 . . . . 0.0 110.083 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.2 p -86.98 71.74 10.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.332 -0.855 . . . . 0.0 110.242 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.02 150.35 64.87 Favored Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.42 -0.8 . . . . 0.0 110.257 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.412 ' HB2' HG23 ' A' ' 13' ' ' VAL . 46.1 Cg_endo -72.34 129.9 15.54 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.898 1.473 . . . . 0.0 110.268 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -76.81 66.79 7.51 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.901 1.474 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.412 HG23 ' HB2' ' A' ' 11' ' ' PRO . 60.0 t -109.07 -52.69 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.533 -0.729 . . . . 0.0 109.925 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' MET . . . . . 0.415 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.415 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.82 -31.74 63.37 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -111.96 46.63 1.12 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.306 -0.872 . . . . 0.0 110.971 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.29 -54.88 2.44 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.191 -0.943 . . . . 0.0 110.214 179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.31 112.74 65.8 Favored Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.65 98.47 1.05 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.932 1.491 . . . . 0.0 110.7 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.497 1.918 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.458 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 121.111 0.481 . . . . 0.0 110.389 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 p -109.24 130.29 55.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.49 -0.757 . . . . 0.0 110.241 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.24 -96.9 0.46 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.548 -0.72 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.7 tp -114.26 -25.73 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.127 -0.983 . . . . 0.0 110.874 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.2 mp 54.88 50.94 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.487 -0.758 . . . . 0.0 110.476 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -114.13 93.4 0.65 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.08 51.1 19.82 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -156.5 36.19 0.32 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.602 -0.94 . . . . 0.0 110.379 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -143.37 -132.03 0.09 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.32 -0.863 . . . . 0.0 109.57 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -138.26 154.34 73.78 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 120.982 -1.074 . . . . 0.0 110.222 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HG2' ' CG1' ' A' ' 14' ' ' VAL . 45.4 Cg_endo -73.53 138.21 26.55 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.959 1.505 . . . . 0.0 110.703 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.13 -37.06 5.03 Favored 'Trans proline' 0 N--CA 1.489 1.224 0 O-C-N 123.879 1.463 . . . . 0.0 111.395 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p -61.52 -36.79 75.48 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.198 -0.939 . . . . 0.0 110.599 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG1' ' HG2' ' A' ' 11' ' ' PRO . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.27 -46.52 83.31 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -83.18 -35.82 25.19 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -110.18 54.51 0.67 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.482 -0.761 . . . . 0.0 109.674 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.51 137.46 70.98 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.525 -0.735 . . . . 0.0 110.505 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.23 -177.19 3.34 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.975 1.513 . . . . 0.0 110.786 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 . . . . . 0 N--CA 1.499 1.992 0 O-C-N 121.341 -0.849 . . . . 0.0 110.739 179.864 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.843 0.354 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.8 m 60.84 -177.88 0.11 Allowed 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.674 -0.641 . . . . 0.0 110.141 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 52.82 68.3 0.85 Allowed 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.324 -0.86 . . . . 0.0 110.465 -179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.9 pt -99.68 61.55 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.343 -0.848 . . . . 0.0 110.361 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp -89.26 134.15 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.311 -0.868 . . . . 0.0 109.769 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -88.23 64.33 3.58 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.59 -48.82 1.75 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 tp -139.11 51.53 1.79 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.465 -1.021 . . . . 0.0 110.078 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.466 ' O ' ' CG1' ' A' ' 10' ' ' ILE . 8.5 m 52.08 49.04 21.5 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.638 -0.664 . . . . 0.0 110.615 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.466 ' CG1' ' O ' ' A' ' 9' ' ' THR . 0.5 OUTLIER 56.82 169.08 0.05 OUTLIER Pre-proline 0 N--CA 1.51 2.557 0 CA-C-O 120.976 0.417 . . . . 0.0 111.689 179.91 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.468 ' HB2' HG12 ' A' ' 13' ' ' VAL . 50.2 Cg_endo -77.14 132.57 12.77 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.528 1.278 . . . . 0.0 110.28 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 -13.01 23.74 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.703 1.37 . . . . 0.0 111.472 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.468 HG12 ' HB2' ' A' ' 11' ' ' PRO . 12.4 p -58.33 -41.42 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.217 -0.927 . . . . 0.0 111.147 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.17 -40.6 67.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -100.2 46.1 0.97 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.434 -0.791 . . . . 0.0 110.431 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 -43.66 8.38 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.6 mt -129.33 139.58 36.11 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.405 -0.809 . . . . 0.0 110.213 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.77 91.09 1.1 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.938 1.494 . . . . 0.0 110.425 179.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 118.219 -0.896 . . . . 0.0 110.208 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 120.987 0.422 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.9 t -152.05 166.34 31.91 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.469 -0.769 . . . . 0.0 110.553 -179.93 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -152.96 -105.34 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.621 -0.674 . . . . 0.0 109.799 179.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.447 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 6.9 mt 60.24 -84.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.225 0 O-C-N 121.392 -0.817 . . . . 0.0 110.897 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.447 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 3.7 mt 64.24 118.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 121.605 -0.685 . . . . 0.0 110.767 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -77.04 73.3 1.98 Allowed Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -147.71 38.92 1.04 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.35 -0.92 14.37 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.463 -1.022 . . . . 0.0 110.941 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -114.37 26.88 9.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.269 -0.894 . . . . 0.0 109.891 179.655 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.05 130.03 9.17 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.27 -0.894 . . . . 0.0 110.138 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.45 ' O ' HG11 ' A' ' 14' ' ' VAL . 45.9 Cg_endo -72.52 174.51 11.53 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.961 1.506 . . . . 0.0 110.664 179.649 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD2' ' HB2' ' A' ' 11' ' ' PRO . 43.0 Cg_endo -69.65 -23.29 31.44 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.532 1.28 . . . . 0.0 111.071 179.83 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.81 -52.69 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.231 -0.918 . . . . 0.0 110.245 179.83 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 11' ' ' PRO . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.09 -44.33 78.88 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.3 t-80 -109.53 46.44 1.0 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.332 -0.855 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.38 -42.7 3.45 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.265 -0.897 . . . . 0.0 110.829 -179.751 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.78 110.56 42.0 Favored Pre-proline 0 N--CA 1.497 1.901 0 O-C-N 121.286 -0.884 . . . . 0.0 110.639 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -75.74 161.8 36.09 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.795 1.418 . . . . 0.0 110.651 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.687 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.089 0.471 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 84.6 m -142.55 108.89 5.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.456 -0.778 . . . . 0.0 110.347 -179.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -158.59 47.01 0.33 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.449 -0.782 . . . . 0.0 110.477 179.757 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 mm -107.11 105.63 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.857 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.55 60.95 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.671 -0.643 . . . . 0.0 110.221 -179.893 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -143.96 -106.26 0.54 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.8 -70.6 0.23 Allowed Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.99 55.04 0.77 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.501 -0.999 . . . . 0.0 109.837 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.9 m 58.37 35.78 25.03 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.615 -0.678 . . . . 0.0 110.477 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.45 111.82 6.47 Favored Pre-proline 0 N--CA 1.499 1.99 0 O-C-N 121.252 -0.905 . . . . 0.0 110.21 179.739 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.664 ' HB2' ' HB ' ' A' ' 14' ' ' VAL . 49.0 Cg_endo -84.75 111.63 1.47 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.835 1.44 . . . . 0.0 110.776 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -83.17 -67.8 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.162 0 O-C-N 123.67 1.353 . . . . 0.0 111.629 -179.68 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t -63.62 -39.06 83.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.142 -0.974 . . . . 0.0 110.669 -179.516 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.664 ' HB ' ' HB2' ' A' ' 11' ' ' PRO . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.14 -36.12 76.81 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -68.62 -33.38 73.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.458 -0.776 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.4 mp -83.76 -73.3 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.394 -0.817 . . . . 0.0 110.24 179.886 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.555 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 0.5 OUTLIER 64.3 158.28 0.12 Allowed Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.844 -0.535 . . . . 0.0 110.885 -179.994 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.555 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.8 Cg_endo -75.43 171.66 17.83 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.587 1.309 . . . . 0.0 110.83 -179.768 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mmm-85 . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.343 -179.963 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.42 ' O ' ' HB ' ' A' ' 2' ' ' THR . 33.9 t70 . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.74 0.305 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.42 ' HB ' ' O ' ' A' ' 1' ' ' ASP . 98.2 m 60.91 101.92 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.291 0.567 . . . . 0.0 110.799 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 56.45 89.05 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.734 -0.604 . . . . 0.0 110.883 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.31 -65.91 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.337 -0.852 . . . . 0.0 110.35 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 8.9 pt -134.41 32.31 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.174 -0.954 . . . . 0.0 111.015 -179.913 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -127.86 37.66 2.26 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.669 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.02 -50.34 3.29 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 57.7 31.71 20.81 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.714 -0.874 . . . . 0.0 110.681 -179.844 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -91.06 64.42 5.34 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.249 -0.907 . . . . 0.0 109.836 179.851 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.75 160.35 26.41 Favored Pre-proline 0 N--CA 1.498 1.943 0 O-C-N 121.451 -0.78 . . . . 0.0 110.153 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.18 114.5 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.886 1.466 . . . . 0.0 110.536 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -81.36 70.51 7.36 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.736 1.387 . . . . 0.0 110.239 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.0 m -106.13 -41.39 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.439 -0.788 . . . . 0.0 110.396 -179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.44 -27.77 69.52 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 73.1 t60 -92.86 -32.98 14.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.459 -0.776 . . . . 0.0 110.796 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.57 38.43 0.98 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.294 -0.879 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.8 tp -130.42 119.87 18.67 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.555 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -72.98 167.71 26.62 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.948 1.499 . . . . 0.0 110.849 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 117.833 -1.08 . . . . 0.0 110.484 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 121.103 0.478 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.9 t -164.28 94.03 0.71 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.562 -0.711 . . . . 0.0 110.1 179.914 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -103.52 60.77 0.76 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.308 -0.87 . . . . 0.0 110.053 -179.578 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.5 tt -159.58 163.34 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.395 -0.816 . . . . 0.0 110.117 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.42 HG21 HD11 ' A' ' 5' ' ' ILE . 0.0 OUTLIER -74.22 145.51 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.396 -0.815 . . . . 0.0 110.188 179.741 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.34 -54.61 0.59 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.26 57.41 8.45 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.808 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.08 14.16 5.71 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.545 -0.974 . . . . 0.0 111.053 -179.744 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.3 m -118.05 85.13 2.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.104 -0.998 . . . . 0.0 109.733 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -106.71 158.95 31.56 Favored Pre-proline 0 N--CA 1.497 1.876 0 O-C-N 121.707 -0.621 . . . . 0.0 110.097 179.855 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.413 ' HG2' HG13 ' A' ' 14' ' ' VAL . 44.6 Cg_endo -71.87 114.53 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.985 1.518 . . . . 0.0 110.751 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -77.03 -35.08 1.92 Allowed 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.828 1.436 . . . . 0.0 111.37 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t -59.81 -51.47 72.45 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.175 0 O-C-N 121.283 -0.885 . . . . 0.0 110.867 -179.285 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.413 HG13 ' HG2' ' A' ' 11' ' ' PRO . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.65 -31.6 11.84 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -97.39 -18.9 18.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.412 -0.805 . . . . 0.0 111.342 -179.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.38 49.24 0.82 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.95 -1.094 . . . . 0.0 110.409 -179.802 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.4 tp -130.54 133.92 25.43 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.146 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.02 102.54 1.35 Allowed 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.785 1.413 . . . . 0.0 110.2 179.608 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.974 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.002 -179.546 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 23.5 t70 . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 120.986 0.422 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 p -127.75 38.42 4.04 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.477 -0.765 . . . . 0.0 110.078 179.722 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.17 113.44 7.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.466 -0.771 . . . . 0.0 109.939 179.679 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mp -125.79 159.42 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.85 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 37.9 mm -69.71 119.38 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.481 -0.762 . . . . 0.0 110.208 -179.905 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.03 -97.27 0.34 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.877 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.13 -33.55 6.07 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 59.11 33.63 22.93 Favored 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.519 -0.989 . . . . 0.0 110.445 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.1 p -138.0 73.99 1.46 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.436 -0.79 . . . . 0.0 109.823 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.9 pt -76.45 135.78 68.67 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.454 -0.779 . . . . 0.0 110.652 -179.842 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.62 155.83 44.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.88 1.463 . . . . 0.0 110.861 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.05 -9.42 23.47 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.979 1.515 . . . . 0.0 111.472 179.735 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t -53.42 -36.18 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.319 -0.863 . . . . 0.0 110.73 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.477 ' HA ' ' HG3' ' A' ' 30' ' ' PRO . . . -64.71 -38.83 92.32 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -29.27 68.59 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.676 -0.64 . . . . 0.0 110.564 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.7 mt -91.15 19.33 5.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.327 -0.858 . . . . 0.0 110.769 179.6 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.67 89.58 0.1 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.634 -0.666 . . . . 0.0 111.139 179.731 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.477 ' HG3' ' HA ' ' A' ' 26' ' ' ALA . 53.9 Cg_endo -81.1 48.05 2.77 Favored 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 123.933 1.491 . . . . 0.0 110.659 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 16.2 mtm-85 . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.111 -0.993 . . . . 0.0 110.349 -179.755 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.498 1.939 0 CA-C-O 120.871 0.367 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.4 p -94.23 19.4 9.43 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.102 -0.999 . . . . 0.0 110.791 179.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -92.63 121.55 34.16 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.167 -0.958 . . . . 0.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.3 mp -102.63 -55.9 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 110.1 -179.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 30.3 mm -111.31 26.71 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.498 -0.752 . . . . 0.0 110.378 179.941 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.15 59.71 8.11 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.23 96.02 2.35 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -84.62 -46.11 11.85 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.537 -0.978 . . . . 0.0 110.557 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.2 p -116.15 92.43 3.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.58 -0.7 . . . . 0.0 110.348 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -91.97 133.92 29.66 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 121.429 -0.794 . . . . 0.0 110.303 179.904 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.43 152.31 49.04 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.783 1.412 . . . . 0.0 110.799 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.56 -23.04 27.62 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.925 1.487 . . . . 0.0 110.983 179.768 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t -62.77 -44.05 99.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.283 -0.885 . . . . 0.0 110.001 179.71 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.44 -37.18 86.15 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -65.15 -33.74 76.74 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.438 -0.789 . . . . 0.0 110.028 179.449 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.39 -40.3 16.62 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.498 -0.751 . . . . 0.0 110.257 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -89.81 116.27 65.95 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.531 -0.73 . . . . 0.0 110.276 -179.854 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -71.75 80.94 1.39 Allowed 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.919 1.484 . . . . 0.0 110.758 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 2.8 tpp180 . . . . . 0 N--CA 1.496 1.854 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.284 179.877 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.043 0.449 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.8 t -166.44 152.25 8.51 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.519 -0.738 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -81.03 97.19 7.4 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.486 -0.759 . . . . 0.0 110.154 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.61 -42.97 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.47 -0.769 . . . . 0.0 110.119 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 20.9 mt -95.99 115.64 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.365 -0.835 . . . . 0.0 109.665 179.834 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.81 162.77 10.08 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.863 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -139.0 -90.64 0.21 Allowed Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.97 42.67 1.13 Allowed 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.442 -1.034 . . . . 0.0 110.571 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 19.6 m 62.44 106.87 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.185 0 CA-C-O 121.513 0.673 . . . . 0.0 111.065 179.639 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.503 HG23 HD13 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -69.72 159.83 82.29 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 121.434 -0.791 . . . . 0.0 110.068 179.629 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 146.13 31.12 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.855 1.45 . . . . 0.0 110.631 179.755 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -76.29 61.87 6.74 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.814 1.428 . . . . 0.0 110.517 179.687 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p -106.22 -33.57 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.287 179.808 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.67 -43.04 73.36 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -104.23 38.57 1.83 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.449 -0.782 . . . . 0.0 110.297 179.548 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.56 -35.04 27.55 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.297 -0.877 . . . . 0.0 110.373 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -62.04 151.19 81.35 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.462 -0.774 . . . . 0.0 110.687 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.25 108.79 2.69 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.855 1.45 . . . . 0.0 110.712 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 117.808 -1.091 . . . . 0.0 110.522 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.19 0.519 . . . . 0.0 110.502 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 t -87.5 177.73 7.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.41 -0.806 . . . . 0.0 110.466 179.834 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -86.56 79.35 8.96 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.495 -0.753 . . . . 0.0 110.165 179.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.5 tt -78.15 -26.39 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.304 -0.873 . . . . 0.0 111.218 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.0 pt -82.35 87.58 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.18 -0.95 . . . . 0.0 110.566 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 155.3 165.96 14.89 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -115.8 -96.97 2.06 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.681 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.4 mt -125.43 41.03 3.61 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.552 -0.969 . . . . 0.0 110.07 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.1 m -122.63 39.68 3.87 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.453 -0.779 . . . . 0.0 110.132 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 pt -141.84 159.61 58.93 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.38 141.79 29.08 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.918 1.483 . . . . 0.0 110.244 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.513 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . 52.1 Cg_endo -77.41 66.92 7.87 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.88 1.463 . . . . 0.0 110.695 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p -70.23 -40.96 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.408 -0.808 . . . . 0.0 110.664 -179.927 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.513 ' HB3' ' HB2' ' A' ' 12' ' ' PRO . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.71 -39.82 74.55 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -108.79 19.87 19.15 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.31 -0.869 . . . . 0.0 110.677 179.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -156.52 44.54 0.41 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.227 -0.92 . . . . 0.0 110.283 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.59 141.28 28.5 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.283 -0.886 . . . . 0.0 110.238 179.856 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.33 160.38 42.13 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 O-C-N 123.883 1.465 . . . . 0.0 110.889 -179.784 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp85 . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.554 179.88 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.074 0.464 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.3 m -131.33 151.16 51.77 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.524 -0.735 . . . . 0.0 110.185 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -99.66 62.55 1.19 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.675 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.5 tp -154.81 149.61 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.383 -0.823 . . . . 0.0 110.43 -179.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.84 162.14 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.487 -0.758 . . . . 0.0 110.242 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.28 151.75 20.3 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.11 -45.75 8.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -116.91 31.32 6.81 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.53 -0.982 . . . . 0.0 110.112 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.3 m -114.36 64.78 0.67 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.267 -0.896 . . . . 0.0 109.927 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -75.38 154.38 85.96 Favored Pre-proline 0 N--CA 1.499 2.012 0 O-C-N 121.412 -0.805 . . . . 0.0 110.561 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -75.76 144.62 28.03 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.924 1.486 . . . . 0.0 110.67 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.78 -19.87 17.98 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.911 1.48 . . . . 0.0 111.077 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -58.92 -42.24 85.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -179.709 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.424 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' MET . . . . . 0.424 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.06 -37.04 72.5 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -73.35 -27.29 61.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.407 -0.808 . . . . 0.0 110.707 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.5 47.51 0.89 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.315 -0.866 . . . . 0.0 110.269 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.2 tp -94.27 119.17 66.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.355 -0.84 . . . . 0.0 110.316 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.43 62.91 7.11 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.871 1.459 . . . . 0.0 110.409 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.2 ttm180 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.338 -0.851 . . . . 0.0 110.648 -179.869 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.496 1.86 0 CA-C-O 120.835 0.35 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.2 m 61.57 172.81 0.12 Allowed 'General case' 0 N--CA 1.505 2.313 0 CA-C-O 121.312 0.577 . . . . 0.0 110.812 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.0 mt-10 -81.37 89.57 6.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.813 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.516 HG23 HG13 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -116.25 -33.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.371 -0.831 . . . . 0.0 110.986 -179.416 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.516 HG13 HG23 ' A' ' 4' ' ' ILE . 7.3 mt -101.72 114.75 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.948 -1.095 . . . . 0.0 110.123 179.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.63 64.38 0.11 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.949 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.4 -96.06 0.11 Allowed Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.4 -81.39 0.06 Allowed 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.598 -0.942 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.491 ' O ' ' HB ' ' A' ' 10' ' ' ILE . 8.0 p -143.46 53.38 1.33 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.007 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.491 ' HB ' ' O ' ' A' ' 9' ' ' THR . 14.3 mt 66.84 139.96 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.311 0 O-C-N 122.052 -0.405 . . . . 0.0 110.756 -179.871 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.409 ' HD2' ' HB ' ' A' ' 14' ' ' VAL . 46.9 Cg_endo -79.48 166.89 21.69 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.742 1.391 . . . . 0.0 110.671 -179.938 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.04 -30.95 38.1 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.967 1.509 . . . . 0.0 110.837 179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t -65.93 -50.59 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.357 -0.839 . . . . 0.0 109.348 179.349 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.409 ' HB ' ' HD2' ' A' ' 11' ' ' PRO . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.66 -36.18 75.82 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -76.06 -22.89 55.16 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.461 -0.774 . . . . 0.0 110.734 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -92.92 52.66 1.87 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.338 -0.851 . . . . 0.0 109.923 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.9 mt -63.55 140.59 97.79 Favored Pre-proline 0 N--CA 1.498 1.968 0 O-C-N 121.573 -0.705 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.77 160.31 43.87 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.95 1.5 . . . . 0.0 110.614 179.684 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.902 0 CA-C-O 117.86 -1.067 . . . . 0.0 110.751 -179.993 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.041 0.448 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 t -152.22 135.16 15.62 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.462 -0.774 . . . . 0.0 110.355 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.72 105.57 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 -179.979 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.454 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 41.9 mm -68.0 -43.2 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.742 . . . . 0.0 110.034 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.454 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 47.1 mt 64.04 116.74 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 CA-C-O 121.5 0.667 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.17 -79.39 1.32 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.36 -51.71 2.5 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.196 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -162.33 -61.13 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 109.595 179.458 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.1 p -153.28 142.59 21.57 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.799 -0.563 . . . . 0.0 109.865 179.754 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.31 121.04 7.63 Favored Pre-proline 0 N--CA 1.495 1.813 0 O-C-N 121.463 -0.773 . . . . 0.0 110.092 179.838 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -82.44 157.66 16.86 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.734 1.386 . . . . 0.0 110.746 -179.622 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.56 -16.91 23.91 Favored 'Trans proline' 0 N--CA 1.49 1.288 0 O-C-N 123.947 1.498 . . . . 0.0 110.993 179.518 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 90.9 t -57.93 -33.3 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.418 -0.801 . . . . 0.0 110.608 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.55 -35.15 75.32 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -84.27 -28.78 26.94 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.5 -0.75 . . . . 0.0 110.285 179.52 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 9.7 mt -94.0 50.79 1.44 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.437 -0.789 . . . . 0.0 110.117 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -79.16 148.42 71.22 Favored Pre-proline 0 N--CA 1.498 1.926 0 O-C-N 121.475 -0.766 . . . . 0.0 110.566 -179.999 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.7 -171.89 1.17 Allowed 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.98 1.516 . . . . 0.0 110.664 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 10.7 mtm105 . . . . . 0 N--CA 1.498 1.943 0 CA-C-O 118.247 -0.883 . . . . 0.0 110.26 179.804 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.019 0.438 . . . . 0.0 110.324 . . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.2 t -113.77 168.26 9.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.54 -0.725 . . . . 0.0 110.039 179.703 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 49.85 70.78 0.46 Allowed 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.709 -0.619 . . . . 0.0 110.532 -179.844 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.6 tt -58.05 -39.67 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.379 -0.826 . . . . 0.0 111.002 -179.547 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 45.0 mm 46.05 60.05 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.527 -0.733 . . . . 0.0 110.215 179.933 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 106.28 -67.59 0.24 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.589 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.6 73.79 0.84 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.864 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -158.88 45.49 0.28 Allowed 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.504 -0.998 . . . . 0.0 110.723 179.94 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.6 m -92.4 73.95 5.24 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.254 -0.904 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.0 pt -139.89 142.21 30.07 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.463 -0.773 . . . . 0.0 110.36 -179.912 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.559 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.3 Cg_endo -73.88 129.63 13.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.918 1.483 . . . . 0.0 110.543 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.37 -43.29 0.71 Allowed 'Trans proline' 0 N--CA 1.489 1.215 0 O-C-N 123.888 1.467 . . . . 0.0 111.203 -179.641 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t -62.63 -46.58 96.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.394 -0.816 . . . . 0.0 109.925 -179.948 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.559 ' HB ' ' HG2' ' A' ' 11' ' ' PRO . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.29 -33.81 75.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.6 m80 -80.46 -35.19 35.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.438 -0.789 . . . . 0.0 110.153 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 mp -59.74 -35.11 73.9 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.456 -0.778 . . . . 0.0 110.767 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -69.0 114.15 21.26 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.383 -0.823 . . . . 0.0 109.919 179.784 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.77 159.8 49.74 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.963 1.507 . . . . 0.0 110.771 -179.703 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 mtt85 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.087 179.863 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.086 0.47 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.6 m -100.74 105.82 17.18 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 0.0 109.966 179.94 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -82.24 91.81 6.81 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.522 -0.737 . . . . 0.0 110.23 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.4 pt -98.8 82.12 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.463 -0.773 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.6 tt -120.23 18.92 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.325 -0.859 . . . . 0.0 110.733 -179.975 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.37 68.8 3.38 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.848 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.44 71.76 0.26 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 37.7 mt -105.0 14.59 29.12 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.521 -0.988 . . . . 0.0 110.97 -179.681 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.8 m -93.67 65.11 3.62 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.174 -0.954 . . . . 0.0 109.676 179.624 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pp -109.98 159.75 30.7 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.394 -0.816 . . . . 0.0 110.166 -179.945 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.14 113.46 3.79 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.861 1.453 . . . . 0.0 110.894 -179.624 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.39 -39.32 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 O-C-N 123.784 1.413 . . . . 0.0 110.787 179.708 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m -64.97 -36.48 77.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.744 -179.774 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.67 -40.15 96.1 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -88.21 2.02 53.15 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.532 -0.73 . . . . 0.0 111.034 179.731 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -77.59 -58.29 3.35 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.059 -1.026 . . . . 0.0 110.245 179.872 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.2 mp 63.76 160.17 0.12 Allowed Pre-proline 0 N--CA 1.504 2.246 0 O-C-N 121.89 -0.506 . . . . 0.0 111.055 179.903 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.41 81.15 2.35 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.641 1.337 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 118.291 -0.861 . . . . 0.0 110.438 179.814 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 120.958 0.408 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -82.11 171.59 14.17 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.389 -0.82 . . . . 0.0 110.358 179.975 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 54.03 66.8 1.13 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.662 -0.649 . . . . 0.0 110.688 -179.912 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' C ' ' A' ' 5' ' ' ILE . 6.4 mt -92.09 -41.38 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.405 -0.81 . . . . 0.0 110.086 179.789 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.429 ' O ' HG23 ' A' ' 5' ' ' ILE . 8.7 tt 31.39 73.73 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.384 0 CA-C-O 121.821 0.82 . . . . 0.0 111.847 179.902 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -126.24 127.21 6.0 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.13 67.41 0.04 OUTLIER Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.878 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -165.85 43.74 0.07 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.546 -0.973 . . . . 0.0 109.989 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.4 t -160.26 -148.5 0.17 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 110.156 -179.616 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.602 ' HB ' ' HD2' ' A' ' 12' ' ' PRO . 26.8 pt -131.14 148.43 70.19 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.277 -0.889 . . . . 0.0 110.089 179.853 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.619 ' N ' ' HD2' ' A' ' 12' ' ' PRO . 45.1 Cg_endo -70.93 -26.87 21.57 Favored 'Trans proline' 0 CA--C 1.556 1.624 0 O-C-N 123.932 1.491 . . . . 0.0 114.841 -179.156 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.619 ' HD2' ' N ' ' A' ' 11' ' ' PRO . 40.7 Cg_endo -65.8 -24.21 54.57 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 119.166 0.738 . . . . 0.0 112.754 -178.437 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.24 -38.26 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 O-C-N 120.771 -1.206 . . . . 0.0 110.615 179.983 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -77.86 -22.37 49.94 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -95.24 -33.02 12.74 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.334 -0.854 . . . . 0.0 110.731 -179.771 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.73 30.68 1.01 Allowed 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.271 -0.893 . . . . 0.0 110.764 -179.792 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.5 tp -132.8 125.95 19.58 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.26 -0.9 . . . . 0.0 109.945 179.743 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.79 74.99 4.2 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 O-C-N 123.929 1.489 . . . . 0.0 110.358 -179.872 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 2.7 ttm105 . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.844 -179.712 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 21.8 t70 . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.843 0.354 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 54.6 p 35.58 64.01 0.5 Allowed 'General case' 0 N--CA 1.507 2.393 0 CA-C-O 121.298 0.571 . . . . 0.0 111.451 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.81 -85.42 0.08 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.347 -0.846 . . . . 0.0 110.386 179.995 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 pt -124.45 42.97 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.297 -0.877 . . . . 0.0 110.422 179.987 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG23 HD13 ' A' ' 5' ' ' ILE . 0.0 OUTLIER -69.5 117.62 12.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.375 -0.828 . . . . 0.0 109.44 179.691 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.98 -68.65 3.46 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.085 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.93 -63.44 0.61 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.75 32.26 6.22 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.618 -0.931 . . . . 0.0 110.212 179.857 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 p -130.6 59.74 1.65 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.381 -0.825 . . . . 0.0 109.981 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.24 99.12 17.87 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.921 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -81.21 157.9 20.06 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 O-C-N 123.841 1.442 . . . . 0.0 110.577 -179.799 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.96 -20.45 25.61 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.774 1.407 . . . . 0.0 111.115 179.757 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p -60.12 -33.29 52.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.341 -0.849 . . . . 0.0 111.069 -179.762 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.412 ' HA ' ' NE2' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.47 -35.98 61.13 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.412 ' NE2' ' HA ' ' A' ' 24' ' ' PHE . 31.5 p80 -117.74 21.77 12.73 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.404 -0.81 . . . . 0.0 110.558 179.468 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -108.28 -40.13 5.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.288 -0.883 . . . . 0.0 110.474 179.942 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 8.6 tp -83.76 124.17 75.31 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.316 -0.865 . . . . 0.0 110.28 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -75.39 80.48 2.51 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 O-C-N 123.92 1.484 . . . . 0.0 110.263 179.944 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 30.8 mtp85 . . . . . 0 N--CA 1.502 2.148 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.837 -179.661 . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 121.115 0.483 . . . . 0.0 110.517 . . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.7 m -77.51 136.23 38.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.525 -0.735 . . . . 0.0 109.845 179.829 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -125.31 101.31 6.91 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.643 -0.661 . . . . 0.0 110.279 -179.867 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.506 ' CG2' HG12 ' A' ' 5' ' ' ILE . 0.1 OUTLIER -80.42 -26.88 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.445 -0.784 . . . . 0.0 110.42 179.929 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.506 HG12 ' CG2' ' A' ' 4' ' ' ILE . 43.8 mm -105.17 55.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.264 -0.898 . . . . 0.0 109.655 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.49 -63.47 0.73 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.892 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.7 -40.3 2.73 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 179.97 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 65.87 16.47 10.49 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.644 -0.915 . . . . 0.0 110.999 -179.516 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.0 m -148.46 23.8 1.01 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.239 -0.913 . . . . 0.0 110.198 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.539 ' HB ' HG13 ' A' ' 14' ' ' VAL . 2.9 pt -145.64 139.75 15.12 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.16 -0.963 . . . . 0.0 110.182 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.451 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 43.9 Cg_endo -71.8 168.34 24.07 Favored 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.791 1.416 . . . . 0.0 110.704 -179.854 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.87 -30.24 17.42 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.668 1.352 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.64 -33.52 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.287 -0.883 . . . . 0.0 110.886 -179.853 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.539 HG13 ' HB ' ' A' ' 10' ' ' ILE . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.14 89.99 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -84.07 -42.22 16.34 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.407 -0.808 . . . . 0.0 110.154 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -63.36 -38.68 92.08 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.532 -0.73 . . . . 0.0 110.419 179.807 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.9 tp -115.12 87.48 15.77 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.416 -0.802 . . . . 0.0 110.031 179.788 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.95 100.39 1.08 Allowed 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 124.048 1.552 . . . . 0.0 110.659 -179.998 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 117.821 -1.085 . . . . 0.0 110.425 -179.995 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 17.7 t70 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 121.159 0.504 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 35.3 m -124.75 157.37 35.87 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.51 -0.744 . . . . 0.0 110.098 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.45 89.28 7.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.444 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 42.4 mt 51.31 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.749 -0.594 . . . . 0.0 110.513 179.674 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.444 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 34.3 mm 64.55 121.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.378 0 CA-C-O 121.48 0.657 . . . . 0.0 110.894 179.823 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.69 -52.96 0.83 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.827 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.92 -32.65 81.6 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.806 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 57.96 29.83 18.25 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.502 -0.999 . . . . 0.0 111.279 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 25.6 m -128.65 19.23 6.19 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.15 -0.969 . . . . 0.0 110.401 179.573 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -143.2 151.67 55.91 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.2 -0.938 . . . . 0.0 110.231 179.808 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.78 122.97 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.938 1.494 . . . . 0.0 110.362 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.95 -43.05 1.33 Allowed 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 123.868 1.457 . . . . 0.0 111.187 -179.659 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t -65.83 -47.82 84.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.331 -0.856 . . . . 0.0 110.008 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.21 -35.97 82.53 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -71.94 -32.3 67.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.411 -0.806 . . . . 0.0 110.504 179.691 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.6 mt -87.16 -48.3 8.16 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 5.9 tp -93.44 114.74 63.72 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.403 -0.81 . . . . 0.0 110.122 179.97 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.78 83.87 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.227 0 O-C-N 123.969 1.51 . . . . 0.0 110.57 179.985 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.216 -179.817 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.048 0.452 . . . . 0.0 110.101 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 p -70.13 107.77 3.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 -179.918 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 4' ' ' ILE . 0.5 OUTLIER -121.64 100.83 7.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.561 -0.712 . . . . 0.0 109.941 -179.833 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.406 ' C ' ' O ' ' A' ' 3' ' ' GLU . 23.2 pt 32.87 58.6 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.576 0 CA-C-O 121.221 0.534 . . . . 0.0 111.887 -179.51 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 24.4 mt 56.74 50.43 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-O 121.443 0.64 . . . . 0.0 110.304 179.891 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -96.19 114.91 5.05 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.982 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.1 -76.6 1.24 Allowed Glycine 0 N--CA 1.497 2.711 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.753 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.404 HD13 HG12 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -148.68 70.97 1.13 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.333 -1.098 . . . . 0.0 109.819 -179.758 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.1 p -79.97 95.48 6.14 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.39 -0.819 . . . . 0.0 110.461 -179.734 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.404 HG12 HD13 ' A' ' 8' ' ' LEU . 14.6 pt -130.7 152.64 80.82 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.519 -0.738 . . . . 0.0 110.137 179.705 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.08 114.89 4.01 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.94 1.495 . . . . 0.0 110.895 -179.745 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.02 -38.51 2.17 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.828 1.436 . . . . 0.0 110.852 179.774 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.35 -43.36 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.422 -0.799 . . . . 0.0 110.28 -179.991 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.45 -30.8 71.87 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -99.52 -6.61 27.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.32 -0.862 . . . . 0.0 111.092 179.807 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.1 mt -104.19 -63.41 1.2 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 179.885 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 61.44 171.06 0.08 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.839 -0.538 . . . . 0.0 111.022 179.926 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.69 113.66 3.71 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.597 1.314 . . . . 0.0 110.596 -179.813 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.9 mtt85 . . . . . 0 N--CA 1.496 1.873 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.348 -179.989 . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.148 0.499 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 30.0 m -132.88 139.87 47.62 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.385 -0.822 . . . . 0.0 110.497 -179.756 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 54.62 31.88 16.01 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.781 -0.574 . . . . 0.0 111.565 179.527 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 47.3 mt 56.62 96.87 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.581 -0.699 . . . . 0.0 110.815 179.675 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.9 tt -62.23 -24.17 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.45 -0.781 . . . . 0.0 110.779 179.599 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -90.83 69.73 2.16 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.591 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.95 -53.21 2.9 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.965 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 tp -163.95 78.27 0.39 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.525 -0.985 . . . . 0.0 109.895 179.902 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 p -74.46 110.68 8.94 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.306 -0.871 . . . . 0.0 109.813 179.967 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -52.42 112.22 3.2 Favored Pre-proline 0 N--CA 1.503 2.178 0 O-C-N 121.916 -0.49 . . . . 0.0 110.999 -179.536 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.456 ' HB2' HG22 ' A' ' 13' ' ' VAL . 50.4 Cg_endo -81.21 140.97 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.679 1.357 . . . . 0.0 110.787 -179.76 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.22 61.28 6.55 Favored 'Trans proline' 0 C--N 1.316 -1.174 0 O-C-N 123.911 1.48 . . . . 0.0 110.541 179.57 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 11' ' ' PRO . 87.0 t -106.07 -45.83 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.848 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.426 ' HA ' HD12 ' A' ' 28' ' ' LEU . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.7 -30.46 70.71 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.8 m80 -80.78 -7.27 59.34 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.476 -0.765 . . . . 0.0 110.854 179.634 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.426 HD12 ' HA ' ' A' ' 25' ' ' PHE . 17.0 mt -91.79 47.55 1.37 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.149 179.772 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.1 pp -96.42 162.22 24.24 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.452 -0.78 . . . . 0.0 110.481 179.984 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.16 128.22 11.98 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.806 1.424 . . . . 0.0 110.549 179.811 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.853 0 CA-C-O 117.856 -1.069 . . . . 0.0 110.414 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.873 0.368 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.07 0 CA-C-O 120.588 0.232 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.444 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t . . . . . 0 N--CA 1.498 1.932 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 17' ' ' VAL . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 N--CA 1.499 1.993 0 CA-C-O 120.925 0.393 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.408 HG13 ' N ' ' A' ' 14' ' ' VAL . 10.6 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.65 0.262 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 13' ' ' VAL . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.44 HD13 ' HA ' ' A' ' 16' ' ' LEU . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.739 0.304 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 120.702 0.286 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.485 HD22 ' HA ' ' A' ' 16' ' ' LEU . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 120.649 0.261 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.473 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 14' ' ' VAL . 28.7 m . . . . . 0 N--CA 1.5 2.066 0 CA-C-O 120.884 0.373 . . . . 0.0 110.443 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.433 ' N ' HG23 ' A' ' 13' ' ' VAL . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.5 2.051 0 CA-C-O 120.796 0.332 . . . . 0.0 110.623 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 14' ' ' VAL . 11.9 p . . . . . 0 N--CA 1.5 2.059 0 CA-C-O 120.575 0.226 . . . . 0.0 111.015 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 18' ' ' VAL . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 14' ' ' VAL . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' MET . . . . . 0.4 ' HG3' ' N ' ' A' ' 20' ' ' SER . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' A' ' 19' ' ' MET . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t . . . . . 0 N--CA 1.498 1.929 0 CA-C-O 120.991 0.424 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 17' ' ' VAL . 79.0 t . . . . . 0 N--CA 1.499 2.012 0 CA-C-O 120.716 0.294 . . . . 0.0 110.325 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 13' ' ' VAL . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 14' ' ' VAL . 13.2 p . . . . . 0 N--CA 1.501 2.084 0 CA-C-O 120.547 0.213 . . . . 0.0 111.369 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 13' ' ' VAL . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 N--CA 1.5 2.033 0 CA-C-O 120.852 0.358 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.543 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.543 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t . . . . . 0 N--CA 1.499 1.99 0 CA-C-O 120.822 0.344 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 14' ' ' VAL . 35.8 m . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.932 0.396 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 13' ' ' VAL . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.0 t . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 121.036 0.446 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 14' ' ' VAL . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.427 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 N--CA 1.5 2.032 0 CA-C-O 120.807 0.336 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 18' ' ' VAL . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 14' ' ' VAL . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.44 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.4 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.531 0.205 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.44 ' N ' HG13 ' A' ' 13' ' ' VAL . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t . . . . . 0 N--CA 1.498 1.955 0 CA-C-O 120.773 0.32 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.493 ' O ' HG23 ' A' ' 18' ' ' VAL . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.672 0.273 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.424 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 14' ' ' VAL . 34.0 m . . . . . 0 N--CA 1.499 1.976 0 CA-C-O 120.749 0.309 . . . . 0.0 110.396 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 14' ' ' VAL . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t . . . . . 0 N--CA 1.503 2.175 0 CA-C-O 120.742 0.306 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 18' ' ' VAL . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 14' ' ' VAL . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t . . . . . 0 N--CA 1.5 2.067 0 CA-C-O 120.602 0.239 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 120.902 0.382 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 18' ' ' VAL . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 14' ' ' VAL . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 120.906 0.384 . . . . 0.0 110.287 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' VAL . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.5 p . . . . . 0 N--CA 1.5 2.055 0 CA-C-O 120.78 0.324 . . . . 0.0 110.664 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' N ' HG13 ' A' ' 13' ' ' VAL . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.073 0 CA-C-O 120.541 0.21 . . . . 0.0 110.691 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.492 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' MET . . . . . 0.492 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t . . . . . 0 N--CA 1.497 1.904 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 17' ' ' VAL . 90.9 t . . . . . 0 N--CA 1.501 2.09 0 CA-C-O 120.581 0.229 . . . . 0.0 110.608 . . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' VAL . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 14' ' ' VAL . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t . . . . . 0 N--CA 1.499 2.011 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 18' ' ' VAL . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.5 2.047 0 CA-C-O 120.638 0.256 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.505 2.282 0 CA-C-O 120.823 0.344 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.499 1.988 0 CA-C-O 120.559 0.218 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.52 ' O ' HG23 ' A' ' 18' ' ' VAL . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.516 ' O ' HD13 ' A' ' 16' ' ' LEU . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 120.508 0.194 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 120.975 0.417 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 120.709 0.29 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 87.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 . . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 14' ' ' VAL . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 . . . . . 0 N--CA 1.496 1.834 0 CA-C-O 121.247 0.546 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -148.16 87.76 1.62 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.451 -0.781 . . . . 0.0 110.17 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -87.04 -48.95 7.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.396 -0.815 . . . . 0.0 110.082 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.0 mt -108.48 -42.04 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.764 -0.585 . . . . 0.0 109.959 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG23 HD23 ' A' ' 8' ' ' LEU . 2.8 mp -88.5 125.2 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.374 -0.829 . . . . 0.0 109.894 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -106.88 -68.42 0.68 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.799 -1.321 . . . . 0.0 109.799 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.26 78.59 0.16 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 HG23 ' A' ' 5' ' ' ILE . 1.0 OUTLIER -92.91 11.94 25.52 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.497 -1.002 . . . . 0.0 111.078 179.787 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.5 m -95.17 64.33 2.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.213 -0.93 . . . . 0.0 109.694 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.526 HG12 HG11 ' A' ' 14' ' ' VAL . 0.1 OUTLIER -121.4 158.94 52.16 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.367 -0.833 . . . . 0.0 109.957 -179.871 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.519 ' HD2' HG12 ' A' ' 10' ' ' ILE . 45.7 Cg_endo -78.03 166.43 24.9 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.942 1.496 . . . . 0.0 110.854 -179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.4 -28.7 38.86 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.853 1.449 . . . . 0.0 111.031 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p -67.44 -36.83 77.61 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.362 -0.836 . . . . 0.0 110.103 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.526 HG11 HG12 ' A' ' 10' ' ' ILE . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.69 -40.93 98.03 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -82.34 -42.01 19.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.58 -0.7 . . . . 0.0 110.418 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.472 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 3.4 mm? -67.36 -46.23 73.96 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER 61.7 169.96 0.08 OUTLIER Pre-proline 0 N--CA 1.501 2.089 0 O-C-N 122.068 -0.395 . . . . 0.0 110.924 -179.92 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.434 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 46.0 Cg_endo -73.72 75.32 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.655 1.344 . . . . 0.0 110.152 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.228 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 . . . . . 0 N--CA 1.498 1.969 0 CA-C-O 120.705 0.288 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 m -120.51 139.94 52.16 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.035 -1.041 . . . . 0.0 110.131 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 53.57 75.2 0.27 Allowed 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 121.372 0.606 . . . . 0.0 110.48 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.2 tt -148.77 155.64 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.361 -0.837 . . . . 0.0 110.074 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 mt -92.55 -87.08 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.278 -0.889 . . . . 0.0 109.926 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -111.66 -61.62 0.47 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.26 -72.04 0.27 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.49 74.84 0.43 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.901 -0.764 . . . . 0.0 110.296 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.6 p -82.72 57.82 3.97 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.451 -0.78 . . . . 0.0 110.207 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 tp -76.82 135.32 67.78 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.341 -0.849 . . . . 0.0 110.364 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.583 ' O ' HG12 ' A' ' 14' ' ' VAL . 51.0 Cg_endo -81.53 131.19 7.28 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.836 1.44 . . . . 0.0 110.81 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.97 -21.75 18.03 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.761 1.4 . . . . 0.0 111.219 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -62.11 -46.33 96.71 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.241 -0.912 . . . . 0.0 110.867 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.583 HG12 ' O ' ' A' ' 11' ' ' PRO . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.444 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.446 ' CE2' HD11 ' A' ' 29' ' ' LEU . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.07 -31.0 66.64 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -106.28 22.1 16.3 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.511 -0.743 . . . . 0.0 110.582 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.505 ' HB3' HD13 ' A' ' 29' ' ' LEU . 0.6 OUTLIER -95.8 -33.79 12.13 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.305 -0.872 . . . . 0.0 110.208 179.656 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 29' ' ' LEU . 0.0 OUTLIER -133.22 158.81 74.82 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.423 -0.798 . . . . 0.0 110.421 179.198 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.416 ' O ' ' HB2' ' A' ' 31' ' ' ARG . 51.3 Cg_endo -86.34 19.0 1.46 Allowed 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.827 1.436 . . . . 0.0 111.553 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 30' ' ' PRO . 15.2 mtt85 . . . . . 0 N--CA 1.504 2.263 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.749 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 120.941 0.4 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 m 56.4 54.63 7.37 Favored 'General case' 0 N--CA 1.501 2.085 0 CA-C-O 121.423 0.63 . . . . 0.0 110.138 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -88.65 116.67 27.06 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.3 -0.875 . . . . 0.0 110.236 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 pt -89.83 64.1 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.51 -0.744 . . . . 0.0 110.447 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.2 pp -87.56 129.71 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.331 -0.855 . . . . 0.0 110.331 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.84 111.5 4.01 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.8 -95.55 1.08 Allowed Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.09 27.79 9.03 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.527 -0.984 . . . . 0.0 110.794 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.2 m -127.02 56.37 1.52 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.24 -0.913 . . . . 0.0 109.853 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.438 HG13 ' HD2' ' A' ' 11' ' ' PRO . 8.1 tt -143.64 134.01 12.13 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.408 -0.807 . . . . 0.0 110.163 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.438 ' HD2' HG13 ' A' ' 10' ' ' ILE . 51.0 Cg_endo -81.81 114.95 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 O-C-N 123.848 1.446 . . . . 0.0 111.019 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.09 -38.83 1.95 Allowed 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.804 1.423 . . . . 0.0 110.754 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t -66.23 -42.8 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.41 -0.806 . . . . 0.0 110.21 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 17' ' ' VAL . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.441 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.14 -34.13 69.92 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.2 m-70 -129.2 30.97 4.94 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.311 -0.868 . . . . 0.0 110.573 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 24' ' ' PHE . 5.0 tp -101.55 -34.8 9.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.29 -0.881 . . . . 0.0 110.647 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -120.05 80.23 26.6 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.286 -0.884 . . . . 0.0 110.752 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.94 59.05 6.32 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.775 1.408 . . . . 0.0 110.454 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.494 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.121 0.486 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -136.46 107.25 6.61 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.425 -0.797 . . . . 0.0 110.319 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -122.38 24.62 9.26 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.537 -0.727 . . . . 0.0 110.781 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.452 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 30.3 mt -110.74 77.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.109 -0.994 . . . . 0.0 109.369 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 32.7 mt 65.19 161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 CA-C-O 121.28 0.562 . . . . 0.0 110.429 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -66.55 -69.54 1.33 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.51 38.64 2.82 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt 51.67 37.77 20.97 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.79 -0.829 . . . . 0.0 110.71 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.2 m 56.96 86.17 0.07 Allowed 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.481 0.658 . . . . 0.0 110.438 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.2 pt -70.54 158.84 86.87 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.4 -0.812 . . . . 0.0 110.581 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.32 122.05 8.33 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.857 1.451 . . . . 0.0 110.772 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.32 -34.74 12.2 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.881 1.464 . . . . 0.0 110.762 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p -62.77 -34.24 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.389 -0.82 . . . . 0.0 110.422 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -85.14 -36.79 20.86 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 17.2 m-70 -72.34 -35.31 68.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.436 -0.79 . . . . 0.0 110.857 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.11 33.52 2.14 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.309 -0.869 . . . . 0.0 110.738 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.3 tt -89.74 134.79 31.51 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.141 -0.975 . . . . 0.0 110.267 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.29 84.43 1.36 Allowed 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.887 1.467 . . . . 0.0 110.355 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mtt-85 . . . . . 0 N--CA 1.502 2.129 0 CA-C-O 117.669 -1.158 . . . . 0.0 110.617 -179.738 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.121 0.486 . . . . 0.0 110.143 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.3 t -155.3 162.88 40.76 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.361 -0.837 . . . . 0.0 110.672 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.659 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 0.8 OUTLIER -125.93 42.75 3.23 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.505 -0.747 . . . . 0.0 110.525 179.89 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.7 mm -98.72 -43.74 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.238 -0.914 . . . . 0.0 110.162 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 mt -101.12 64.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.375 -0.828 . . . . 0.0 110.036 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.12 66.66 1.93 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.659 ' HA3' ' HA ' ' A' ' 3' ' ' GLU . . . -101.74 -79.93 1.44 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 7' ' ' GLY . 0.6 OUTLIER 32.28 60.23 0.36 Allowed 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.511 0.672 . . . . 0.0 112.122 179.911 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 t -92.71 16.27 12.64 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.263 -0.898 . . . . 0.0 110.98 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.503 ' N ' HD13 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -132.58 128.25 20.9 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.23 -0.919 . . . . 0.0 109.803 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.75 ' HG2' ' HD3' ' A' ' 12' ' ' PRO . 37.0 Cg_endo -66.72 -34.34 31.97 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.849 1.447 . . . . 0.0 113.157 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.75 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 55.8 Cg_endo -81.1 57.18 6.39 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 122.422 0.696 . . . . 0.0 110.382 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.408 HG13 ' N ' ' A' ' 14' ' ' VAL . 10.6 p -67.48 -39.87 83.35 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.335 -0.853 . . . . 0.0 110.891 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 13' ' ' VAL . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -84.64 -30.92 24.5 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -76.78 -43.09 38.29 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.351 -0.843 . . . . 0.0 110.507 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.83 -46.44 21.48 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.417 -0.802 . . . . 0.0 110.436 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.0 mt -113.3 134.05 21.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.244 -0.91 . . . . 0.0 110.273 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.77 102.93 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.984 1.518 . . . . 0.0 110.653 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.919 0 CA-C-O 117.914 -1.041 . . . . 0.0 110.741 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 . . . . . 0 N--CA 1.496 1.843 0 CA-C-O 120.904 0.383 . . . . 0.0 110.138 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 m -126.5 59.77 1.35 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.568 -0.707 . . . . 0.0 110.189 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -155.66 73.63 0.84 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.365 -0.834 . . . . 0.0 110.347 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.453 HG23 HD12 ' A' ' 5' ' ' ILE . 2.7 tt -171.11 145.99 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.512 -0.743 . . . . 0.0 110.248 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.453 HD12 HG23 ' A' ' 4' ' ' ILE . 19.1 mt 63.07 163.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.28 0 CA-C-O 121.497 0.665 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.88 -31.57 3.33 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.59 -45.86 1.34 Allowed Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 12.1 mt -99.52 30.46 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.483 -1.01 . . . . 0.0 110.712 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 p -129.98 34.71 4.22 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.186 -0.946 . . . . 0.0 110.019 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.9 142.91 21.26 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.418 -0.801 . . . . 0.0 110.149 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -75.73 115.7 4.26 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.85 1.447 . . . . 0.0 110.689 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.17 -39.76 2.84 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 123.769 1.405 . . . . 0.0 110.737 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m -64.62 -35.8 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.376 -0.827 . . . . 0.0 110.503 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.63 -37.53 70.85 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.56 29.54 7.92 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.348 -0.845 . . . . 0.0 110.499 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.9 tp -146.69 -51.69 0.22 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.281 -0.887 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 64.86 159.21 0.12 Allowed Pre-proline 0 N--CA 1.502 2.152 0 O-C-N 121.991 -0.443 . . . . 0.0 110.994 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.25 114.41 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.738 1.389 . . . . 0.0 110.487 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 117.867 -1.063 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.412 ' HB2' HG22 ' A' ' 4' ' ' ILE . 7.9 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.936 0.398 . . . . 0.0 110.133 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.8 p -67.12 126.5 29.4 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 110.146 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 56.13 81.89 0.12 Allowed 'General case' 0 N--CA 1.5 2.045 0 CA-C-O 121.429 0.633 . . . . 0.0 110.565 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.412 HG22 ' HB2' ' A' ' 1' ' ' ASP . 1.8 pt -83.79 55.54 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.361 -0.837 . . . . 0.0 110.445 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.4 tt -163.45 133.01 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.318 -0.863 . . . . 0.0 109.957 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.35 97.94 0.16 Allowed Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.45 -62.49 1.15 Allowed Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.12 46.54 2.65 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.218 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.5 p -95.27 63.33 2.57 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.347 -0.846 . . . . 0.0 110.154 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.486 HG13 ' HD2' ' A' ' 11' ' ' PRO . 21.0 tt -80.44 141.52 53.02 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.486 ' HD2' HG13 ' A' ' 10' ' ' ILE . 50.4 Cg_endo -79.13 113.29 3.18 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.852 1.448 . . . . 0.0 110.668 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.95 -38.99 3.53 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.727 1.383 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p -62.2 -36.8 76.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.449 -0.782 . . . . 0.0 110.596 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.485 HD22 ' HA ' ' A' ' 16' ' ' LEU . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.81 -37.03 73.21 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 12.4 m-70 -72.98 -33.89 66.11 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.496 -0.753 . . . . 0.0 110.645 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -80.3 -46.03 16.86 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.395 -0.815 . . . . 0.0 110.43 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.52 92.93 0.06 OUTLIER Pre-proline 0 N--CA 1.5 2.041 0 O-C-N 121.801 -0.562 . . . . 0.0 110.482 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.95 158.07 56.37 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.819 1.431 . . . . 0.0 110.4 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mmp_? . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 118.209 -0.901 . . . . 0.0 110.244 -179.912 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.062 0.458 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 m -96.7 56.14 1.46 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.372 -0.83 . . . . 0.0 109.855 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -132.47 40.16 3.31 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.482 -0.761 . . . . 0.0 110.576 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.535 HG22 HG12 ' A' ' 5' ' ' ILE . 2.4 mp -124.66 159.0 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.308 -0.87 . . . . 0.0 109.495 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.535 HG12 HG22 ' A' ' 4' ' ' ILE . 38.8 mm 59.93 83.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 CA-C-O 121.412 0.625 . . . . 0.0 110.406 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -110.26 -95.5 2.34 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.93 -94.15 2.33 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -155.21 72.52 0.83 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.519 -0.989 . . . . 0.0 110.051 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.6 t -125.23 18.69 8.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.422 -0.799 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.503 HG13 ' HD2' ' A' ' 11' ' ' PRO . 19.2 tt -150.33 137.84 11.79 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.153 -0.967 . . . . 0.0 110.314 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.693 ' HB2' HG22 ' A' ' 13' ' ' VAL . 47.7 Cg_endo -76.67 151.93 32.71 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.85 1.448 . . . . 0.0 110.536 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.99 -24.27 24.24 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.843 1.444 . . . . 0.0 111.239 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.693 HG22 ' HB2' ' A' ' 11' ' ' PRO . 33.5 m -60.25 -36.13 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 121.366 -0.834 . . . . 0.0 110.868 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 11' ' ' PRO . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.401 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.06 -22.62 66.98 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 8.4 m-70 -97.53 -20.09 17.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.335 -0.853 . . . . 0.0 110.785 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.9 mt -107.88 34.83 3.36 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.112 -0.992 . . . . 0.0 111.064 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 25' ' ' PHE . 0.1 OUTLIER -143.39 140.16 17.31 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.086 -1.009 . . . . 0.0 110.42 179.604 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.479 ' C ' ' HG2' ' A' ' 31' ' ' ARG . 51.2 Cg_endo -77.76 172.78 15.13 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 124.118 1.589 . . . . 0.0 110.536 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.479 ' HG2' ' C ' ' A' ' 30' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.494 0 CA-C-O 117.658 -1.163 . . . . 0.0 111.946 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.5 t70 . . . . . 0 N--CA 1.495 1.794 0 CA-C-O 120.976 0.417 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 p -145.48 101.95 3.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.536 -0.727 . . . . 0.0 110.41 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -115.38 109.74 18.34 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 56.5 mt 57.49 88.44 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 CA-C-O 121.569 0.699 . . . . 0.0 110.735 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.7 tt -109.41 18.73 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.341 -0.849 . . . . 0.0 110.738 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.29 -110.3 3.44 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -66.79 0.39 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -152.37 32.7 0.52 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.439 -1.036 . . . . 0.0 110.875 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 39.1 p -120.13 58.5 0.91 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.083 -1.011 . . . . 0.0 110.043 179.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.1 pt -87.31 148.03 43.67 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.337 -0.852 . . . . 0.0 110.294 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.31 142.89 30.83 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.811 1.427 . . . . 0.0 110.321 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.35 64.71 8.87 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.918 1.483 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 14' ' ' VAL . 28.7 m -77.38 -41.05 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.307 -0.87 . . . . 0.0 110.443 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.433 ' N ' HG23 ' A' ' 13' ' ' VAL . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.96 -27.04 67.86 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -103.83 24.14 11.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.265 -0.897 . . . . 0.0 110.853 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -154.1 40.35 0.48 Allowed 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.077 -1.014 . . . . 0.0 110.578 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.9 tp -135.74 126.86 17.13 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.217 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.36 141.37 31.77 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.868 1.457 . . . . 0.0 110.439 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.337 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 121.191 0.52 . . . . 0.0 110.563 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -82.34 144.4 30.59 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.456 -0.778 . . . . 0.0 110.586 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -160.56 41.8 0.18 Allowed 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.533 -0.729 . . . . 0.0 110.392 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 5' ' ' ILE . 10.3 tt -164.93 -41.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.209 -0.932 . . . . 0.0 110.715 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 4' ' ' ILE . 2.2 pt -114.26 119.04 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.308 -0.87 . . . . 0.0 110.12 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.27 -98.11 0.15 Allowed Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -111.46 46.69 1.13 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 mp 50.41 58.71 5.2 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.697 -0.884 . . . . 0.0 110.761 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 p -87.84 56.44 3.89 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.28 -0.888 . . . . 0.0 110.165 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -74.03 155.13 88.6 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.455 -0.778 . . . . 0.0 110.458 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HB2' HG12 ' A' ' 13' ' ' VAL . 45.7 Cg_endo -72.28 149.37 51.13 Favored 'Trans proline' 0 C--N 1.313 -1.297 0 O-C-N 123.769 1.405 . . . . 0.0 110.451 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.2 -28.36 23.23 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.848 1.447 . . . . 0.0 111.391 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.534 HG12 ' HB2' ' A' ' 11' ' ' PRO . 11.4 p -62.26 -37.04 77.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.268 -0.895 . . . . 0.0 110.623 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.18 -38.55 91.47 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 15.3 t-80 -109.11 55.97 0.63 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.356 -0.84 . . . . 0.0 110.151 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.54 -54.89 1.65 Allowed 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.33 -0.856 . . . . 0.0 110.457 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 6.0 tt -141.2 132.22 13.45 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.414 -0.804 . . . . 0.0 110.04 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.5 Cg_endo -74.44 126.18 10.14 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.885 1.466 . . . . 0.0 110.476 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 . . . . . 0 N--CA 1.5 2.056 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.515 179.942 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.16 0.505 . . . . 0.0 110.508 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.1 m -101.35 105.75 16.84 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.529 -0.732 . . . . 0.0 110.022 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -101.33 74.36 1.55 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.463 -0.773 . . . . 0.0 110.028 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.0 mp 52.12 63.67 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.708 -0.62 . . . . 0.0 110.348 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 5' ' ' ILE . 48.2 mm -111.86 1.12 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.382 -0.824 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -94.88 62.4 1.58 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.97 -48.16 1.51 Allowed Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.17 51.65 0.77 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.423 -1.045 . . . . 0.0 110.243 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.4 p 36.03 77.62 0.04 OUTLIER 'General case' 0 N--CA 1.507 2.389 0 CA-C-O 121.181 0.515 . . . . 0.0 111.699 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.1 pt -60.21 144.19 87.75 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.368 -0.832 . . . . 0.0 110.569 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.512 ' O ' HG22 ' A' ' 14' ' ' VAL . 45.0 Cg_endo -71.42 162.49 42.16 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.919 1.484 . . . . 0.0 111.053 -179.537 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.45 -17.87 23.41 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 O-C-N 123.848 1.446 . . . . 0.0 111.17 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 14' ' ' VAL . 11.9 p -62.91 -39.89 86.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.276 -0.89 . . . . 0.0 111.015 -179.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 18' ' ' VAL . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 14' ' ' VAL . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' MET . . . . . 0.4 ' HG3' ' N ' ' A' ' 20' ' ' SER . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' A' ' 19' ' ' MET . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.88 36.66 0.81 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -172.63 -41.88 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.188 -0.945 . . . . 0.0 111.059 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -54.31 -37.05 64.38 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.454 -0.779 . . . . 0.0 111.824 -179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.431 ' O ' HD12 ' A' ' 29' ' ' LEU . 0.2 OUTLIER -124.15 121.43 26.2 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.2 -0.938 . . . . 0.0 110.369 -179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.85 97.91 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.829 1.437 . . . . 0.0 110.383 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.933 0 CA-C-O 117.845 -1.074 . . . . 0.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.9 0.381 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.3 m 53.63 72.07 0.46 Allowed 'General case' 0 N--CA 1.499 2.023 0 CA-C-O 121.427 0.632 . . . . 0.0 109.811 -179.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -78.71 67.56 4.48 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.346 -0.846 . . . . 0.0 110.129 -179.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 49.3 mm -112.04 -46.46 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.416 -0.802 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.57 149.12 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.399 -0.813 . . . . 0.0 110.185 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -68.02 -49.0 50.63 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.84 44.93 1.7 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.584 ' HB3' ' CG1' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -108.42 14.48 24.71 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.343 -1.092 . . . . 0.0 110.745 179.677 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 m 56.6 31.52 19.29 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.512 -0.742 . . . . 0.0 110.924 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.584 ' CG1' ' HB3' ' A' ' 8' ' ' LEU . 1.1 pt -146.64 106.79 4.03 Favored Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.106 -0.996 . . . . 0.0 110.168 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -81.27 138.56 11.2 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.811 1.427 . . . . 0.0 110.69 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -77.76 66.65 8.09 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.911 1.48 . . . . 0.0 110.489 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t -81.53 -49.61 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.383 -0.823 . . . . 0.0 110.2 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.09 -26.8 68.49 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -102.98 -36.64 8.11 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.391 -0.818 . . . . 0.0 110.424 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 0.2 OUTLIER -78.41 -43.28 27.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.32 -0.862 . . . . 0.0 110.615 -179.908 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.6 OUTLIER 62.92 165.99 0.11 Allowed Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 121.989 -0.444 . . . . 0.0 110.995 -179.824 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 47.9 Cg_endo -75.2 82.49 2.03 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.676 1.356 . . . . 0.0 110.184 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 . . . . . 0 N--CA 1.495 1.799 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.477 -179.659 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 N--CA 1.495 1.802 0 CA-C-O 121.214 0.53 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 t -158.06 152.46 24.57 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.406 -0.809 . . . . 0.0 110.335 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -112.74 30.45 7.13 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.447 -0.783 . . . . 0.0 110.648 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt 52.58 54.28 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.222 0 O-C-N 121.538 -0.726 . . . . 0.0 110.506 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp 58.51 -89.69 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.7 -0.625 . . . . 0.0 110.668 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 49.22 6.42 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.19 -85.34 0.77 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 79.1 mt -115.49 38.98 3.09 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.59 -0.947 . . . . 0.0 109.787 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -144.65 54.58 1.25 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.479 -0.763 . . . . 0.0 109.941 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.424 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 18.4 tt -73.76 135.46 77.81 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.289 -0.882 . . . . 0.0 110.656 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 10' ' ' ILE . 50.5 Cg_endo -82.62 120.35 3.14 Favored 'Trans proline' 0 C--N 1.316 -1.152 0 O-C-N 123.847 1.446 . . . . 0.0 110.842 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.92 -40.19 1.95 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.805 1.424 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 17' ' ' VAL . 79.0 t -62.68 -44.56 99.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.398 -0.814 . . . . 0.0 110.325 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 13' ' ' VAL . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.5 -40.68 79.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -111.27 35.22 3.67 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.444 -0.785 . . . . 0.0 110.064 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 7.1 tp -148.85 -50.41 0.16 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.401 -0.812 . . . . 0.0 110.323 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 24.1 mt 64.74 157.69 0.12 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 122.111 -0.368 . . . . 0.0 111.115 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -75.51 84.58 1.71 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.738 1.388 . . . . 0.0 110.622 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 9.0 ttm-85 . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.803 -179.924 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.901 0.382 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -74.93 83.77 2.22 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.43 -0.794 . . . . 0.0 110.193 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -90.06 63.95 6.05 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.345 -0.847 . . . . 0.0 110.411 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.53 HG22 HG23 ' A' ' 5' ' ' ILE . 3.3 mt -82.04 -43.47 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.347 -0.845 . . . . 0.0 109.755 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.53 HG23 HG22 ' A' ' 4' ' ' ILE . 5.8 pt -139.58 65.36 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.521 -0.737 . . . . 0.0 109.69 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.62 -113.69 0.59 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.92 -56.48 0.49 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.1 14.16 4.7 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.524 -0.986 . . . . 0.0 110.502 179.507 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 t -168.6 100.42 0.41 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.339 -0.851 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.4 128.31 67.58 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.435 -0.79 . . . . 0.0 110.885 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.411 ' HB2' HG22 ' A' ' 14' ' ' VAL . 49.8 Cg_endo -80.35 112.34 2.75 Favored 'Trans proline' 0 C--N 1.317 -1.121 0 O-C-N 123.797 1.419 . . . . 0.0 110.65 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -76.23 -29.62 6.2 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 O-C-N 123.739 1.389 . . . . 0.0 111.451 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 14' ' ' VAL . 13.2 p -62.31 -42.53 95.76 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.305 -0.872 . . . . 0.0 111.369 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 13' ' ' VAL . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.39 -38.17 84.26 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 29.8 t-80 -103.35 51.76 0.79 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.52 -0.738 . . . . 0.0 110.046 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -109.46 -50.45 2.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.351 -0.843 . . . . 0.0 110.381 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.7 tp 58.12 87.87 0.13 Allowed Pre-proline 0 N--CA 1.502 2.14 0 O-C-N 121.742 -0.598 . . . . 0.0 111.027 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.4 77.47 2.1 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 124.022 1.538 . . . . 0.0 110.519 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.9 mtp85 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.149 -0.929 . . . . 0.0 110.257 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.028 0.442 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.84 161.29 19.54 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.538 -0.726 . . . . 0.0 110.214 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 58.14 74.09 0.44 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-O 121.511 0.672 . . . . 0.0 110.601 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.6 tt -90.91 -27.05 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.403 -0.81 . . . . 0.0 110.691 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.0 tt -147.09 157.18 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.288 -0.883 . . . . 0.0 110.294 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.27 -67.08 0.23 Allowed Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.46 50.42 3.18 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mt 51.59 47.2 25.27 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.709 -0.877 . . . . 0.0 110.806 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -90.51 60.89 4.76 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.266 -0.896 . . . . 0.0 109.965 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -73.67 139.63 77.68 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.565 -0.709 . . . . 0.0 110.525 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.548 ' HG2' HG23 ' A' ' 14' ' ' VAL . 47.6 Cg_endo -74.84 147.61 34.89 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.837 1.44 . . . . 0.0 110.737 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.52 -21.54 25.77 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.89 1.468 . . . . 0.0 111.03 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.91 -36.61 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.419 -0.8 . . . . 0.0 110.227 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.548 HG23 ' HG2' ' A' ' 11' ' ' PRO . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.543 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.543 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.5 -41.33 85.12 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.2 t-80 -105.35 22.46 15.37 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.406 -0.809 . . . . 0.0 110.475 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -154.28 43.22 0.52 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.329 -0.857 . . . . 0.0 110.345 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -85.99 135.99 36.79 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.49 69.4 5.93 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.876 1.461 . . . . 0.0 110.714 -179.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.192 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.498 1.927 0 CA-C-O 121.126 0.489 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.7 t -76.92 150.27 35.97 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.424 -0.797 . . . . 0.0 110.433 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' HB3' HD12 ' A' ' 4' ' ' ILE . 19.8 mt-10 -105.81 -77.98 0.58 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.486 -0.759 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.672 HG22 HG23 ' A' ' 5' ' ' ILE . 2.6 mp -133.92 -60.09 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.437 -0.789 . . . . 0.0 109.761 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 4' ' ' ILE . 1.1 pt -117.93 -175.33 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.479 -0.763 . . . . 0.0 110.413 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -178.31 145.53 6.96 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.33 64.41 0.39 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.2 39.46 2.92 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.441 -1.034 . . . . 0.0 110.407 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.1 t -72.17 -20.97 61.51 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.329 -0.857 . . . . 0.0 110.741 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.455 ' CG1' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -144.68 160.44 47.44 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.356 -0.84 . . . . 0.0 109.749 179.784 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HD2' ' CG1' ' A' ' 10' ' ' ILE . 49.2 Cg_endo -80.53 120.35 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.922 1.485 . . . . 0.0 110.706 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.73 -36.19 5.07 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.865 1.455 . . . . 0.0 110.933 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t -63.66 -44.12 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.404 -0.81 . . . . 0.0 110.394 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 29' ' ' LEU . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.56 -30.08 68.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 41.3 t60 -93.4 -39.16 11.07 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.47 -0.769 . . . . 0.0 110.281 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.479 ' HA ' HD13 ' A' ' 28' ' ' LEU . 3.6 mm? -80.29 -57.79 3.44 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.366 -0.834 . . . . 0.0 110.438 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 25' ' ' PHE . 0.1 OUTLIER 64.57 166.98 0.11 Allowed Pre-proline 0 N--CA 1.502 2.172 0 O-C-N 121.845 -0.534 . . . . 0.0 110.793 -179.908 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.411 ' HD3' ' CZ ' ' A' ' 25' ' ' PHE . 49.9 Cg_endo -77.62 172.05 16.45 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.625 1.329 . . . . 0.0 110.826 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.367 179.839 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.978 0.418 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.0 p -143.72 84.47 1.79 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.504 -0.747 . . . . 0.0 110.403 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -98.96 64.18 1.4 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.204 -0.935 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.0 mt -91.8 -42.91 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.235 -0.916 . . . . 0.0 109.683 179.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 35.1 mm -119.21 61.35 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.547 -0.721 . . . . 0.0 109.484 179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.21 -80.44 1.82 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.83 -49.52 2.01 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.43 60.47 0.88 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.499 -1.0 . . . . 0.0 109.923 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 68.2 p -102.66 28.5 6.02 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.462 -0.774 . . . . 0.0 110.794 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.4 pp -121.49 155.98 58.71 Favored Pre-proline 0 N--CA 1.497 1.881 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.4 Cg_endo -73.64 122.19 7.64 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.809 1.426 . . . . 0.0 110.508 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.7 -44.28 1.51 Allowed 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.827 1.435 . . . . 0.0 110.893 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 14' ' ' VAL . 35.8 m -60.83 -34.52 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.381 -0.824 . . . . 0.0 110.17 179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 13' ' ' VAL . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.81 -32.18 71.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -110.97 54.99 0.66 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 109.679 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 28' ' ' LEU . 0.2 OUTLIER -124.16 -66.09 1.01 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.384 -0.822 . . . . 0.0 110.767 -179.596 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.453 HD13 ' HD2' ' A' ' 30' ' ' PRO . 0.2 OUTLIER -157.52 114.4 1.88 Allowed Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 -179.727 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.453 ' HD2' HD13 ' A' ' 29' ' ' LEU . 46.9 Cg_endo -72.55 86.91 0.98 Allowed 'Trans proline' 0 C--N 1.313 -1.32 0 O-C-N 123.997 1.525 . . . . 0.0 110.419 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 13.6 mtt-85 . . . . . 0 N--CA 1.502 2.13 0 CA-C-O 117.663 -1.16 . . . . 0.0 110.713 -179.903 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 N--CA 1.498 1.947 0 CA-C-O 121.072 0.463 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -106.58 96.87 6.76 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.249 -0.907 . . . . 0.0 110.107 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.82 110.75 1.72 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.557 -0.714 . . . . 0.0 110.161 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.2 pt -128.76 167.33 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.447 -0.783 . . . . 0.0 110.066 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 23.6 mt 57.24 83.17 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 CA-C-O 121.361 0.6 . . . . 0.0 110.393 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.04 79.16 1.93 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.89 -57.99 4.63 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 tp -122.43 55.1 1.16 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.36 -1.082 . . . . 0.0 110.083 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.2 p -86.98 71.74 10.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.332 -0.855 . . . . 0.0 110.242 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.02 150.35 64.87 Favored Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.42 -0.8 . . . . 0.0 110.257 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.34 129.9 15.54 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.898 1.473 . . . . 0.0 110.268 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -76.81 66.79 7.51 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.901 1.474 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.0 t -109.07 -52.69 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.533 -0.729 . . . . 0.0 109.925 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 14' ' ' VAL . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.427 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' O ' HD23 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.82 -31.74 63.37 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -111.96 46.63 1.12 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.306 -0.872 . . . . 0.0 110.971 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.658 HD23 ' O ' ' A' ' 24' ' ' PHE . 0.2 OUTLIER -116.29 -54.88 2.44 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.191 -0.943 . . . . 0.0 110.214 179.485 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.31 112.74 65.8 Favored Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.65 98.47 1.05 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.932 1.491 . . . . 0.0 110.7 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.497 1.918 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.458 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 121.111 0.481 . . . . 0.0 110.389 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 p -109.24 130.29 55.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.49 -0.757 . . . . 0.0 110.241 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.24 -96.9 0.46 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.548 -0.72 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.43 ' C ' HD12 ' A' ' 5' ' ' ILE . 5.7 tp -114.26 -25.73 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.127 -0.983 . . . . 0.0 110.874 179.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.469 HG22 ' O ' ' A' ' 5' ' ' ILE . 3.2 mp 54.88 50.94 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.487 -0.758 . . . . 0.0 110.476 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -114.13 93.4 0.65 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.08 51.1 19.82 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -156.5 36.19 0.32 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.602 -0.94 . . . . 0.0 110.379 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -143.37 -132.03 0.09 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.32 -0.863 . . . . 0.0 109.57 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -138.26 154.34 73.78 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 120.982 -1.074 . . . . 0.0 110.222 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.435 ' HG2' ' CG1' ' A' ' 14' ' ' VAL . 45.4 Cg_endo -73.53 138.21 26.55 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.959 1.505 . . . . 0.0 110.703 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.13 -37.06 5.03 Favored 'Trans proline' 0 N--CA 1.489 1.224 0 O-C-N 123.879 1.463 . . . . 0.0 111.395 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p -61.52 -36.79 75.48 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.198 -0.939 . . . . 0.0 110.599 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.435 ' CG1' ' HG2' ' A' ' 11' ' ' PRO . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 14' ' ' VAL . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.27 -46.52 83.31 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -83.18 -35.82 25.19 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -110.18 54.51 0.67 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.482 -0.761 . . . . 0.0 109.674 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.51 137.46 70.98 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.525 -0.735 . . . . 0.0 110.505 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.23 -177.19 3.34 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.975 1.513 . . . . 0.0 110.786 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 . . . . . 0 N--CA 1.499 1.992 0 O-C-N 121.341 -0.849 . . . . 0.0 110.739 179.864 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.843 0.354 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.587 HG22 ' H ' ' A' ' 3' ' ' GLU . 2.8 m 60.84 -177.88 0.11 Allowed 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.674 -0.641 . . . . 0.0 110.141 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.587 ' H ' HG22 ' A' ' 2' ' ' THR . 21.5 mt-10 52.82 68.3 0.85 Allowed 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.324 -0.86 . . . . 0.0 110.465 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.9 pt -99.68 61.55 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.343 -0.848 . . . . 0.0 110.361 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp -89.26 134.15 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.311 -0.868 . . . . 0.0 109.769 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -88.23 64.33 3.58 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.59 -48.82 1.75 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 tp -139.11 51.53 1.79 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.465 -1.021 . . . . 0.0 110.078 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.466 ' O ' ' CG1' ' A' ' 10' ' ' ILE . 8.5 m 52.08 49.04 21.5 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.638 -0.664 . . . . 0.0 110.615 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.501 ' HB ' ' HD2' ' A' ' 11' ' ' PRO . 0.5 OUTLIER 56.82 169.08 0.05 OUTLIER Pre-proline 0 N--CA 1.51 2.557 0 CA-C-O 120.976 0.417 . . . . 0.0 111.689 179.91 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.633 ' HB2' HG12 ' A' ' 13' ' ' VAL . 50.2 Cg_endo -77.14 132.57 12.77 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.528 1.278 . . . . 0.0 110.28 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 -13.01 23.74 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.703 1.37 . . . . 0.0 111.472 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.633 HG12 ' HB2' ' A' ' 11' ' ' PRO . 12.4 p -58.33 -41.42 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.217 -0.927 . . . . 0.0 111.147 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 11' ' ' PRO . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.17 -40.6 67.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -100.2 46.1 0.97 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.434 -0.791 . . . . 0.0 110.431 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 -43.66 8.38 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.6 mt -129.33 139.58 36.11 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.405 -0.809 . . . . 0.0 110.213 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.77 91.09 1.1 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.938 1.494 . . . . 0.0 110.425 179.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 118.219 -0.896 . . . . 0.0 110.208 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 120.987 0.422 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.9 t -152.05 166.34 31.91 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.469 -0.769 . . . . 0.0 110.553 -179.93 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.434 ' HG2' HD12 ' A' ' 5' ' ' ILE . 4.4 tt0 -152.96 -105.34 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.621 -0.674 . . . . 0.0 109.799 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.459 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 6.9 mt 60.24 -84.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.225 0 O-C-N 121.392 -0.817 . . . . 0.0 110.897 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 3.7 mt 64.24 118.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 121.605 -0.685 . . . . 0.0 110.767 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -77.04 73.3 1.98 Allowed Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.966 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -147.71 38.92 1.04 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.35 -0.92 14.37 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.463 -1.022 . . . . 0.0 110.941 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -114.37 26.88 9.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.269 -0.894 . . . . 0.0 109.891 179.655 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.05 130.03 9.17 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.27 -0.894 . . . . 0.0 110.138 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.479 ' O ' HG12 ' A' ' 14' ' ' VAL . 45.9 Cg_endo -72.52 174.51 11.53 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.961 1.506 . . . . 0.0 110.664 179.649 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 11' ' ' PRO . 43.0 Cg_endo -69.65 -23.29 31.44 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.532 1.28 . . . . 0.0 111.071 179.83 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.81 -52.69 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.231 -0.918 . . . . 0.0 110.245 179.83 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.493 ' O ' HG23 ' A' ' 18' ' ' VAL . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.501 ' O ' HD23 ' A' ' 28' ' ' LEU . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.09 -44.33 78.88 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.3 t-80 -109.53 46.44 1.0 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.332 -0.855 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.501 HD23 ' O ' ' A' ' 24' ' ' PHE . 0.2 OUTLIER -113.38 -42.7 3.45 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.265 -0.897 . . . . 0.0 110.829 -179.751 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.78 110.56 42.0 Favored Pre-proline 0 N--CA 1.497 1.901 0 O-C-N 121.286 -0.884 . . . . 0.0 110.639 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -75.74 161.8 36.09 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.795 1.418 . . . . 0.0 110.651 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.687 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.089 0.471 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 84.6 m -142.55 108.89 5.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.456 -0.778 . . . . 0.0 110.347 -179.949 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -158.59 47.01 0.33 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.449 -0.782 . . . . 0.0 110.477 179.757 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 mm -107.11 105.63 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.857 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.55 60.95 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.671 -0.643 . . . . 0.0 110.221 -179.893 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -143.96 -106.26 0.54 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.8 -70.6 0.23 Allowed Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.99 55.04 0.77 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.501 -0.999 . . . . 0.0 109.837 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.9 m 58.37 35.78 25.03 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.615 -0.678 . . . . 0.0 110.477 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.45 111.82 6.47 Favored Pre-proline 0 N--CA 1.499 1.99 0 O-C-N 121.252 -0.905 . . . . 0.0 110.21 179.739 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.691 ' HB2' ' HB ' ' A' ' 14' ' ' VAL . 49.0 Cg_endo -84.75 111.63 1.47 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.835 1.44 . . . . 0.0 110.776 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -83.17 -67.8 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.162 0 O-C-N 123.67 1.353 . . . . 0.0 111.629 -179.68 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t -63.62 -39.06 83.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.142 -0.974 . . . . 0.0 110.669 -179.516 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.691 ' HB ' ' HB2' ' A' ' 11' ' ' PRO . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.424 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 29' ' ' LEU . . . -60.14 -36.12 76.81 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -68.62 -33.38 73.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.458 -0.776 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.4 mp -83.76 -73.3 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.394 -0.817 . . . . 0.0 110.24 179.886 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.59 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 0.5 OUTLIER 64.3 158.28 0.12 Allowed Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.844 -0.535 . . . . 0.0 110.885 -179.994 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.59 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.8 Cg_endo -75.43 171.66 17.83 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.587 1.309 . . . . 0.0 110.83 -179.768 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mmm-85 . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.343 -179.963 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.432 ' O ' ' HB ' ' A' ' 2' ' ' THR . 33.9 t70 . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.74 0.305 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 1' ' ' ASP . 98.2 m 60.91 101.92 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.291 0.567 . . . . 0.0 110.799 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 56.45 89.05 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.734 -0.604 . . . . 0.0 110.883 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.551 HG22 HG23 ' A' ' 5' ' ' ILE . 3.1 mp -118.31 -65.91 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.337 -0.852 . . . . 0.0 110.35 -179.954 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.551 HG23 HG22 ' A' ' 4' ' ' ILE . 8.9 pt -134.41 32.31 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.174 -0.954 . . . . 0.0 111.015 -179.913 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -127.86 37.66 2.26 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.669 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.02 -50.34 3.29 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 57.7 31.71 20.81 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.714 -0.874 . . . . 0.0 110.681 -179.844 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -91.06 64.42 5.34 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.249 -0.907 . . . . 0.0 109.836 179.851 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.75 160.35 26.41 Favored Pre-proline 0 N--CA 1.498 1.943 0 O-C-N 121.451 -0.78 . . . . 0.0 110.153 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.18 114.5 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.886 1.466 . . . . 0.0 110.536 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -81.36 70.51 7.36 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.736 1.387 . . . . 0.0 110.239 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 14' ' ' VAL . 34.0 m -106.13 -41.39 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.439 -0.788 . . . . 0.0 110.396 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 14' ' ' VAL . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.44 -27.77 69.52 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 73.1 t60 -92.86 -32.98 14.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.459 -0.776 . . . . 0.0 110.796 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.57 38.43 0.98 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.294 -0.879 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.8 tp -130.42 119.87 18.67 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.555 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -72.98 167.71 26.62 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.948 1.499 . . . . 0.0 110.849 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 117.833 -1.08 . . . . 0.0 110.484 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 121.103 0.478 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.476 HG23 ' O ' ' A' ' 2' ' ' THR . 2.9 t -164.28 94.03 0.71 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.562 -0.711 . . . . 0.0 110.1 179.914 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -103.52 60.77 0.76 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.308 -0.87 . . . . 0.0 110.053 -179.578 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.5 tt -159.58 163.34 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.395 -0.816 . . . . 0.0 110.117 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -74.22 145.51 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.396 -0.815 . . . . 0.0 110.188 179.741 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' N ' HD13 ' A' ' 5' ' ' ILE . . . 117.34 -54.61 0.59 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.951 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.26 57.41 8.45 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.808 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.08 14.16 5.71 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.545 -0.974 . . . . 0.0 111.053 -179.744 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.3 m -118.05 85.13 2.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.104 -0.998 . . . . 0.0 109.733 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -106.71 158.95 31.56 Favored Pre-proline 0 N--CA 1.497 1.876 0 O-C-N 121.707 -0.621 . . . . 0.0 110.097 179.855 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HG2' HG11 ' A' ' 14' ' ' VAL . 44.6 Cg_endo -71.87 114.53 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.985 1.518 . . . . 0.0 110.751 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -77.03 -35.08 1.92 Allowed 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.828 1.436 . . . . 0.0 111.37 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t -59.81 -51.47 72.45 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.175 0 O-C-N 121.283 -0.885 . . . . 0.0 110.867 -179.285 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 18' ' ' VAL . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 14' ' ' VAL . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.65 -31.6 11.84 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -97.39 -18.9 18.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.412 -0.805 . . . . 0.0 111.342 -179.664 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.38 49.24 0.82 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.95 -1.094 . . . . 0.0 110.409 -179.802 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.4 tp -130.54 133.92 25.43 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.146 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.02 102.54 1.35 Allowed 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.785 1.413 . . . . 0.0 110.2 179.608 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.974 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.002 -179.546 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 23.5 t70 . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 120.986 0.422 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 p -127.75 38.42 4.04 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.477 -0.765 . . . . 0.0 110.078 179.722 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.17 113.44 7.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.466 -0.771 . . . . 0.0 109.939 179.679 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mp -125.79 159.42 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.85 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 37.9 mm -69.71 119.38 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.481 -0.762 . . . . 0.0 110.208 -179.905 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.03 -97.27 0.34 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.877 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.13 -33.55 6.07 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 59.11 33.63 22.93 Favored 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.519 -0.989 . . . . 0.0 110.445 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.1 p -138.0 73.99 1.46 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.436 -0.79 . . . . 0.0 109.823 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.9 pt -76.45 135.78 68.67 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.454 -0.779 . . . . 0.0 110.652 -179.842 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.62 155.83 44.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.88 1.463 . . . . 0.0 110.861 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.05 -9.42 23.47 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.979 1.515 . . . . 0.0 111.472 179.735 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t -53.42 -36.18 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.319 -0.863 . . . . 0.0 110.73 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.449 ' HA ' ' HG3' ' A' ' 30' ' ' PRO . . . -64.71 -38.83 92.32 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -29.27 68.59 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.676 -0.64 . . . . 0.0 110.564 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.7 mt -91.15 19.33 5.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.327 -0.858 . . . . 0.0 110.769 179.6 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.67 89.58 0.1 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.634 -0.666 . . . . 0.0 111.139 179.731 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.449 ' HG3' ' HA ' ' A' ' 26' ' ' ALA . 53.9 Cg_endo -81.1 48.05 2.77 Favored 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 123.933 1.491 . . . . 0.0 110.659 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 16.2 mtm-85 . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.111 -0.993 . . . . 0.0 110.349 -179.755 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.498 1.939 0 CA-C-O 120.871 0.367 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.4 p -94.23 19.4 9.43 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.102 -0.999 . . . . 0.0 110.791 179.604 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -92.63 121.55 34.16 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.167 -0.958 . . . . 0.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.3 mp -102.63 -55.9 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 110.1 -179.609 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 5' ' ' ILE . 30.3 mm -111.31 26.71 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.498 -0.752 . . . . 0.0 110.378 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.15 59.71 8.11 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.23 96.02 2.35 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -84.62 -46.11 11.85 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.537 -0.978 . . . . 0.0 110.557 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.2 p -116.15 92.43 3.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.58 -0.7 . . . . 0.0 110.348 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -91.97 133.92 29.66 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 121.429 -0.794 . . . . 0.0 110.303 179.904 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.43 152.31 49.04 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.783 1.412 . . . . 0.0 110.799 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.56 -23.04 27.62 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.925 1.487 . . . . 0.0 110.983 179.768 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t -62.77 -44.05 99.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.283 -0.885 . . . . 0.0 110.001 179.71 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 18' ' ' VAL . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 14' ' ' VAL . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.44 -37.18 86.15 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -65.15 -33.74 76.74 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.438 -0.789 . . . . 0.0 110.028 179.449 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.39 -40.3 16.62 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.498 -0.751 . . . . 0.0 110.257 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.463 HD23 ' HB3' ' A' ' 31' ' ' ARG . 0.5 OUTLIER -89.81 116.27 65.95 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.531 -0.73 . . . . 0.0 110.276 -179.854 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -71.75 80.94 1.39 Allowed 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.919 1.484 . . . . 0.0 110.758 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.463 ' HB3' HD23 ' A' ' 29' ' ' LEU . 2.8 tpp180 . . . . . 0 N--CA 1.496 1.854 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.043 0.449 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.8 t -166.44 152.25 8.51 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.519 -0.738 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -81.03 97.19 7.4 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.486 -0.759 . . . . 0.0 110.154 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.61 -42.97 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.47 -0.769 . . . . 0.0 110.119 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 20.9 mt -95.99 115.64 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.365 -0.835 . . . . 0.0 109.665 179.834 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.81 162.77 10.08 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.863 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -139.0 -90.64 0.21 Allowed Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.97 42.67 1.13 Allowed 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.442 -1.034 . . . . 0.0 110.571 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 19.6 m 62.44 106.87 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.185 0 CA-C-O 121.513 0.673 . . . . 0.0 111.065 179.639 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -69.72 159.83 82.29 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 121.434 -0.791 . . . . 0.0 110.068 179.629 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 146.13 31.12 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.855 1.45 . . . . 0.0 110.631 179.755 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -76.29 61.87 6.74 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.814 1.428 . . . . 0.0 110.517 179.687 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p -106.22 -33.57 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.287 179.808 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' VAL . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.478 ' HA ' HD12 ' A' ' 28' ' ' LEU . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.67 -43.04 73.36 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -104.23 38.57 1.83 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.449 -0.782 . . . . 0.0 110.297 179.548 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.478 HD12 ' HA ' ' A' ' 25' ' ' PHE . 0.5 OUTLIER -82.56 -35.04 27.55 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.297 -0.877 . . . . 0.0 110.373 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -62.04 151.19 81.35 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.462 -0.774 . . . . 0.0 110.687 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.25 108.79 2.69 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.855 1.45 . . . . 0.0 110.712 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 117.808 -1.091 . . . . 0.0 110.522 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.19 0.519 . . . . 0.0 110.502 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 t -87.5 177.73 7.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.41 -0.806 . . . . 0.0 110.466 179.834 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -86.56 79.35 8.96 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.495 -0.753 . . . . 0.0 110.165 179.768 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.5 tt -78.15 -26.39 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.304 -0.873 . . . . 0.0 111.218 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.0 pt -82.35 87.58 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.18 -0.95 . . . . 0.0 110.566 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 155.3 165.96 14.89 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -115.8 -96.97 2.06 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.681 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.4 mt -125.43 41.03 3.61 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.552 -0.969 . . . . 0.0 110.07 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.1 m -122.63 39.68 3.87 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.453 -0.779 . . . . 0.0 110.132 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 pt -141.84 159.61 58.93 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.38 141.79 29.08 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.918 1.483 . . . . 0.0 110.244 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.534 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . 52.1 Cg_endo -77.41 66.92 7.87 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.88 1.463 . . . . 0.0 110.695 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.5 p -70.23 -40.96 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.408 -0.808 . . . . 0.0 110.664 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' N ' HG13 ' A' ' 13' ' ' VAL . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 12' ' ' PRO . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.71 -39.82 74.55 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -108.79 19.87 19.15 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.31 -0.869 . . . . 0.0 110.677 179.65 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -156.52 44.54 0.41 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.227 -0.92 . . . . 0.0 110.283 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.59 141.28 28.5 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.283 -0.886 . . . . 0.0 110.238 179.856 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.33 160.38 42.13 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 O-C-N 123.883 1.465 . . . . 0.0 110.889 -179.784 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp85 . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.554 179.88 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.074 0.464 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.3 m -131.33 151.16 51.77 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.524 -0.735 . . . . 0.0 110.185 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -99.66 62.55 1.19 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.675 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.5 tp -154.81 149.61 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.383 -0.823 . . . . 0.0 110.43 -179.908 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 5' ' ' ILE . 0.1 OUTLIER -137.84 162.14 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.487 -0.758 . . . . 0.0 110.242 179.909 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.28 151.75 20.3 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.11 -45.75 8.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.952 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.452 HD13 ' HA ' ' A' ' 8' ' ' LEU . 2.0 mm? -116.91 31.32 6.81 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.53 -0.982 . . . . 0.0 110.112 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.3 m -114.36 64.78 0.67 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.267 -0.896 . . . . 0.0 109.927 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -75.38 154.38 85.96 Favored Pre-proline 0 N--CA 1.499 2.012 0 O-C-N 121.412 -0.805 . . . . 0.0 110.561 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.54 ' O ' HG12 ' A' ' 14' ' ' VAL . 48.7 Cg_endo -75.76 144.62 28.03 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.924 1.486 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.78 -19.87 17.98 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.911 1.48 . . . . 0.0 111.077 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -58.92 -42.24 85.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -179.709 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.54 HG12 ' O ' ' A' ' 11' ' ' PRO . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.492 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' MET . . . . . 0.492 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.06 -37.04 72.5 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -73.35 -27.29 61.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.407 -0.808 . . . . 0.0 110.707 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.5 47.51 0.89 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.315 -0.866 . . . . 0.0 110.269 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.2 tp -94.27 119.17 66.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.355 -0.84 . . . . 0.0 110.316 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.43 62.91 7.11 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.871 1.459 . . . . 0.0 110.409 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.2 ttm180 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.338 -0.851 . . . . 0.0 110.648 -179.869 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.496 1.86 0 CA-C-O 120.835 0.35 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.425 HG22 ' H ' ' A' ' 3' ' ' GLU . 6.2 m 61.57 172.81 0.12 Allowed 'General case' 0 N--CA 1.505 2.313 0 CA-C-O 121.312 0.577 . . . . 0.0 110.812 179.894 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.425 ' H ' HG22 ' A' ' 2' ' ' THR . 16.0 mt-10 -81.37 89.57 6.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.813 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.634 ' O ' HD13 ' A' ' 4' ' ' ILE . 0.2 OUTLIER -116.25 -33.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.371 -0.831 . . . . 0.0 110.986 -179.416 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.632 HG13 HG23 ' A' ' 4' ' ' ILE . 7.3 mt -101.72 114.75 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.948 -1.095 . . . . 0.0 110.123 179.944 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.63 64.38 0.11 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.949 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.4 -96.06 0.11 Allowed Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.4 -81.39 0.06 Allowed 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.598 -0.942 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.504 ' O ' ' HB ' ' A' ' 10' ' ' ILE . 8.0 p -143.46 53.38 1.33 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.007 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 9' ' ' THR . 14.3 mt 66.84 139.96 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.311 0 O-C-N 122.052 -0.405 . . . . 0.0 110.756 -179.871 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -79.48 166.89 21.69 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.742 1.391 . . . . 0.0 110.671 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.04 -30.95 38.1 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.967 1.509 . . . . 0.0 110.837 179.955 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t -65.93 -50.59 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.357 -0.839 . . . . 0.0 109.348 179.349 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.66 -36.18 75.82 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -76.06 -22.89 55.16 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.461 -0.774 . . . . 0.0 110.734 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.468 ' HA ' HD13 ' A' ' 28' ' ' LEU . 2.8 mm? -92.92 52.66 1.87 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.338 -0.851 . . . . 0.0 109.923 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.9 mt -63.55 140.59 97.79 Favored Pre-proline 0 N--CA 1.498 1.968 0 O-C-N 121.573 -0.705 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.77 160.31 43.87 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.95 1.5 . . . . 0.0 110.614 179.684 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.902 0 CA-C-O 117.86 -1.067 . . . . 0.0 110.751 -179.993 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.041 0.448 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 t -152.22 135.16 15.62 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.462 -0.774 . . . . 0.0 110.355 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.72 105.57 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 -179.979 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.467 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 41.9 mm -68.0 -43.2 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.742 . . . . 0.0 110.034 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.467 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 47.1 mt 64.04 116.74 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 CA-C-O 121.5 0.667 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.17 -79.39 1.32 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.36 -51.71 2.5 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.196 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 9' ' ' THR . 0.8 OUTLIER -162.33 -61.13 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 109.595 179.458 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 8' ' ' LEU . 1.1 p -153.28 142.59 21.57 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.799 -0.563 . . . . 0.0 109.865 179.754 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.31 121.04 7.63 Favored Pre-proline 0 N--CA 1.495 1.813 0 O-C-N 121.463 -0.773 . . . . 0.0 110.092 179.838 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.601 ' O ' HG22 ' A' ' 14' ' ' VAL . 49.8 Cg_endo -82.44 157.66 16.86 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.734 1.386 . . . . 0.0 110.746 -179.622 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.56 -16.91 23.91 Favored 'Trans proline' 0 N--CA 1.49 1.288 0 O-C-N 123.947 1.498 . . . . 0.0 110.993 179.518 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 17' ' ' VAL . 90.9 t -57.93 -33.3 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.418 -0.801 . . . . 0.0 110.608 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 11' ' ' PRO . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' VAL . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 14' ' ' VAL . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.55 -35.15 75.32 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -84.27 -28.78 26.94 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.5 -0.75 . . . . 0.0 110.285 179.52 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 9.7 mt -94.0 50.79 1.44 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.437 -0.789 . . . . 0.0 110.117 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -79.16 148.42 71.22 Favored Pre-proline 0 N--CA 1.498 1.926 0 O-C-N 121.475 -0.766 . . . . 0.0 110.566 -179.999 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.7 -171.89 1.17 Allowed 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.98 1.516 . . . . 0.0 110.664 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 10.7 mtm105 . . . . . 0 N--CA 1.498 1.943 0 CA-C-O 118.247 -0.883 . . . . 0.0 110.26 179.804 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.019 0.438 . . . . 0.0 110.324 . . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.2 t -113.77 168.26 9.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.54 -0.725 . . . . 0.0 110.039 179.703 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 49.85 70.78 0.46 Allowed 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.709 -0.619 . . . . 0.0 110.532 -179.844 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.422 HG23 ' N ' ' A' ' 5' ' ' ILE . 13.6 tt -58.05 -39.67 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.379 -0.826 . . . . 0.0 111.002 -179.547 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.422 ' N ' HG23 ' A' ' 4' ' ' ILE . 45.0 mm 46.05 60.05 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.527 -0.733 . . . . 0.0 110.215 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 106.28 -67.59 0.24 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.589 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.6 73.79 0.84 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -158.88 45.49 0.28 Allowed 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.504 -0.998 . . . . 0.0 110.723 179.94 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.6 m -92.4 73.95 5.24 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.254 -0.904 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.0 pt -139.89 142.21 30.07 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.463 -0.773 . . . . 0.0 110.36 -179.912 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.564 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.3 Cg_endo -73.88 129.63 13.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.918 1.483 . . . . 0.0 110.543 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.37 -43.29 0.71 Allowed 'Trans proline' 0 N--CA 1.489 1.215 0 O-C-N 123.888 1.467 . . . . 0.0 111.203 -179.641 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t -62.63 -46.58 96.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.394 -0.816 . . . . 0.0 109.925 -179.948 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.564 ' HB ' ' HG2' ' A' ' 11' ' ' PRO . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.29 -33.81 75.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.6 m80 -80.46 -35.19 35.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.438 -0.789 . . . . 0.0 110.153 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 mp -59.74 -35.11 73.9 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.456 -0.778 . . . . 0.0 110.767 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.438 HD22 ' HA ' ' A' ' 29' ' ' LEU . 0.3 OUTLIER -69.0 114.15 21.26 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.383 -0.823 . . . . 0.0 109.919 179.784 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.77 159.8 49.74 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.963 1.507 . . . . 0.0 110.771 -179.703 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 mtt85 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.087 179.863 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.086 0.47 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.428 HG22 HG23 ' A' ' 4' ' ' ILE . 8.6 m -100.74 105.82 17.18 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 0.0 109.966 179.94 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -82.24 91.81 6.81 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.522 -0.737 . . . . 0.0 110.23 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.428 HG23 HG22 ' A' ' 2' ' ' THR . 2.4 pt -98.8 82.12 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.463 -0.773 . . . . 0.0 110.375 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.6 tt -120.23 18.92 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.325 -0.859 . . . . 0.0 110.733 -179.975 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.37 68.8 3.38 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.848 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.44 71.76 0.26 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 37.7 mt -105.0 14.59 29.12 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.521 -0.988 . . . . 0.0 110.97 -179.681 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.8 m -93.67 65.11 3.62 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.174 -0.954 . . . . 0.0 109.676 179.624 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pp -109.98 159.75 30.7 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.394 -0.816 . . . . 0.0 110.166 -179.945 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.14 113.46 3.79 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.861 1.453 . . . . 0.0 110.894 -179.624 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.39 -39.32 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 O-C-N 123.784 1.413 . . . . 0.0 110.787 179.708 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m -64.97 -36.48 77.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.744 -179.774 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.67 -40.15 96.1 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -88.21 2.02 53.15 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.532 -0.73 . . . . 0.0 111.034 179.731 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -77.59 -58.29 3.35 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.059 -1.026 . . . . 0.0 110.245 179.872 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.2 mp 63.76 160.17 0.12 Allowed Pre-proline 0 N--CA 1.504 2.246 0 O-C-N 121.89 -0.506 . . . . 0.0 111.055 179.903 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.41 81.15 2.35 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.641 1.337 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 118.291 -0.861 . . . . 0.0 110.438 179.814 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 120.958 0.408 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -82.11 171.59 14.17 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.389 -0.82 . . . . 0.0 110.358 179.975 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 54.03 66.8 1.13 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.662 -0.649 . . . . 0.0 110.688 -179.912 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' C ' ' A' ' 5' ' ' ILE . 6.4 mt -92.09 -41.38 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.405 -0.81 . . . . 0.0 110.086 179.789 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.416 HG23 ' O ' ' A' ' 5' ' ' ILE . 8.7 tt 31.39 73.73 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.384 0 CA-C-O 121.821 0.82 . . . . 0.0 111.847 179.902 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -126.24 127.21 6.0 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.13 67.41 0.04 OUTLIER Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.878 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -165.85 43.74 0.07 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.546 -0.973 . . . . 0.0 109.989 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.4 t -160.26 -148.5 0.17 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 110.156 -179.616 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.782 HG13 HG13 ' A' ' 13' ' ' VAL . 26.8 pt -131.14 148.43 70.19 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.277 -0.889 . . . . 0.0 110.089 179.853 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.646 ' N ' ' HD2' ' A' ' 12' ' ' PRO . 45.1 Cg_endo -70.93 -26.87 21.57 Favored 'Trans proline' 0 CA--C 1.556 1.624 0 O-C-N 123.932 1.491 . . . . 0.0 114.841 -179.156 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 11' ' ' PRO . 40.7 Cg_endo -65.8 -24.21 54.57 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 119.166 0.738 . . . . 0.0 112.754 -178.437 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.782 HG13 HG13 ' A' ' 10' ' ' ILE . 35.9 m -60.24 -38.26 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 O-C-N 120.771 -1.206 . . . . 0.0 110.615 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -77.86 -22.37 49.94 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -95.24 -33.02 12.74 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.334 -0.854 . . . . 0.0 110.731 -179.771 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.73 30.68 1.01 Allowed 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.271 -0.893 . . . . 0.0 110.764 -179.792 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.5 tp -132.8 125.95 19.58 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.26 -0.9 . . . . 0.0 109.945 179.743 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.79 74.99 4.2 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 O-C-N 123.929 1.489 . . . . 0.0 110.358 -179.872 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 2.7 ttm105 . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.844 -179.712 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 21.8 t70 . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.843 0.354 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 54.6 p 35.58 64.01 0.5 Allowed 'General case' 0 N--CA 1.507 2.393 0 CA-C-O 121.298 0.571 . . . . 0.0 111.451 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.81 -85.42 0.08 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.347 -0.846 . . . . 0.0 110.386 179.995 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 pt -124.45 42.97 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.297 -0.877 . . . . 0.0 110.422 179.987 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.616 ' C ' HD13 ' A' ' 5' ' ' ILE . 0.0 OUTLIER -69.5 117.62 12.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.375 -0.828 . . . . 0.0 109.44 179.691 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.98 -68.65 3.46 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.085 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.93 -63.44 0.61 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.75 32.26 6.22 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.618 -0.931 . . . . 0.0 110.212 179.857 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 p -130.6 59.74 1.65 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.381 -0.825 . . . . 0.0 109.981 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.24 99.12 17.87 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.921 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.743 ' O ' HG22 ' A' ' 14' ' ' VAL . 47.3 Cg_endo -81.21 157.9 20.06 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 O-C-N 123.841 1.442 . . . . 0.0 110.577 -179.799 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.96 -20.45 25.61 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.774 1.407 . . . . 0.0 111.115 179.757 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p -60.12 -33.29 52.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.341 -0.849 . . . . 0.0 111.069 -179.762 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 11' ' ' PRO . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.516 ' O ' HD13 ' A' ' 16' ' ' LEU . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.45 ' HA ' ' NE2' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.47 -35.98 61.13 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.45 ' NE2' ' HA ' ' A' ' 24' ' ' PHE . 31.5 p80 -117.74 21.77 12.73 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.404 -0.81 . . . . 0.0 110.558 179.468 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -108.28 -40.13 5.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.288 -0.883 . . . . 0.0 110.474 179.942 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 8.6 tp -83.76 124.17 75.31 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.316 -0.865 . . . . 0.0 110.28 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -75.39 80.48 2.51 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 O-C-N 123.92 1.484 . . . . 0.0 110.263 179.944 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 30.8 mtp85 . . . . . 0 N--CA 1.502 2.148 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.837 -179.661 . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 121.115 0.483 . . . . 0.0 110.517 . . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.7 m -77.51 136.23 38.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.525 -0.735 . . . . 0.0 109.845 179.829 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -125.31 101.31 6.91 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.643 -0.661 . . . . 0.0 110.279 -179.867 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.655 ' O ' HD13 ' A' ' 4' ' ' ILE . 0.1 OUTLIER -80.42 -26.88 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.445 -0.784 . . . . 0.0 110.42 179.929 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG12 ' CG2' ' A' ' 4' ' ' ILE . 43.8 mm -105.17 55.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.264 -0.898 . . . . 0.0 109.655 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.49 -63.47 0.73 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.892 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.7 -40.3 2.73 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 179.97 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 65.87 16.47 10.49 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.644 -0.915 . . . . 0.0 110.999 -179.516 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.0 m -148.46 23.8 1.01 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.239 -0.913 . . . . 0.0 110.198 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.563 ' HB ' HG11 ' A' ' 14' ' ' VAL . 2.9 pt -145.64 139.75 15.12 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.16 -0.963 . . . . 0.0 110.182 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.655 ' O ' HG12 ' A' ' 14' ' ' VAL . 43.9 Cg_endo -71.8 168.34 24.07 Favored 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.791 1.416 . . . . 0.0 110.704 -179.854 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.87 -30.24 17.42 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.668 1.352 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.64 -33.52 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.287 -0.883 . . . . 0.0 110.886 -179.853 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.655 HG12 ' O ' ' A' ' 11' ' ' PRO . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.14 89.99 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -84.07 -42.22 16.34 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.407 -0.808 . . . . 0.0 110.154 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.411 HD13 ' HA ' ' A' ' 28' ' ' LEU . 3.3 mm? -63.36 -38.68 92.08 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.532 -0.73 . . . . 0.0 110.419 179.807 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.9 tp -115.12 87.48 15.77 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.416 -0.802 . . . . 0.0 110.031 179.788 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.95 100.39 1.08 Allowed 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 124.048 1.552 . . . . 0.0 110.659 -179.998 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 117.821 -1.085 . . . . 0.0 110.425 -179.995 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 17.7 t70 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 121.159 0.504 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 35.3 m -124.75 157.37 35.87 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.51 -0.744 . . . . 0.0 110.098 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.45 89.28 7.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.457 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 42.4 mt 51.31 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.749 -0.594 . . . . 0.0 110.513 179.674 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.46 HD11 ' HB3' ' A' ' 12' ' ' PRO . 34.3 mm 64.55 121.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.378 0 CA-C-O 121.48 0.657 . . . . 0.0 110.894 179.823 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.69 -52.96 0.83 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.827 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.92 -32.65 81.6 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.806 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 57.96 29.83 18.25 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.502 -0.999 . . . . 0.0 111.279 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 9' ' ' THR . 25.6 m -128.65 19.23 6.19 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.15 -0.969 . . . . 0.0 110.401 179.573 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -143.2 151.67 55.91 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.2 -0.938 . . . . 0.0 110.231 179.808 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.78 122.97 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.938 1.494 . . . . 0.0 110.362 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.46 ' HB3' HD11 ' A' ' 5' ' ' ILE . 44.6 Cg_endo -71.95 -43.05 1.33 Allowed 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 123.868 1.457 . . . . 0.0 111.187 -179.659 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t -65.83 -47.82 84.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.331 -0.856 . . . . 0.0 110.008 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.21 -35.97 82.53 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -71.94 -32.3 67.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.411 -0.806 . . . . 0.0 110.504 179.691 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.6 mt -87.16 -48.3 8.16 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 5.9 tp -93.44 114.74 63.72 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.403 -0.81 . . . . 0.0 110.122 179.97 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.78 83.87 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.227 0 O-C-N 123.969 1.51 . . . . 0.0 110.57 179.985 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.216 -179.817 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.048 0.452 . . . . 0.0 110.101 . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 p -70.13 107.77 3.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 -179.918 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 4' ' ' ILE . 0.5 OUTLIER -121.64 100.83 7.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.561 -0.712 . . . . 0.0 109.941 -179.833 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.406 ' C ' ' O ' ' A' ' 3' ' ' GLU . 23.2 pt 32.87 58.6 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.576 0 CA-C-O 121.221 0.534 . . . . 0.0 111.887 -179.51 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 24.4 mt 56.74 50.43 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-O 121.443 0.64 . . . . 0.0 110.304 179.891 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -96.19 114.91 5.05 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.982 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.1 -76.6 1.24 Allowed Glycine 0 N--CA 1.497 2.711 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.753 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 8' ' ' LEU . 0.2 OUTLIER -148.68 70.97 1.13 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.333 -1.098 . . . . 0.0 109.819 -179.758 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.1 p -79.97 95.48 6.14 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.39 -0.819 . . . . 0.0 110.461 -179.734 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.6 pt -130.7 152.64 80.82 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.519 -0.738 . . . . 0.0 110.137 179.705 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.08 114.89 4.01 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.94 1.495 . . . . 0.0 110.895 -179.745 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.02 -38.51 2.17 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.828 1.436 . . . . 0.0 110.852 179.774 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.35 -43.36 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.422 -0.799 . . . . 0.0 110.28 -179.991 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.45 -30.8 71.87 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -99.52 -6.61 27.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.32 -0.862 . . . . 0.0 111.092 179.807 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.1 mt -104.19 -63.41 1.2 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 179.885 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.481 HD23 ' HD2' ' A' ' 30' ' ' PRO . 0.1 OUTLIER 61.44 171.06 0.08 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.839 -0.538 . . . . 0.0 111.022 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.481 ' HD2' HD23 ' A' ' 29' ' ' LEU . 44.7 Cg_endo -71.69 113.66 3.71 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.597 1.314 . . . . 0.0 110.596 -179.813 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.9 mtt85 . . . . . 0 N--CA 1.496 1.873 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.348 -179.989 . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.148 0.499 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 30.0 m -132.88 139.87 47.62 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.385 -0.822 . . . . 0.0 110.497 -179.756 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 54.62 31.88 16.01 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.781 -0.574 . . . . 0.0 111.565 179.527 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 47.3 mt 56.62 96.87 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.581 -0.699 . . . . 0.0 110.815 179.675 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.9 tt -62.23 -24.17 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.45 -0.781 . . . . 0.0 110.779 179.599 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -90.83 69.73 2.16 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.591 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.95 -53.21 2.9 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.965 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 tp -163.95 78.27 0.39 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.525 -0.985 . . . . 0.0 109.895 179.902 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 p -74.46 110.68 8.94 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.306 -0.871 . . . . 0.0 109.813 179.967 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -52.42 112.22 3.2 Favored Pre-proline 0 N--CA 1.503 2.178 0 O-C-N 121.916 -0.49 . . . . 0.0 110.999 -179.536 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.449 ' HB2' HG23 ' A' ' 13' ' ' VAL . 50.4 Cg_endo -81.21 140.97 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.679 1.357 . . . . 0.0 110.787 -179.76 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.22 61.28 6.55 Favored 'Trans proline' 0 C--N 1.316 -1.174 0 O-C-N 123.911 1.48 . . . . 0.0 110.541 179.57 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 11' ' ' PRO . 87.0 t -106.07 -45.83 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.848 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 14' ' ' VAL . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.401 ' HA ' HD12 ' A' ' 28' ' ' LEU . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.7 -30.46 70.71 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.8 m80 -80.78 -7.27 59.34 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.476 -0.765 . . . . 0.0 110.854 179.634 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 25' ' ' PHE . 17.0 mt -91.79 47.55 1.37 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.149 179.772 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.1 pp -96.42 162.22 24.24 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.452 -0.78 . . . . 0.0 110.481 179.984 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.16 128.22 11.98 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.806 1.424 . . . . 0.0 110.549 179.811 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.853 0 CA-C-O 117.856 -1.069 . . . . 0.0 110.414 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.873 0.368 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.07 0 CA-C-O 120.588 0.232 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.444 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t . . . . . 0 N--CA 1.498 1.932 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 17' ' ' VAL . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p . . . . . 0 N--CA 1.499 1.993 0 CA-C-O 120.925 0.393 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.408 HG13 ' N ' ' A' ' 14' ' ' VAL . 10.6 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.65 0.262 . . . . 0.0 110.891 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 13' ' ' VAL . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.44 HD13 ' HA ' ' A' ' 16' ' ' LEU . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.739 0.304 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.499 1.985 0 CA-C-O 120.702 0.286 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.485 HD22 ' HA ' ' A' ' 16' ' ' LEU . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 120.649 0.261 . . . . 0.0 110.868 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.473 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 14' ' ' VAL . 28.7 m . . . . . 0 N--CA 1.5 2.066 0 CA-C-O 120.884 0.373 . . . . 0.0 110.443 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.433 ' N ' HG23 ' A' ' 13' ' ' VAL . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.5 2.051 0 CA-C-O 120.796 0.332 . . . . 0.0 110.623 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 14' ' ' VAL . 11.9 p . . . . . 0 N--CA 1.5 2.059 0 CA-C-O 120.575 0.226 . . . . 0.0 111.015 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 18' ' ' VAL . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 14' ' ' VAL . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . 0.4 ' HG3' ' N ' ' A' ' 20' ' ' SER . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' A' ' 19' ' ' MET . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t . . . . . 0 N--CA 1.498 1.929 0 CA-C-O 120.991 0.424 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 17' ' ' VAL . 79.0 t . . . . . 0 N--CA 1.499 2.012 0 CA-C-O 120.716 0.294 . . . . 0.0 110.325 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 13' ' ' VAL . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 14' ' ' VAL . 13.2 p . . . . . 0 N--CA 1.501 2.084 0 CA-C-O 120.547 0.213 . . . . 0.0 111.369 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 13' ' ' VAL . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t . . . . . 0 N--CA 1.5 2.033 0 CA-C-O 120.852 0.358 . . . . 0.0 110.227 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.543 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.543 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t . . . . . 0 N--CA 1.499 1.99 0 CA-C-O 120.822 0.344 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 14' ' ' VAL . 35.8 m . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.932 0.396 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 13' ' ' VAL . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.0 t . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 121.036 0.446 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 14' ' ' VAL . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.427 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 N--CA 1.5 2.032 0 CA-C-O 120.807 0.336 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' O ' HG23 ' A' ' 18' ' ' VAL . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 14' ' ' VAL . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.44 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.4 p . . . . . 0 N--CA 1.501 2.101 0 CA-C-O 120.531 0.205 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.44 ' N ' HG13 ' A' ' 13' ' ' VAL . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t . . . . . 0 N--CA 1.498 1.955 0 CA-C-O 120.773 0.32 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.493 ' O ' HG23 ' A' ' 18' ' ' VAL . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t . . . . . 0 N--CA 1.501 2.081 0 CA-C-O 120.672 0.273 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.424 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 14' ' ' VAL . 34.0 m . . . . . 0 N--CA 1.499 1.976 0 CA-C-O 120.749 0.309 . . . . 0.0 110.396 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 14' ' ' VAL . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t . . . . . 0 N--CA 1.503 2.175 0 CA-C-O 120.742 0.306 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 18' ' ' VAL . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 14' ' ' VAL . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t . . . . . 0 N--CA 1.5 2.067 0 CA-C-O 120.602 0.239 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 120.902 0.382 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 18' ' ' VAL . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 14' ' ' VAL . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 120.906 0.384 . . . . 0.0 110.287 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' VAL . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.5 p . . . . . 0 N--CA 1.5 2.055 0 CA-C-O 120.78 0.324 . . . . 0.0 110.664 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' N ' HG13 ' A' ' 13' ' ' VAL . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t . . . . . 0 N--CA 1.5 2.073 0 CA-C-O 120.541 0.21 . . . . 0.0 110.691 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.492 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . 0.492 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t . . . . . 0 N--CA 1.497 1.904 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 17' ' ' VAL . 90.9 t . . . . . 0 N--CA 1.501 2.09 0 CA-C-O 120.581 0.229 . . . . 0.0 110.608 . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 18' ' ' VAL . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' VAL . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 14' ' ' VAL . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t . . . . . 0 N--CA 1.499 2.011 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 18' ' ' VAL . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.5 2.047 0 CA-C-O 120.638 0.256 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.505 2.282 0 CA-C-O 120.823 0.344 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.499 1.988 0 CA-C-O 120.559 0.218 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.52 ' O ' HG23 ' A' ' 18' ' ' VAL . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.516 ' O ' HD13 ' A' ' 16' ' ' LEU . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 120.508 0.194 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 120.975 0.417 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 120.709 0.29 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 87.0 t . . . . . 0 N--CA 1.495 1.792 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 14' ' ' VAL . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 . . . . . 0 N--CA 1.496 1.834 0 CA-C-O 121.247 0.546 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -148.16 87.76 1.62 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.451 -0.781 . . . . 0.0 110.17 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -87.04 -48.95 7.66 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.396 -0.815 . . . . 0.0 110.082 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 64.0 mt -108.48 -42.04 5.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.764 -0.585 . . . . 0.0 109.959 179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG23 HD23 ' A' ' 8' ' ' LEU . 2.8 mp -88.5 125.2 41.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.374 -0.829 . . . . 0.0 109.894 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -106.88 -68.42 0.68 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.799 -1.321 . . . . 0.0 109.799 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.26 78.59 0.16 Allowed Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 HG23 ' A' ' 5' ' ' ILE . 1.0 OUTLIER -92.91 11.94 25.52 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.497 -1.002 . . . . 0.0 111.078 179.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.5 m -95.17 64.33 2.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.213 -0.93 . . . . 0.0 109.694 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.526 HG12 HG11 ' A' ' 14' ' ' VAL . 0.1 OUTLIER -121.4 158.94 52.16 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.367 -0.833 . . . . 0.0 109.957 -179.871 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.519 ' HD2' HG12 ' A' ' 10' ' ' ILE . 45.7 Cg_endo -78.03 166.43 24.9 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.942 1.496 . . . . 0.0 110.854 -179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.4 -28.7 38.86 Favored 'Trans proline' 0 N--CA 1.49 1.277 0 O-C-N 123.853 1.449 . . . . 0.0 111.031 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.5 p -67.44 -36.83 77.61 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.362 -0.836 . . . . 0.0 110.103 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.526 HG11 HG12 ' A' ' 10' ' ' ILE . 44.4 t -72.51 -48.14 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.425 -0.797 . . . . 0.0 109.448 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.04 -36.84 78.17 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.66 -0.65 . . . . 0.0 110.027 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.51 -41.13 96.6 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.592 -0.693 . . . . 0.0 110.134 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.0 -30.2 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.427 -0.796 . . . . 0.0 110.213 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.9 t -75.36 -40.62 42.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.244 -0.91 . . . . 0.0 109.923 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.7 tpt -64.2 -45.98 85.9 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.468 -0.77 . . . . 0.0 110.522 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 p -62.55 -39.02 92.28 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.506 -0.746 . . . . 0.0 110.497 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 66.6 ttp85 -62.24 -41.73 98.68 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.421 -0.799 . . . . 0.0 110.122 179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 53.1 t80 -61.59 -48.36 81.3 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.556 -0.715 . . . . 0.0 109.886 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.04 -31.98 82.67 Favored Glycine 0 N--CA 1.497 2.718 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -58.73 -57.13 14.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.516 -0.991 . . . . 0.0 110.24 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.23 -34.58 76.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.515 -0.741 . . . . 0.0 110.491 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.69 -40.93 98.03 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.357 -0.839 . . . . 0.0 110.148 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -82.34 -42.01 19.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.58 -0.7 . . . . 0.0 110.418 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.472 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 3.4 mm? -67.36 -46.23 73.96 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.472 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.9 OUTLIER 61.7 169.96 0.08 OUTLIER Pre-proline 0 N--CA 1.501 2.089 0 O-C-N 122.068 -0.395 . . . . 0.0 110.924 -179.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.434 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 46.0 Cg_endo -73.72 75.32 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.655 1.344 . . . . 0.0 110.152 179.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.228 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 . . . . . 0 N--CA 1.498 1.969 0 CA-C-O 120.705 0.288 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.9 m -120.51 139.94 52.16 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.035 -1.041 . . . . 0.0 110.131 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 53.57 75.2 0.27 Allowed 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 121.372 0.606 . . . . 0.0 110.48 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.2 tt -148.77 155.64 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.361 -0.837 . . . . 0.0 110.074 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 mt -92.55 -87.08 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.278 -0.889 . . . . 0.0 109.926 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -111.66 -61.62 0.47 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.26 -72.04 0.27 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.261 -1.535 . . . . 0.0 109.261 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.49 74.84 0.43 Allowed 'General case' 0 N--CA 1.499 2.004 0 O-C-N 121.901 -0.764 . . . . 0.0 110.296 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 17.6 p -82.72 57.82 3.97 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.451 -0.78 . . . . 0.0 110.207 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 tp -76.82 135.32 67.78 Favored Pre-proline 0 N--CA 1.498 1.947 0 O-C-N 121.341 -0.849 . . . . 0.0 110.364 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.583 ' O ' HG12 ' A' ' 14' ' ' VAL . 51.0 Cg_endo -81.53 131.19 7.28 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.836 1.44 . . . . 0.0 110.81 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.97 -21.75 18.03 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.761 1.4 . . . . 0.0 111.219 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -62.11 -46.33 96.71 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.241 -0.912 . . . . 0.0 110.867 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.583 HG12 ' O ' ' A' ' 11' ' ' PRO . 9.9 p -59.52 -35.23 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.131 0 O-C-N 121.32 -0.863 . . . . 0.0 110.431 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.51 -36.57 63.21 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.415 -0.803 . . . . 0.0 109.633 178.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -67.32 -39.44 85.86 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.564 -0.71 . . . . 0.0 109.959 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.444 ' O ' ' HD3' ' A' ' 21' ' ' ARG . 44.6 t -61.38 -47.37 93.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.618 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.2 t -58.03 -38.4 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.595 -0.691 . . . . 0.0 109.874 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 mtm -63.76 -41.26 98.02 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.494 -0.754 . . . . 0.0 110.215 179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.1 t -61.59 -45.26 94.85 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.418 -0.801 . . . . 0.0 110.026 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 0.5 OUTLIER -62.52 -38.53 90.33 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.532 -0.73 . . . . 0.0 109.828 179.395 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -60.87 -42.09 97.19 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.615 -0.678 . . . . 0.0 110.057 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.74 -39.54 97.58 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -69.97 -44.93 68.46 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.507 -0.996 . . . . 0.0 109.78 179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.446 ' CE2' HD11 ' A' ' 29' ' ' LEU . 13.4 t80 -59.59 -29.05 67.69 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.708 -0.62 . . . . 0.0 110.599 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.07 -31.0 66.64 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.435 -0.791 . . . . 0.0 110.53 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -106.28 22.1 16.3 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.511 -0.743 . . . . 0.0 110.582 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.505 ' HB3' HD13 ' A' ' 29' ' ' LEU . 0.6 OUTLIER -95.8 -33.79 12.13 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.305 -0.872 . . . . 0.0 110.208 179.656 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.789 HD13 ' N ' ' A' ' 29' ' ' LEU . 0.0 OUTLIER -133.22 158.81 74.82 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.423 -0.798 . . . . 0.0 110.421 179.198 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.416 ' O ' ' HB2' ' A' ' 31' ' ' ARG . 51.3 Cg_endo -86.34 19.0 1.46 Allowed 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.827 1.436 . . . . 0.0 111.553 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 30' ' ' PRO . 15.2 mtt85 . . . . . 0 N--CA 1.504 2.263 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.749 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 N--CA 1.495 1.822 0 CA-C-O 120.941 0.4 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.2 m 56.4 54.63 7.37 Favored 'General case' 0 N--CA 1.501 2.085 0 CA-C-O 121.423 0.63 . . . . 0.0 110.138 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -88.65 116.67 27.06 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.3 -0.875 . . . . 0.0 110.236 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 pt -89.83 64.1 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.51 -0.744 . . . . 0.0 110.447 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.2 pp -87.56 129.71 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.331 -0.855 . . . . 0.0 110.331 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.84 111.5 4.01 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.8 -95.55 1.08 Allowed Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.09 27.79 9.03 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.527 -0.984 . . . . 0.0 110.794 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.2 m -127.02 56.37 1.52 Allowed 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.24 -0.913 . . . . 0.0 109.853 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.438 HG13 ' HD2' ' A' ' 11' ' ' PRO . 8.1 tt -143.64 134.01 12.13 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.408 -0.807 . . . . 0.0 110.163 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.438 ' HD2' HG13 ' A' ' 10' ' ' ILE . 51.0 Cg_endo -81.81 114.95 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 O-C-N 123.848 1.446 . . . . 0.0 111.019 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.09 -38.83 1.95 Allowed 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.804 1.423 . . . . 0.0 110.754 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 79.0 t -66.23 -42.8 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.41 -0.806 . . . . 0.0 110.21 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 76.3 t -58.97 -36.27 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.044 0 O-C-N 121.443 -0.786 . . . . 0.0 110.132 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.25 -40.43 71.03 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.261 -0.899 . . . . 0.0 110.031 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -75.35 -36.56 60.97 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.465 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 14' ' ' VAL . 0.5 OUTLIER -66.72 -14.15 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.426 -0.796 . . . . 0.0 110.795 179.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -100.18 -44.0 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.252 -0.905 . . . . 0.0 109.76 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 52.6 ttp -61.85 -50.29 72.84 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.518 -0.738 . . . . 0.0 110.559 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.3 t -68.11 -40.98 82.42 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.377 -0.827 . . . . 0.0 110.246 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 17' ' ' VAL . 27.7 ttp85 -63.14 -35.6 80.81 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.53 -0.731 . . . . 0.0 110.566 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -56.44 -43.57 79.61 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.371 -0.831 . . . . 0.0 109.865 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.81 -34.43 27.61 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.441 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.2 OUTLIER -66.42 -45.23 80.61 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.388 -1.066 . . . . 0.0 110.634 179.88 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -50.63 -33.73 23.45 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.669 -0.644 . . . . 0.0 111.083 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.14 -34.13 69.92 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.507 -0.745 . . . . 0.0 110.774 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.2 m-70 -129.2 30.97 4.94 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.311 -0.868 . . . . 0.0 110.573 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.441 ' HB2' ' O ' ' A' ' 24' ' ' PHE . 5.0 tp -101.55 -34.8 9.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.29 -0.881 . . . . 0.0 110.647 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -120.05 80.23 26.6 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.286 -0.884 . . . . 0.0 110.752 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.94 59.05 6.32 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.775 1.408 . . . . 0.0 110.454 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.494 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.121 0.486 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -136.46 107.25 6.61 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.425 -0.797 . . . . 0.0 110.319 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -122.38 24.62 9.26 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.537 -0.727 . . . . 0.0 110.781 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.452 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 30.3 mt -110.74 77.51 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.109 -0.994 . . . . 0.0 109.369 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 32.7 mt 65.19 161.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 CA-C-O 121.28 0.562 . . . . 0.0 110.429 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -66.55 -69.54 1.33 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.51 38.64 2.82 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt 51.67 37.77 20.97 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.79 -0.829 . . . . 0.0 110.71 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.2 m 56.96 86.17 0.07 Allowed 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.481 0.658 . . . . 0.0 110.438 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.2 pt -70.54 158.84 86.87 Favored Pre-proline 0 N--CA 1.499 1.976 0 O-C-N 121.4 -0.812 . . . . 0.0 110.581 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.32 122.05 8.33 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 O-C-N 123.857 1.451 . . . . 0.0 110.772 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.32 -34.74 12.2 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.881 1.464 . . . . 0.0 110.762 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.5 p -62.77 -34.24 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.389 -0.82 . . . . 0.0 110.422 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.7 -44.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.322 -0.861 . . . . 0.0 109.533 179.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.22 -35.77 79.92 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.588 -0.695 . . . . 0.0 110.291 179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.3 tp -67.87 -41.55 82.67 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.45 -0.781 . . . . 0.0 110.367 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.7 t -62.85 -22.91 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.316 -0.865 . . . . 0.0 110.424 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -96.42 -38.01 7.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.169 -0.957 . . . . 0.0 110.294 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.1 ttm -80.93 -50.09 10.17 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.409 -0.807 . . . . 0.0 111.298 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 65.6 m -60.93 -36.39 79.18 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.184 -0.947 . . . . 0.0 110.753 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.2 tmm_? -55.41 -47.95 75.15 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.547 -0.72 . . . . 0.0 110.11 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -63.47 -43.82 96.22 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.571 -0.706 . . . . 0.0 109.735 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.36 -43.37 99.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -59.82 -39.82 86.34 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.547 -0.972 . . . . 0.0 109.928 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -61.06 -34.93 75.66 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.534 -0.729 . . . . 0.0 110.221 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -85.14 -36.79 20.86 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.545 -0.722 . . . . 0.0 110.473 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 17.2 m-70 -72.34 -35.31 68.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.436 -0.79 . . . . 0.0 110.857 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.11 33.52 2.14 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.309 -0.869 . . . . 0.0 110.738 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.3 tt -89.74 134.79 31.51 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.141 -0.975 . . . . 0.0 110.267 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.29 84.43 1.36 Allowed 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.887 1.467 . . . . 0.0 110.355 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mtt-85 . . . . . 0 N--CA 1.502 2.129 0 CA-C-O 117.669 -1.158 . . . . 0.0 110.617 -179.738 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.121 0.486 . . . . 0.0 110.143 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.3 t -155.3 162.88 40.76 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.361 -0.837 . . . . 0.0 110.672 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.659 ' HA ' ' HA3' ' A' ' 7' ' ' GLY . 0.8 OUTLIER -125.93 42.75 3.23 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.505 -0.747 . . . . 0.0 110.525 179.89 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.7 mm -98.72 -43.74 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.238 -0.914 . . . . 0.0 110.162 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 mt -101.12 64.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.375 -0.828 . . . . 0.0 110.036 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.12 66.66 1.93 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.659 ' HA3' ' HA ' ' A' ' 3' ' ' GLU . . . -101.74 -79.93 1.44 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 7' ' ' GLY . 0.6 OUTLIER 32.28 60.23 0.36 Allowed 'General case' 0 N--CA 1.508 2.474 0 CA-C-O 121.511 0.672 . . . . 0.0 112.122 179.911 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 t -92.71 16.27 12.64 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.263 -0.898 . . . . 0.0 110.98 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.503 ' N ' HD13 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -132.58 128.25 20.9 Favored Pre-proline 0 N--CA 1.497 1.92 0 O-C-N 121.23 -0.919 . . . . 0.0 109.803 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.75 ' HG2' ' HD3' ' A' ' 12' ' ' PRO . 37.0 Cg_endo -66.72 -34.34 31.97 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.849 1.447 . . . . 0.0 113.157 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.75 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 55.8 Cg_endo -81.1 57.18 6.39 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 122.422 0.696 . . . . 0.0 110.382 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.408 HG13 ' N ' ' A' ' 14' ' ' VAL . 10.6 p -67.48 -39.87 83.35 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.335 -0.853 . . . . 0.0 110.891 -179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 13' ' ' VAL . 61.1 t -67.14 -46.08 85.14 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.996 0 O-C-N 121.163 -0.961 . . . . 0.0 109.057 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.98 -35.32 80.32 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.746 -0.597 . . . . 0.0 109.901 179.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -64.94 -40.74 95.49 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.534 -0.729 . . . . 0.0 110.294 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.7 t -66.51 -31.52 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.521 -0.737 . . . . 0.0 110.292 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 83.8 t -84.12 -44.54 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.325 -0.859 . . . . 0.0 109.74 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 tpt -60.49 -39.66 88.47 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.574 -0.704 . . . . 0.0 110.764 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 p -62.76 -44.33 96.48 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.357 -0.839 . . . . 0.0 110.37 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -62.09 -37.99 87.16 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.613 -0.679 . . . . 0.0 110.283 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -63.44 -45.53 90.47 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.447 -0.783 . . . . 0.0 110.198 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -68.48 -46.69 61.5 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.99 -41.98 84.18 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.473 -1.016 . . . . 0.0 110.273 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -61.85 -33.85 74.92 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.503 -0.748 . . . . 0.0 110.387 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -84.64 -30.92 24.5 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.459 -0.776 . . . . 0.0 110.475 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -76.78 -43.09 38.29 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.351 -0.843 . . . . 0.0 110.507 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.83 -46.44 21.48 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.417 -0.802 . . . . 0.0 110.436 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.0 mt -113.3 134.05 21.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.244 -0.91 . . . . 0.0 110.273 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.77 102.93 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.984 1.518 . . . . 0.0 110.653 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.919 0 CA-C-O 117.914 -1.041 . . . . 0.0 110.741 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 . . . . . 0 N--CA 1.496 1.843 0 CA-C-O 120.904 0.383 . . . . 0.0 110.138 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 m -126.5 59.77 1.35 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.568 -0.707 . . . . 0.0 110.189 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -155.66 73.63 0.84 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.365 -0.834 . . . . 0.0 110.347 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.453 HG23 HD12 ' A' ' 5' ' ' ILE . 2.7 tt -171.11 145.99 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.512 -0.743 . . . . 0.0 110.248 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.453 HD12 HG23 ' A' ' 4' ' ' ILE . 19.1 mt 63.07 163.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.28 0 CA-C-O 121.497 0.665 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.88 -31.57 3.33 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.59 -45.86 1.34 Allowed Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 12.1 mt -99.52 30.46 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.483 -1.01 . . . . 0.0 110.712 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 p -129.98 34.71 4.22 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.186 -0.946 . . . . 0.0 110.019 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.9 142.91 21.26 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.418 -0.801 . . . . 0.0 110.149 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -75.73 115.7 4.26 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.85 1.447 . . . . 0.0 110.689 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.17 -39.76 2.84 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 123.769 1.405 . . . . 0.0 110.737 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.7 m -64.62 -35.8 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.376 -0.827 . . . . 0.0 110.503 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 73.0 t -66.73 -42.19 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.285 -0.884 . . . . 0.0 109.755 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.06 -33.35 75.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.512 -0.742 . . . . 0.0 110.552 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.0 tp -73.26 -38.78 65.85 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.379 -0.825 . . . . 0.0 110.592 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.1 t -63.33 -32.9 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.085 0 O-C-N 121.3 -0.875 . . . . 0.0 110.121 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 89.3 t -78.79 -33.37 16.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.278 -0.888 . . . . 0.0 109.817 179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 12.3 tpp -64.1 -45.39 88.84 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.487 -0.758 . . . . 0.0 110.707 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 18.8 p -61.53 -49.4 76.86 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.328 -0.857 . . . . 0.0 110.127 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.59 -40.33 96.68 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -62.52 -44.55 96.08 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.569 -0.707 . . . . 0.0 109.936 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -57.46 -41.11 93.15 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -46.95 47.94 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.396 -1.061 . . . . 0.0 109.882 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -59.18 -32.99 70.41 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.458 -0.776 . . . . 0.0 110.538 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.63 -37.53 70.85 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.379 -0.826 . . . . 0.0 110.645 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.56 29.54 7.92 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.348 -0.845 . . . . 0.0 110.499 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.9 tp -146.69 -51.69 0.22 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.281 -0.887 . . . . 0.0 110.147 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 64.86 159.21 0.12 Allowed Pre-proline 0 N--CA 1.502 2.152 0 O-C-N 121.991 -0.443 . . . . 0.0 110.994 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.25 114.41 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.738 1.389 . . . . 0.0 110.487 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 117.867 -1.063 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.412 ' HB2' HG22 ' A' ' 4' ' ' ILE . 7.9 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.936 0.398 . . . . 0.0 110.133 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.8 p -67.12 126.5 29.4 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.431 -0.793 . . . . 0.0 110.146 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 56.13 81.89 0.12 Allowed 'General case' 0 N--CA 1.5 2.045 0 CA-C-O 121.429 0.633 . . . . 0.0 110.565 -179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.412 HG22 ' HB2' ' A' ' 1' ' ' ASP . 1.8 pt -83.79 55.54 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.361 -0.837 . . . . 0.0 110.445 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.4 tt -163.45 133.01 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.318 -0.863 . . . . 0.0 109.957 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.35 97.94 0.16 Allowed Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.45 -62.49 1.15 Allowed Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.12 46.54 2.65 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.218 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 16.5 p -95.27 63.33 2.57 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.347 -0.846 . . . . 0.0 110.154 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.486 HG13 ' HD2' ' A' ' 11' ' ' PRO . 21.0 tt -80.44 141.52 53.02 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.486 ' HD2' HG13 ' A' ' 10' ' ' ILE . 50.4 Cg_endo -79.13 113.29 3.18 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.852 1.448 . . . . 0.0 110.668 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.95 -38.99 3.53 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.727 1.383 . . . . 0.0 110.862 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 p -62.2 -36.8 76.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.449 -0.782 . . . . 0.0 110.596 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.28 -47.62 83.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.251 -0.906 . . . . 0.0 109.682 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.81 -34.09 77.35 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.479 -0.763 . . . . 0.0 110.189 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.485 HD22 ' HA ' ' A' ' 16' ' ' LEU . 1.2 tm? -67.26 -45.52 76.41 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.405 -0.809 . . . . 0.0 110.348 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.5 t -65.5 -19.04 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.342 -0.849 . . . . 0.0 111.232 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -100.68 -42.19 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 120.971 -1.08 . . . . 0.0 110.532 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 14.9 ttt -74.55 -44.37 51.35 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.454 -0.779 . . . . 0.0 111.259 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 67.8 m -69.02 -40.54 78.58 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.149 -0.969 . . . . 0.0 110.738 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.3 ttp85 -53.5 -44.44 69.05 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.442 -0.786 . . . . 0.0 110.353 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -76.07 -44.85 37.01 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.54 -0.725 . . . . 0.0 110.057 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.66 -44.49 97.8 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -62.44 -42.75 99.69 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.48 -1.012 . . . . 0.0 110.056 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -57.05 -42.53 80.68 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.459 -0.775 . . . . 0.0 109.924 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.81 -37.03 73.21 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.638 -0.664 . . . . 0.0 110.036 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 12.4 m-70 -72.98 -33.89 66.11 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.496 -0.753 . . . . 0.0 110.645 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -80.3 -46.03 16.86 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.395 -0.815 . . . . 0.0 110.43 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.52 92.93 0.06 OUTLIER Pre-proline 0 N--CA 1.5 2.041 0 O-C-N 121.801 -0.562 . . . . 0.0 110.482 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.95 158.07 56.37 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.819 1.431 . . . . 0.0 110.4 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mmp_? . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 118.209 -0.901 . . . . 0.0 110.244 -179.912 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.062 0.458 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 m -96.7 56.14 1.46 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.372 -0.83 . . . . 0.0 109.855 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -132.47 40.16 3.31 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.482 -0.761 . . . . 0.0 110.576 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.535 HG22 HG12 ' A' ' 5' ' ' ILE . 2.4 mp -124.66 159.0 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.308 -0.87 . . . . 0.0 109.495 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.535 HG12 HG22 ' A' ' 4' ' ' ILE . 38.8 mm 59.93 83.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.171 0 CA-C-O 121.412 0.625 . . . . 0.0 110.406 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -110.26 -95.5 2.34 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.93 -94.15 2.33 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -155.21 72.52 0.83 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.519 -0.989 . . . . 0.0 110.051 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.6 t -125.23 18.69 8.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.422 -0.799 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.503 HG13 ' HD2' ' A' ' 11' ' ' PRO . 19.2 tt -150.33 137.84 11.79 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.153 -0.967 . . . . 0.0 110.314 179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.693 ' HB2' HG22 ' A' ' 13' ' ' VAL . 47.7 Cg_endo -76.67 151.93 32.71 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.85 1.448 . . . . 0.0 110.536 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.99 -24.27 24.24 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 123.843 1.444 . . . . 0.0 111.239 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.693 HG22 ' HB2' ' A' ' 11' ' ' PRO . 33.5 m -60.25 -36.13 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.105 0 O-C-N 121.366 -0.834 . . . . 0.0 110.868 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 11' ' ' PRO . 3.9 p -66.1 -33.16 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.166 -0.959 . . . . 0.0 110.142 179.679 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.32 70.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.356 -0.84 . . . . 0.0 109.438 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.4 tt -62.75 -39.33 93.81 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.713 -0.617 . . . . 0.0 109.868 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 82.8 t -67.65 -38.78 81.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.522 -0.736 . . . . 0.0 109.725 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -62.3 -37.73 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.43 -0.793 . . . . 0.0 109.761 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.6 ttt -65.92 -49.57 67.51 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.514 -0.741 . . . . 0.0 109.864 179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.8 t -65.07 -40.26 94.44 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.487 -0.758 . . . . 0.0 109.462 179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.8 ttp180 -57.38 -42.41 82.1 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.808 -0.557 . . . . 0.0 109.733 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -61.8 -46.24 90.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.477 -0.765 . . . . 0.0 109.843 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.61 -42.34 95.58 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 179.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -63.8 -41.53 97.89 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.656 -0.908 . . . . 0.0 109.895 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.401 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 2.2 m-85 -59.5 -43.48 93.35 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.596 -0.69 . . . . 0.0 110.01 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.06 -22.62 66.98 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.434 -0.791 . . . . 0.0 110.58 179.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 8.4 m-70 -97.53 -20.09 17.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.335 -0.853 . . . . 0.0 110.785 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.9 mt -107.88 34.83 3.36 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.112 -0.992 . . . . 0.0 111.064 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 25' ' ' PHE . 0.1 OUTLIER -143.39 140.16 17.31 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.086 -1.009 . . . . 0.0 110.42 179.604 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.479 ' C ' ' HG2' ' A' ' 31' ' ' ARG . 51.2 Cg_endo -77.76 172.78 15.13 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 124.118 1.589 . . . . 0.0 110.536 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.479 ' HG2' ' C ' ' A' ' 30' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.494 0 CA-C-O 117.658 -1.163 . . . . 0.0 111.946 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.5 t70 . . . . . 0 N--CA 1.495 1.794 0 CA-C-O 120.976 0.417 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.7 p -145.48 101.95 3.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.536 -0.727 . . . . 0.0 110.41 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -115.38 109.74 18.34 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 56.5 mt 57.49 88.44 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.259 0 CA-C-O 121.569 0.699 . . . . 0.0 110.735 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.7 tt -109.41 18.73 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.341 -0.849 . . . . 0.0 110.738 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 105.29 -110.3 3.44 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -66.79 0.39 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -152.37 32.7 0.52 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.439 -1.036 . . . . 0.0 110.875 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 39.1 p -120.13 58.5 0.91 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.083 -1.011 . . . . 0.0 110.043 179.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.1 pt -87.31 148.03 43.67 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.337 -0.852 . . . . 0.0 110.294 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.31 142.89 30.83 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.811 1.427 . . . . 0.0 110.321 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.35 64.71 8.87 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.918 1.483 . . . . 0.0 110.834 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.433 HG23 ' N ' ' A' ' 14' ' ' VAL . 28.7 m -77.38 -41.05 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.066 0 O-C-N 121.307 -0.87 . . . . 0.0 110.443 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.433 ' N ' HG23 ' A' ' 13' ' ' VAL . 35.6 m -66.7 -34.2 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.275 -0.89 . . . . 0.0 109.889 179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.67 -38.61 83.98 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.607 -0.683 . . . . 0.0 109.836 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tt -65.6 -41.53 92.67 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.497 -0.752 . . . . 0.0 110.071 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.0 t -64.1 -40.72 90.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.536 -0.728 . . . . 0.0 109.842 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -66.57 -49.02 78.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.46 -0.775 . . . . 0.0 109.61 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -64.18 -36.22 83.35 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.708 -0.62 . . . . 0.0 110.224 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.6 t -57.83 -43.02 85.53 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.467 -0.77 . . . . 0.0 109.801 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.58 -43.38 97.15 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.561 -0.712 . . . . 0.0 109.692 179.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 17.8 m-85 -64.17 -44.12 93.02 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.515 -0.741 . . . . 0.0 109.934 179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.54 -41.24 96.29 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -59.47 -45.44 91.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.496 -1.002 . . . . 0.0 110.139 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -65.8 -42.35 90.78 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.403 -0.811 . . . . 0.0 110.249 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.96 -27.04 67.86 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.405 -0.809 . . . . 0.0 110.913 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 31.9 m-70 -103.83 24.14 11.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.265 -0.897 . . . . 0.0 110.853 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -154.1 40.35 0.48 Allowed 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.077 -1.014 . . . . 0.0 110.578 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.9 tp -135.74 126.86 17.13 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.217 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.36 141.37 31.77 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.868 1.457 . . . . 0.0 110.439 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.337 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 121.191 0.52 . . . . 0.0 110.563 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 15.1 t -82.34 144.4 30.59 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.456 -0.778 . . . . 0.0 110.586 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -160.56 41.8 0.18 Allowed 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.533 -0.729 . . . . 0.0 110.392 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.42 HG23 ' N ' ' A' ' 5' ' ' ILE . 10.3 tt -164.93 -41.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.209 -0.932 . . . . 0.0 110.715 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 4' ' ' ILE . 2.2 pt -114.26 119.04 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.308 -0.87 . . . . 0.0 110.12 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.27 -98.11 0.15 Allowed Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -111.46 46.69 1.13 Allowed Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 mp 50.41 58.71 5.2 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.697 -0.884 . . . . 0.0 110.761 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 p -87.84 56.44 3.89 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.28 -0.888 . . . . 0.0 110.165 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -74.03 155.13 88.6 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.455 -0.778 . . . . 0.0 110.458 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HB2' HG12 ' A' ' 13' ' ' VAL . 45.7 Cg_endo -72.28 149.37 51.13 Favored 'Trans proline' 0 C--N 1.313 -1.297 0 O-C-N 123.769 1.405 . . . . 0.0 110.451 179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.2 -28.36 23.23 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.848 1.447 . . . . 0.0 111.391 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.534 HG12 ' HB2' ' A' ' 11' ' ' PRO . 11.4 p -62.26 -37.04 77.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.268 -0.895 . . . . 0.0 110.623 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.9 t -70.55 -43.15 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.261 -0.9 . . . . 0.0 109.622 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.36 -37.69 86.66 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.545 -0.722 . . . . 0.0 110.245 179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -64.78 -41.64 95.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.454 -0.779 . . . . 0.0 110.158 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 50.4 t -63.13 -36.1 74.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.523 -0.736 . . . . 0.0 109.979 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.5 t -74.83 -32.9 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.385 -0.822 . . . . 0.0 110.158 179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.4 mtp -61.48 -43.32 99.07 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.429 -0.795 . . . . 0.0 110.265 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 83.5 p -78.27 -17.93 55.98 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.471 -0.768 . . . . 0.0 110.729 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 mmt180 -67.53 -14.81 63.26 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.201 -0.937 . . . . 0.0 111.207 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -54.92 -30.0 57.45 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.335 -0.853 . . . . 0.0 110.85 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.19 -33.52 9.47 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -60.62 -52.04 66.85 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.537 -0.978 . . . . 0.0 110.361 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -65.06 -34.08 77.57 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.465 -0.772 . . . . 0.0 110.598 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.18 -38.55 91.47 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.473 -0.767 . . . . 0.0 110.606 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 15.3 t-80 -109.11 55.97 0.63 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.356 -0.84 . . . . 0.0 110.151 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.54 -54.89 1.65 Allowed 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.33 -0.856 . . . . 0.0 110.457 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 6.0 tt -141.2 132.22 13.45 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.414 -0.804 . . . . 0.0 110.04 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.5 Cg_endo -74.44 126.18 10.14 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.885 1.466 . . . . 0.0 110.476 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 . . . . . 0 N--CA 1.5 2.056 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.515 179.942 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.16 0.505 . . . . 0.0 110.508 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.1 m -101.35 105.75 16.84 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.529 -0.732 . . . . 0.0 110.022 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -101.33 74.36 1.55 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.463 -0.773 . . . . 0.0 110.028 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.0 mp 52.12 63.67 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.708 -0.62 . . . . 0.0 110.348 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.465 HG22 ' O ' ' A' ' 5' ' ' ILE . 48.2 mm -111.86 1.12 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.382 -0.824 . . . . 0.0 110.721 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -94.88 62.4 1.58 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.97 -48.16 1.51 Allowed Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.17 51.65 0.77 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.423 -1.045 . . . . 0.0 110.243 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.4 p 36.03 77.62 0.04 OUTLIER 'General case' 0 N--CA 1.507 2.389 0 CA-C-O 121.181 0.515 . . . . 0.0 111.699 179.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.1 pt -60.21 144.19 87.75 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.368 -0.832 . . . . 0.0 110.569 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.512 ' O ' HG22 ' A' ' 14' ' ' VAL . 45.0 Cg_endo -71.42 162.49 42.16 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.919 1.484 . . . . 0.0 111.053 -179.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.45 -17.87 23.41 Favored 'Trans proline' 0 C--N 1.312 -1.376 0 O-C-N 123.848 1.446 . . . . 0.0 111.17 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.419 HG13 ' N ' ' A' ' 14' ' ' VAL . 11.9 p -62.91 -39.89 86.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.059 0 O-C-N 121.276 -0.89 . . . . 0.0 111.015 -179.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 18' ' ' VAL . 30.8 m -72.83 -34.16 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.061 0 O-C-N 121.049 -1.032 . . . . 0.0 110.19 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.08 -38.72 79.17 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.377 -0.827 . . . . 0.0 109.901 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.5 tp -65.37 -39.82 92.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.568 -0.707 . . . . 0.0 110.093 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.3 t -65.23 -35.27 74.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.387 -0.821 . . . . 0.0 110.042 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 14' ' ' VAL . 73.3 t -62.14 -47.76 91.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.481 -0.762 . . . . 0.0 110.176 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . 0.4 ' HG3' ' N ' ' A' ' 20' ' ' SER . 21.6 ptp -77.66 -33.11 53.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.452 -0.78 . . . . 0.0 110.584 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' A' ' 19' ' ' MET . 31.4 m -64.06 -44.88 91.1 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.337 -0.852 . . . . 0.0 109.722 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 tmm_? -65.42 -36.26 83.41 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.574 -0.704 . . . . 0.0 109.753 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 25.3 t80 -60.0 -42.52 94.42 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.505 -0.747 . . . . 0.0 109.957 179.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.46 -44.7 92.7 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -64.41 -41.17 96.78 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.527 -0.984 . . . . 0.0 110.189 179.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -63.67 -21.48 66.4 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.5 -0.75 . . . . 0.0 111.114 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.88 36.66 0.81 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.059 -1.025 . . . . 0.0 110.961 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -172.63 -41.88 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.188 -0.945 . . . . 0.0 111.059 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -54.31 -37.05 64.38 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.454 -0.779 . . . . 0.0 111.824 -179.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.431 ' O ' HD12 ' A' ' 29' ' ' LEU . 0.2 OUTLIER -124.15 121.43 26.2 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.2 -0.938 . . . . 0.0 110.369 -179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.85 97.91 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.829 1.437 . . . . 0.0 110.383 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.933 0 CA-C-O 117.845 -1.074 . . . . 0.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.9 0.381 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.3 m 53.63 72.07 0.46 Allowed 'General case' 0 N--CA 1.499 2.023 0 CA-C-O 121.427 0.632 . . . . 0.0 109.811 -179.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -78.71 67.56 4.48 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.346 -0.846 . . . . 0.0 110.129 -179.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 49.3 mm -112.04 -46.46 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.416 -0.802 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.57 149.12 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.399 -0.813 . . . . 0.0 110.185 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -68.02 -49.0 50.63 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.84 44.93 1.7 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.584 ' HB3' ' CG1' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -108.42 14.48 24.71 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.343 -1.092 . . . . 0.0 110.745 179.677 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.9 m 56.6 31.52 19.29 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.512 -0.742 . . . . 0.0 110.924 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.584 ' CG1' ' HB3' ' A' ' 8' ' ' LEU . 1.1 pt -146.64 106.79 4.03 Favored Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.106 -0.996 . . . . 0.0 110.168 179.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -81.27 138.56 11.2 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.811 1.427 . . . . 0.0 110.69 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -77.76 66.65 8.09 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 O-C-N 123.911 1.48 . . . . 0.0 110.489 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 63.1 t -81.53 -49.61 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.383 -0.823 . . . . 0.0 110.2 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.9 p -60.38 -34.67 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.396 -0.815 . . . . 0.0 110.401 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.7 -39.32 76.97 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.428 -0.795 . . . . 0.0 110.084 179.482 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 12.1 tp -66.09 -38.21 87.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.55 -0.719 . . . . 0.0 110.259 179.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.17 -42.94 88.69 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.417 -0.802 . . . . 0.0 109.988 179.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -60.23 -39.41 80.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.432 -0.793 . . . . 0.0 109.97 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 3.0 ttt -63.39 -47.73 80.8 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.424 -0.797 . . . . 0.0 109.734 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.2 m -64.92 -44.67 88.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.481 -0.762 . . . . 0.0 109.845 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -60.41 -35.01 74.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.6 -0.687 . . . . 0.0 110.116 179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -63.41 -47.49 81.76 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.497 -0.752 . . . . 0.0 109.727 179.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.39 -40.47 79.82 Favored Glycine 0 N--CA 1.495 2.612 0 N-CA-C 109.223 -1.551 . . . . 0.0 109.223 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -62.97 -51.63 66.14 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.542 -0.975 . . . . 0.0 109.904 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -64.2 -32.23 73.73 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.592 -0.692 . . . . 0.0 110.448 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.09 -26.8 68.49 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.356 -0.84 . . . . 0.0 110.329 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 m-70 -102.98 -36.64 8.11 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.391 -0.818 . . . . 0.0 110.424 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 0.2 OUTLIER -78.41 -43.28 27.8 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.32 -0.862 . . . . 0.0 110.615 -179.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 0.6 OUTLIER 62.92 165.99 0.11 Allowed Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 121.989 -0.444 . . . . 0.0 110.995 -179.824 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD2' ' HB3' ' A' ' 29' ' ' LEU . 47.9 Cg_endo -75.2 82.49 2.03 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.676 1.356 . . . . 0.0 110.184 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 20.1 tpp180 . . . . . 0 N--CA 1.495 1.799 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.477 -179.659 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 N--CA 1.495 1.802 0 CA-C-O 121.214 0.53 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 t -158.06 152.46 24.57 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.406 -0.809 . . . . 0.0 110.335 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -112.74 30.45 7.13 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.447 -0.783 . . . . 0.0 110.648 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.8 mt 52.58 54.28 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.222 0 O-C-N 121.538 -0.726 . . . . 0.0 110.506 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp 58.51 -89.69 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.7 -0.625 . . . . 0.0 110.668 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 49.22 6.42 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.19 -85.34 0.77 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 79.1 mt -115.49 38.98 3.09 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.59 -0.947 . . . . 0.0 109.787 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -144.65 54.58 1.25 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.479 -0.763 . . . . 0.0 109.941 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.424 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 18.4 tt -73.76 135.46 77.81 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.289 -0.882 . . . . 0.0 110.656 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 10' ' ' ILE . 50.5 Cg_endo -82.62 120.35 3.14 Favored 'Trans proline' 0 C--N 1.316 -1.152 0 O-C-N 123.847 1.446 . . . . 0.0 110.842 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.92 -40.19 1.95 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.805 1.424 . . . . 0.0 111.13 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 17' ' ' VAL . 79.0 t -62.68 -44.56 99.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.398 -0.814 . . . . 0.0 110.325 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 63.8 t -56.84 -49.05 80.14 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.413 -0.805 . . . . 0.0 109.655 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.13 -38.72 91.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.529 -0.732 . . . . 0.0 109.562 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.64 -40.42 87.59 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.683 -0.636 . . . . 0.0 110.078 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 13' ' ' VAL . 75.3 t -63.89 -41.34 92.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.432 -0.793 . . . . 0.0 109.499 179.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.8 t -68.91 -44.32 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.755 . . . . 0.0 109.094 178.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 34.8 mtp -60.13 -41.52 92.84 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.797 -0.564 . . . . 0.0 109.965 179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.3 t -58.98 -43.78 91.47 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.483 -0.76 . . . . 0.0 109.917 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -40.7 98.53 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.487 -0.758 . . . . 0.0 109.888 179.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -61.1 -40.42 93.65 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.512 -0.743 . . . . 0.0 110.193 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.67 -39.48 96.65 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.44 -43.09 51.5 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.467 -1.019 . . . . 0.0 109.688 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -59.66 -30.73 68.94 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.579 -0.701 . . . . 0.0 110.648 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.5 -40.68 79.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -111.27 35.22 3.67 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.444 -0.785 . . . . 0.0 110.064 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 29' ' ' LEU . 7.1 tp -148.85 -50.41 0.16 Allowed 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.401 -0.812 . . . . 0.0 110.323 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.511 ' HB2' ' O ' ' A' ' 28' ' ' LEU . 24.1 mt 64.74 157.69 0.12 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 122.111 -0.368 . . . . 0.0 111.115 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -75.51 84.58 1.71 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.738 1.388 . . . . 0.0 110.622 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 9.0 ttm-85 . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.803 -179.924 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 120.901 0.382 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.4 p -74.93 83.77 2.22 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.43 -0.794 . . . . 0.0 110.193 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -90.06 63.95 6.05 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.345 -0.847 . . . . 0.0 110.411 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.53 HG22 HG23 ' A' ' 5' ' ' ILE . 3.3 mt -82.04 -43.47 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.347 -0.845 . . . . 0.0 109.755 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.53 HG23 HG22 ' A' ' 4' ' ' ILE . 5.8 pt -139.58 65.36 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.521 -0.737 . . . . 0.0 109.69 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.62 -113.69 0.59 Allowed Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.92 -56.48 0.49 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -132.1 14.16 4.7 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.524 -0.986 . . . . 0.0 110.502 179.507 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 t -168.6 100.42 0.41 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.339 -0.851 . . . . 0.0 109.199 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.4 128.31 67.58 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.435 -0.79 . . . . 0.0 110.885 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.411 ' HB2' HG22 ' A' ' 14' ' ' VAL . 49.8 Cg_endo -80.35 112.34 2.75 Favored 'Trans proline' 0 C--N 1.317 -1.121 0 O-C-N 123.797 1.419 . . . . 0.0 110.65 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -76.23 -29.62 6.2 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 O-C-N 123.739 1.389 . . . . 0.0 111.451 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 14' ' ' VAL . 13.2 p -62.31 -42.53 95.76 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.084 0 O-C-N 121.305 -0.872 . . . . 0.0 111.369 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.471 HG13 HG13 ' A' ' 13' ' ' VAL . 33.6 m -74.22 -35.24 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 120.945 -1.097 . . . . 0.0 110.152 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.62 -38.95 84.66 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.329 -0.857 . . . . 0.0 109.896 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.4 tp -66.93 -39.62 87.37 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.563 -0.711 . . . . 0.0 110.269 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.76 -41.59 93.08 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.445 -0.785 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -64.63 -39.19 84.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.5 -0.75 . . . . 0.0 109.891 179.481 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 11.7 ttm -65.65 -42.4 91.47 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.457 -0.777 . . . . 0.0 110.312 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.6 t -61.8 -42.41 98.98 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.448 -0.783 . . . . 0.0 110.031 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.3 tmm_? -63.85 -38.11 89.88 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.54 -0.725 . . . . 0.0 109.83 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -60.52 -42.88 97.33 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.621 -0.674 . . . . 0.0 110.017 179.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.23 -32.13 79.16 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.39 -53.37 55.95 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.536 -0.979 . . . . 0.0 110.21 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -61.91 -34.2 75.62 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.584 -0.697 . . . . 0.0 110.365 179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.39 -38.17 84.26 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.363 -0.835 . . . . 0.0 110.058 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 29.8 t-80 -103.35 51.76 0.79 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.52 -0.738 . . . . 0.0 110.046 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -109.46 -50.45 2.99 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.351 -0.843 . . . . 0.0 110.381 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.7 tp 58.12 87.87 0.13 Allowed Pre-proline 0 N--CA 1.502 2.14 0 O-C-N 121.742 -0.598 . . . . 0.0 111.027 179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.4 77.47 2.1 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 124.022 1.538 . . . . 0.0 110.519 179.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 3.9 mtp85 . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.149 -0.929 . . . . 0.0 110.257 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.028 0.442 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -116.84 161.29 19.54 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.538 -0.726 . . . . 0.0 110.214 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 58.14 74.09 0.44 Allowed 'General case' 0 N--CA 1.5 2.058 0 CA-C-O 121.511 0.672 . . . . 0.0 110.601 -179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.6 tt -90.91 -27.05 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.403 -0.81 . . . . 0.0 110.691 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.0 tt -147.09 157.18 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.288 -0.883 . . . . 0.0 110.294 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.27 -67.08 0.23 Allowed Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.46 50.42 3.18 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 mt 51.59 47.2 25.27 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.709 -0.877 . . . . 0.0 110.806 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.3 p -90.51 60.89 4.76 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.266 -0.896 . . . . 0.0 109.965 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -73.67 139.63 77.68 Favored Pre-proline 0 N--CA 1.5 2.053 0 O-C-N 121.565 -0.709 . . . . 0.0 110.525 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.548 ' HG2' HG23 ' A' ' 14' ' ' VAL . 47.6 Cg_endo -74.84 147.61 34.89 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.837 1.44 . . . . 0.0 110.737 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.52 -21.54 25.77 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.89 1.468 . . . . 0.0 111.03 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.91 -36.61 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.419 -0.8 . . . . 0.0 110.227 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.548 HG23 ' HG2' ' A' ' 11' ' ' PRO . 92.9 t -59.6 -44.14 92.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.507 -0.746 . . . . 0.0 109.762 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.25 87.0 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.521 -0.737 . . . . 0.0 109.971 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.5 tt -67.64 -40.06 84.61 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.564 -0.71 . . . . 0.0 110.44 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.1 t -61.71 -37.03 77.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.405 -0.81 . . . . 0.0 110.162 179.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.2 t -73.88 -32.09 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.439 -0.788 . . . . 0.0 109.938 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.0 ttm -65.99 -48.34 71.54 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.395 -0.815 . . . . 0.0 110.27 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 41.3 p -62.69 -40.62 97.7 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.505 -0.747 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.543 ' HG3' ' N ' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -62.36 -29.85 70.77 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.357 -0.839 . . . . 0.0 109.989 179.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.543 ' N ' ' HG3' ' A' ' 21' ' ' ARG . 3.2 t80 -68.59 -44.48 74.26 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.759 . . . . 0.0 109.577 178.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.55 -32.69 82.34 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.399 -1.48 . . . . 0.0 109.399 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -61.14 -50.46 73.1 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.476 -1.014 . . . . 0.0 110.089 179.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 16.2 t80 -66.04 -31.41 72.28 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.374 -0.829 . . . . 0.0 110.436 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.5 -41.33 85.12 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.447 -0.783 . . . . 0.0 110.372 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 4.2 t-80 -105.35 22.46 15.37 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.406 -0.809 . . . . 0.0 110.475 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -154.28 43.22 0.52 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.329 -0.857 . . . . 0.0 110.345 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -85.99 135.99 36.79 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.49 69.4 5.93 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.876 1.461 . . . . 0.0 110.714 -179.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.881 0 CA-C-O 117.905 -1.045 . . . . 0.0 110.192 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 . . . . . 0 N--CA 1.498 1.927 0 CA-C-O 121.126 0.489 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 12.7 t -76.92 150.27 35.97 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.424 -0.797 . . . . 0.0 110.433 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.452 ' HB3' HD12 ' A' ' 4' ' ' ILE . 19.8 mt-10 -105.81 -77.98 0.58 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.486 -0.759 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.672 HG22 HG23 ' A' ' 5' ' ' ILE . 2.6 mp -133.92 -60.09 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.437 -0.789 . . . . 0.0 109.761 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.672 HG23 HG22 ' A' ' 4' ' ' ILE . 1.1 pt -117.93 -175.33 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.999 0 O-C-N 121.479 -0.763 . . . . 0.0 110.413 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -178.31 145.53 6.96 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -150.33 64.41 0.39 Allowed Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -115.2 39.46 2.92 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.441 -1.034 . . . . 0.0 110.407 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.1 t -72.17 -20.97 61.51 Favored 'General case' 0 N--CA 1.499 2.012 0 O-C-N 121.329 -0.857 . . . . 0.0 110.741 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.455 ' CG1' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -144.68 160.44 47.44 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.356 -0.84 . . . . 0.0 109.749 179.784 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HD2' ' CG1' ' A' ' 10' ' ' ILE . 49.2 Cg_endo -80.53 120.35 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.922 1.485 . . . . 0.0 110.706 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.73 -36.19 5.07 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.865 1.455 . . . . 0.0 110.933 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.3 t -63.66 -44.12 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.404 -0.81 . . . . 0.0 110.394 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.6 t -58.77 -44.02 89.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.444 -0.785 . . . . 0.0 110.146 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.32 -39.72 94.47 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.457 -0.777 . . . . 0.0 110.278 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.0 tp -64.7 -37.75 88.64 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.442 -0.786 . . . . 0.0 110.242 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.8 t -66.46 -41.1 88.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.486 -0.759 . . . . 0.0 109.675 179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -61.22 -35.06 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.461 -0.775 . . . . 0.0 109.681 179.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.6 ttp -67.69 -36.19 80.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.453 -0.78 . . . . 0.0 109.814 178.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.3 m -81.79 -4.89 57.53 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.523 -0.736 . . . . 0.0 110.854 179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mmm180 -104.45 -57.87 1.97 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.245 -0.909 . . . . 0.0 109.87 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.93 -42.8 14.64 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 109.783 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.5 -43.58 98.66 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.88 91.52 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.5 -1.0 . . . . 0.0 109.787 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 29' ' ' LEU . 85.9 t80 -62.96 -36.9 85.03 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.517 -0.739 . . . . 0.0 110.182 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.56 -30.08 68.38 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.458 -0.776 . . . . 0.0 110.224 179.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 41.3 t60 -93.4 -39.16 11.07 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.47 -0.769 . . . . 0.0 110.281 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.479 ' HA ' HD13 ' A' ' 28' ' ' LEU . 3.6 mm? -80.29 -57.79 3.44 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.366 -0.834 . . . . 0.0 110.438 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 25' ' ' PHE . 0.1 OUTLIER 64.57 166.98 0.11 Allowed Pre-proline 0 N--CA 1.502 2.172 0 O-C-N 121.845 -0.534 . . . . 0.0 110.793 -179.908 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.411 ' HD3' ' CZ ' ' A' ' 25' ' ' PHE . 49.9 Cg_endo -77.62 172.05 16.45 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.625 1.329 . . . . 0.0 110.826 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 6.0 mtp85 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.367 179.839 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.495 1.813 0 CA-C-O 120.978 0.418 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.0 p -143.72 84.47 1.79 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.504 -0.747 . . . . 0.0 110.403 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -98.96 64.18 1.4 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.204 -0.935 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.0 mt -91.8 -42.91 13.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.935 0 O-C-N 121.235 -0.916 . . . . 0.0 109.683 179.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 35.1 mm -119.21 61.35 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.547 -0.721 . . . . 0.0 109.484 179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.21 -80.44 1.82 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.83 -49.52 2.01 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -120.43 60.47 0.88 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.499 -1.0 . . . . 0.0 109.923 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 68.2 p -102.66 28.5 6.02 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.462 -0.774 . . . . 0.0 110.794 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.4 pp -121.49 155.98 58.71 Favored Pre-proline 0 N--CA 1.497 1.881 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.4 Cg_endo -73.64 122.19 7.64 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.809 1.426 . . . . 0.0 110.508 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.7 -44.28 1.51 Allowed 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.827 1.435 . . . . 0.0 110.893 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 14' ' ' VAL . 35.8 m -60.83 -34.52 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.381 -0.824 . . . . 0.0 110.17 179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.542 HG23 HG23 ' A' ' 13' ' ' VAL . 59.3 t -80.02 -45.42 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.284 -0.885 . . . . 0.0 109.512 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.68 -40.9 93.84 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.491 -0.756 . . . . 0.0 110.363 179.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -62.47 -43.99 97.49 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.53 -0.731 . . . . 0.0 110.244 179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.8 t -64.03 -37.37 79.64 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.982 0 O-C-N 121.528 -0.733 . . . . 0.0 109.92 179.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 76.2 t -64.47 -44.11 96.96 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.528 -0.733 . . . . 0.0 110.058 179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 mtm -61.54 -39.76 92.22 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.451 -0.781 . . . . 0.0 110.245 179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.23 -26.08 68.35 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.447 -0.783 . . . . 0.0 110.451 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.37 19.54 18.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.392 -0.817 . . . . 0.0 110.526 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 72.8 t80 -106.57 -58.55 1.91 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.325 -0.859 . . . . 0.0 109.951 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.65 -41.66 74.3 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.716 -1.353 . . . . 0.0 109.716 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -61.95 -47.25 85.71 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.471 -1.017 . . . . 0.0 110.074 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -62.76 -38.85 92.21 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.585 -0.697 . . . . 0.0 110.129 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.81 -32.18 71.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.55 -0.719 . . . . 0.0 110.327 179.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 34.6 m170 -110.97 54.99 0.66 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.435 -0.791 . . . . 0.0 109.679 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 28' ' ' LEU . 0.2 OUTLIER -124.16 -66.09 1.01 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.384 -0.822 . . . . 0.0 110.767 -179.596 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.453 HD13 ' HD2' ' A' ' 30' ' ' PRO . 0.2 OUTLIER -157.52 114.4 1.88 Allowed Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 -179.727 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.453 ' HD2' HD13 ' A' ' 29' ' ' LEU . 46.9 Cg_endo -72.55 86.91 0.98 Allowed 'Trans proline' 0 C--N 1.313 -1.32 0 O-C-N 123.997 1.525 . . . . 0.0 110.419 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 13.6 mtt-85 . . . . . 0 N--CA 1.502 2.13 0 CA-C-O 117.663 -1.16 . . . . 0.0 110.713 -179.903 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 N--CA 1.498 1.947 0 CA-C-O 121.072 0.463 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -106.58 96.87 6.76 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.249 -0.907 . . . . 0.0 110.107 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.82 110.75 1.72 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.557 -0.714 . . . . 0.0 110.161 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.2 pt -128.76 167.33 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.447 -0.783 . . . . 0.0 110.066 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 23.6 mt 57.24 83.17 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 CA-C-O 121.361 0.6 . . . . 0.0 110.393 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.04 79.16 1.93 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.89 -57.99 4.63 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 tp -122.43 55.1 1.16 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.36 -1.082 . . . . 0.0 110.083 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 15.2 p -86.98 71.74 10.21 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.332 -0.855 . . . . 0.0 110.242 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -82.02 150.35 64.87 Favored Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.42 -0.8 . . . . 0.0 110.257 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.34 129.9 15.54 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 123.898 1.473 . . . . 0.0 110.268 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -76.81 66.79 7.51 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.901 1.474 . . . . 0.0 110.72 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 60.0 t -109.07 -52.69 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.533 -0.729 . . . . 0.0 109.925 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.8 p -60.77 -37.37 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.487 -0.758 . . . . 0.0 110.485 179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.88 77.54 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.225 -0.922 . . . . 0.0 110.11 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 17.4 tp -62.54 -31.23 71.98 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.562 -0.711 . . . . 0.0 110.43 179.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 91.4 t -80.08 -35.0 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.316 -0.865 . . . . 0.0 109.944 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 14' ' ' VAL . 97.6 t -74.15 -39.36 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.376 -0.828 . . . . 0.0 110.999 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 20' ' ' SER . 18.1 ptp -61.66 -30.87 71.0 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.196 -0.94 . . . . 0.0 110.755 -179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.427 ' N ' ' HG3' ' A' ' 19' ' ' MET . 0.4 OUTLIER -85.63 -27.35 25.48 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.171 -0.956 . . . . 0.0 109.967 179.089 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.9 mtp85 -60.15 -58.94 6.39 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.465 -0.772 . . . . 0.0 110.981 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -67.8 -31.75 71.84 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.437 -0.789 . . . . 0.0 110.634 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.71 -41.65 95.72 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' O ' HD23 ' A' ' 28' ' ' LEU . 0.9 OUTLIER -63.79 -55.4 23.32 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.937 . . . . 0.0 109.976 179.543 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -57.26 -34.79 68.98 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.499 -0.751 . . . . 0.0 110.75 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.82 -31.74 63.37 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.437 -0.789 . . . . 0.0 110.868 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -111.96 46.63 1.12 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.306 -0.872 . . . . 0.0 110.971 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.658 HD23 ' O ' ' A' ' 24' ' ' PHE . 0.2 OUTLIER -116.29 -54.88 2.44 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.191 -0.943 . . . . 0.0 110.214 179.485 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -102.31 112.74 65.8 Favored Pre-proline 0 N--CA 1.495 1.782 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.65 98.47 1.05 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.932 1.491 . . . . 0.0 110.7 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.497 1.918 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.458 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 121.111 0.481 . . . . 0.0 110.389 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 p -109.24 130.29 55.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.49 -0.757 . . . . 0.0 110.241 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -116.24 -96.9 0.46 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.548 -0.72 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.43 ' C ' HD12 ' A' ' 5' ' ' ILE . 5.7 tp -114.26 -25.73 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.127 -0.983 . . . . 0.0 110.874 179.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.469 HG22 ' O ' ' A' ' 5' ' ' ILE . 3.2 mp 54.88 50.94 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.487 -0.758 . . . . 0.0 110.476 179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -114.13 93.4 0.65 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 71.08 51.1 19.82 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -156.5 36.19 0.32 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.602 -0.94 . . . . 0.0 110.379 -179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -143.37 -132.03 0.09 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.32 -0.863 . . . . 0.0 109.57 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -138.26 154.34 73.78 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 120.982 -1.074 . . . . 0.0 110.222 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.435 ' HG2' ' CG1' ' A' ' 14' ' ' VAL . 45.4 Cg_endo -73.53 138.21 26.55 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.959 1.505 . . . . 0.0 110.703 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.13 -37.06 5.03 Favored 'Trans proline' 0 N--CA 1.489 1.224 0 O-C-N 123.879 1.463 . . . . 0.0 111.395 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.7 p -61.52 -36.79 75.48 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.032 0 O-C-N 121.198 -0.939 . . . . 0.0 110.599 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.435 ' CG1' ' HG2' ' A' ' 11' ' ' PRO . 0.4 OUTLIER -74.62 -34.97 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.297 -0.877 . . . . 0.0 109.56 179.268 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.14 -38.02 75.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.464 -0.772 . . . . 0.0 110.067 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 11.4 tp -62.73 -41.99 99.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.554 -0.716 . . . . 0.0 109.962 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.1 t -63.71 -39.29 84.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.464 -0.772 . . . . 0.0 109.399 179.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 14' ' ' VAL . 98.2 t -70.99 -32.49 48.57 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.43 -0.794 . . . . 0.0 109.797 179.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.8 tmm? -59.3 -50.65 73.15 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.571 -0.705 . . . . 0.0 110.253 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.7 t -60.64 -41.53 95.13 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.426 -0.796 . . . . 0.0 109.626 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 -65.43 -43.04 91.74 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.662 -0.648 . . . . 0.0 109.678 179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -65.41 -39.28 91.98 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.678 -0.639 . . . . 0.0 110.181 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.71 -42.98 98.17 Favored Glycine 0 N--CA 1.496 2.682 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -61.47 -40.7 95.49 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.491 -1.006 . . . . 0.0 109.829 179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -70.83 -25.66 62.94 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.535 -0.728 . . . . 0.0 110.535 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.27 -46.52 83.31 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.299 -0.876 . . . . 0.0 110.095 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 7.8 t-80 -83.18 -35.82 25.19 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.1 mp -110.18 54.51 0.67 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.482 -0.761 . . . . 0.0 109.674 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -75.51 137.46 70.98 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.525 -0.735 . . . . 0.0 110.505 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.23 -177.19 3.34 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.975 1.513 . . . . 0.0 110.786 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 . . . . . 0 N--CA 1.499 1.992 0 O-C-N 121.341 -0.849 . . . . 0.0 110.739 179.864 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 120.843 0.354 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.587 HG22 ' H ' ' A' ' 3' ' ' GLU . 2.8 m 60.84 -177.88 0.11 Allowed 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.674 -0.641 . . . . 0.0 110.141 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.587 ' H ' HG22 ' A' ' 2' ' ' THR . 21.5 mt-10 52.82 68.3 0.85 Allowed 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.324 -0.86 . . . . 0.0 110.465 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.9 pt -99.68 61.55 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 O-C-N 121.343 -0.848 . . . . 0.0 110.361 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 mp -89.26 134.15 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.311 -0.868 . . . . 0.0 109.769 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -88.23 64.33 3.58 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.59 -48.82 1.75 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 tp -139.11 51.53 1.79 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.465 -1.021 . . . . 0.0 110.078 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.466 ' O ' ' CG1' ' A' ' 10' ' ' ILE . 8.5 m 52.08 49.04 21.5 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.638 -0.664 . . . . 0.0 110.615 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.501 ' HB ' ' HD2' ' A' ' 11' ' ' PRO . 0.5 OUTLIER 56.82 169.08 0.05 OUTLIER Pre-proline 0 N--CA 1.51 2.557 0 CA-C-O 120.976 0.417 . . . . 0.0 111.689 179.91 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.633 ' HB2' HG12 ' A' ' 13' ' ' VAL . 50.2 Cg_endo -77.14 132.57 12.77 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.528 1.278 . . . . 0.0 110.28 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 -13.01 23.74 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.703 1.37 . . . . 0.0 111.472 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.633 HG12 ' HB2' ' A' ' 11' ' ' PRO . 12.4 p -58.33 -41.42 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 O-C-N 121.217 -0.927 . . . . 0.0 111.147 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 11' ' ' PRO . 35.8 m -69.05 -37.5 77.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.107 0 O-C-N 121.123 -0.985 . . . . 0.0 110.091 179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.83 -38.75 89.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.349 -0.844 . . . . 0.0 109.834 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.6 tt -65.34 -31.8 73.12 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.613 -0.679 . . . . 0.0 110.359 179.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 53.2 t -79.07 -32.29 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.37 -0.831 . . . . 0.0 110.62 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -71.88 -48.12 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.138 -0.976 . . . . 0.0 110.622 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.48 -26.06 68.33 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.328 -0.858 . . . . 0.0 111.019 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.2 p -86.84 -24.75 24.85 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.115 -0.991 . . . . 0.0 110.448 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.9 ttp85 -57.97 -58.8 6.83 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.452 -0.78 . . . . 0.0 110.429 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -64.13 -37.03 85.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.475 -0.766 . . . . 0.0 110.254 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.91 98.51 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -62.92 -48.19 80.0 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.527 -0.984 . . . . 0.0 110.107 179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -56.31 -39.92 73.54 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.471 -0.768 . . . . 0.0 110.46 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.17 -40.6 67.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.507 -0.746 . . . . 0.0 110.433 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -100.2 46.1 0.97 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.434 -0.791 . . . . 0.0 110.431 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.1 -43.66 8.38 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.6 mt -129.33 139.58 36.11 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.405 -0.809 . . . . 0.0 110.213 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.77 91.09 1.1 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.938 1.494 . . . . 0.0 110.425 179.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 118.219 -0.896 . . . . 0.0 110.208 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 120.987 0.422 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.9 t -152.05 166.34 31.91 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.469 -0.769 . . . . 0.0 110.553 -179.93 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.434 ' HG2' HD12 ' A' ' 5' ' ' ILE . 4.4 tt0 -152.96 -105.34 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.621 -0.674 . . . . 0.0 109.799 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.459 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 6.9 mt 60.24 -84.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.225 0 O-C-N 121.392 -0.817 . . . . 0.0 110.897 179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 3.7 mt 64.24 118.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 121.605 -0.685 . . . . 0.0 110.767 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -77.04 73.3 1.98 Allowed Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.966 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -147.71 38.92 1.04 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.35 -0.92 14.37 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.463 -1.022 . . . . 0.0 110.941 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -114.37 26.88 9.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.269 -0.894 . . . . 0.0 109.891 179.655 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.05 130.03 9.17 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.27 -0.894 . . . . 0.0 110.138 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.479 ' O ' HG12 ' A' ' 14' ' ' VAL . 45.9 Cg_endo -72.52 174.51 11.53 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.961 1.506 . . . . 0.0 110.664 179.649 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 11' ' ' PRO . 43.0 Cg_endo -69.65 -23.29 31.44 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.532 1.28 . . . . 0.0 111.071 179.83 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.8 t -70.81 -52.69 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.231 -0.918 . . . . 0.0 110.245 179.83 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.493 ' O ' HG23 ' A' ' 18' ' ' VAL . 5.6 p -62.25 -34.44 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.962 0 O-C-N 121.352 -0.842 . . . . 0.0 110.32 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.9 89.34 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.292 -0.88 . . . . 0.0 109.699 179.179 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 5.2 tp -66.79 -39.04 87.65 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.687 -0.633 . . . . 0.0 110.0 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 71.9 t -63.37 -32.66 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.51 -0.744 . . . . 0.0 109.94 179.497 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.3 t -75.34 -42.64 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 O-C-N 121.384 -0.822 . . . . 0.0 109.788 179.374 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.59 -35.48 81.12 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.59 -0.694 . . . . 0.0 110.502 179.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -88.53 48.41 1.63 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.234 -0.916 . . . . 0.0 109.83 179.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.14 -59.05 0.39 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.461 -0.775 . . . . 0.0 110.495 -179.752 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -62.3 -55.56 27.02 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.481 -0.762 . . . . 0.0 110.422 -179.696 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.7 -30.1 70.85 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.432 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.501 ' O ' HD23 ' A' ' 28' ' ' LEU . 0.2 OUTLIER -64.34 -41.0 97.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.988 . . . . 0.0 110.395 179.792 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -57.88 -30.98 66.28 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.612 -0.68 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.09 -44.33 78.88 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.518 -0.739 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.3 t-80 -109.53 46.44 1.0 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.332 -0.855 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.501 HD23 ' O ' ' A' ' 24' ' ' PHE . 0.2 OUTLIER -113.38 -42.7 3.45 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.265 -0.897 . . . . 0.0 110.829 -179.751 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.78 110.56 42.0 Favored Pre-proline 0 N--CA 1.497 1.901 0 O-C-N 121.286 -0.884 . . . . 0.0 110.639 -179.756 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -75.74 161.8 36.09 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.795 1.418 . . . . 0.0 110.651 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.502 2.155 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.687 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.089 0.471 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 84.6 m -142.55 108.89 5.28 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.456 -0.778 . . . . 0.0 110.347 -179.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -158.59 47.01 0.33 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.449 -0.782 . . . . 0.0 110.477 179.757 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 mm -107.11 105.63 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.96 0 O-C-N 121.151 -0.968 . . . . 0.0 110.205 179.857 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 pt -133.55 60.95 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.671 -0.643 . . . . 0.0 110.221 -179.893 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -143.96 -106.26 0.54 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.8 -70.6 0.23 Allowed Glycine 0 N--CA 1.495 2.629 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.99 55.04 0.77 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.501 -0.999 . . . . 0.0 109.837 179.675 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.9 m 58.37 35.78 25.03 Favored 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.615 -0.678 . . . . 0.0 110.477 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.45 111.82 6.47 Favored Pre-proline 0 N--CA 1.499 1.99 0 O-C-N 121.252 -0.905 . . . . 0.0 110.21 179.739 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.691 ' HB2' ' HB ' ' A' ' 14' ' ' VAL . 49.0 Cg_endo -84.75 111.63 1.47 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.835 1.44 . . . . 0.0 110.776 -179.909 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -83.17 -67.8 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.162 0 O-C-N 123.67 1.353 . . . . 0.0 111.629 -179.68 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 94.2 t -63.62 -39.06 83.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 O-C-N 121.142 -0.974 . . . . 0.0 110.669 -179.516 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.691 ' HB ' ' HB2' ' A' ' 11' ' ' PRO . 74.9 t -56.73 -43.03 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 O-C-N 121.353 -0.842 . . . . 0.0 109.802 179.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.11 92.96 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 109.973 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.424 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.1 OUTLIER -64.1 -41.42 97.29 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.554 -0.716 . . . . 0.0 109.908 179.403 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 52.6 t -62.89 -41.73 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.441 -0.787 . . . . 0.0 109.742 179.325 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -63.01 -38.9 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.54 -0.725 . . . . 0.0 109.472 179.15 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 8.0 tpt -62.45 -40.91 98.13 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.535 -0.728 . . . . 0.0 109.755 179.212 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.7 t -62.2 -40.57 96.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.559 -0.713 . . . . 0.0 109.64 179.043 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 mtm-85 -60.92 -43.4 98.63 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.629 -0.669 . . . . 0.0 109.76 179.182 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -62.07 -40.69 96.67 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.617 -0.677 . . . . 0.0 110.014 179.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.22 -41.92 95.09 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.515 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.23 -45.13 85.91 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.943 . . . . 0.0 109.584 179.214 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -64.14 -40.22 95.7 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 109.892 179.294 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 29' ' ' LEU . . . -60.14 -36.12 76.81 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.553 -0.717 . . . . 0.0 110.189 179.39 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -68.62 -33.38 73.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.458 -0.776 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.4 mp -83.76 -73.3 0.42 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.394 -0.817 . . . . 0.0 110.24 179.886 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.59 ' HG ' ' HD2' ' A' ' 30' ' ' PRO . 0.5 OUTLIER 64.3 158.28 0.12 Allowed Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.844 -0.535 . . . . 0.0 110.885 -179.994 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.59 ' HD2' ' HG ' ' A' ' 29' ' ' LEU . 48.8 Cg_endo -75.43 171.66 17.83 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.587 1.309 . . . . 0.0 110.83 -179.768 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 15.0 mmm-85 . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.343 -179.963 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.432 ' O ' ' HB ' ' A' ' 2' ' ' THR . 33.9 t70 . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.74 0.305 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 1' ' ' ASP . 98.2 m 60.91 101.92 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.291 0.567 . . . . 0.0 110.799 179.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 56.45 89.05 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.734 -0.604 . . . . 0.0 110.883 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.551 HG22 HG23 ' A' ' 5' ' ' ILE . 3.1 mp -118.31 -65.91 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.337 -0.852 . . . . 0.0 110.35 -179.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.551 HG23 HG22 ' A' ' 4' ' ' ILE . 8.9 pt -134.41 32.31 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.07 0 O-C-N 121.174 -0.954 . . . . 0.0 111.015 -179.913 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -127.86 37.66 2.26 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.669 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.02 -50.34 3.29 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 57.7 31.71 20.81 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.714 -0.874 . . . . 0.0 110.681 -179.844 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -91.06 64.42 5.34 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.249 -0.907 . . . . 0.0 109.836 179.851 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -105.75 160.35 26.41 Favored Pre-proline 0 N--CA 1.498 1.943 0 O-C-N 121.451 -0.78 . . . . 0.0 110.153 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.18 114.5 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.886 1.466 . . . . 0.0 110.536 179.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -81.36 70.51 7.36 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.736 1.387 . . . . 0.0 110.239 179.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 14' ' ' VAL . 34.0 m -106.13 -41.39 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.439 -0.788 . . . . 0.0 110.396 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.456 ' O ' HG23 ' A' ' 18' ' ' VAL . 10.7 p -72.29 -35.42 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.251 -0.906 . . . . 0.0 110.019 179.51 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.6 -37.02 71.02 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.423 -0.798 . . . . 0.0 109.867 179.217 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.1 tp -68.96 -38.57 79.5 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.636 -0.665 . . . . 0.0 110.168 179.575 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.1 t -61.85 -36.94 76.77 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.049 0 O-C-N 121.374 -0.829 . . . . 0.0 109.892 179.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 14' ' ' VAL . 66.1 t -71.96 -33.54 47.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.438 -0.789 . . . . 0.0 109.742 179.271 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 17.5 mmt -67.81 -40.82 83.79 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.5 -0.75 . . . . 0.0 110.495 179.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 25.3 p -74.91 -18.59 60.39 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.36 -0.838 . . . . 0.0 110.949 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 52.0 ttp85 -54.3 -39.73 67.26 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.36 -0.838 . . . . 0.0 110.652 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.77 -47.71 77.16 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.427 -0.796 . . . . 0.0 110.165 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.78 -46.16 90.53 Favored Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.684 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -60.62 -41.23 94.4 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.964 . . . . 0.0 110.18 179.564 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -62.52 -41.49 98.9 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.534 -0.729 . . . . 0.0 110.15 179.63 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.44 -27.77 69.52 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.502 -0.749 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 73.1 t60 -92.86 -32.98 14.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.459 -0.776 . . . . 0.0 110.796 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.57 38.43 0.98 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.294 -0.879 . . . . 0.0 110.911 -179.704 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 12.8 tp -130.42 119.87 18.67 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.555 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -72.98 167.71 26.62 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.948 1.499 . . . . 0.0 110.849 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 117.833 -1.08 . . . . 0.0 110.484 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 121.103 0.478 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.476 HG23 ' O ' ' A' ' 2' ' ' THR . 2.9 t -164.28 94.03 0.71 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.562 -0.711 . . . . 0.0 110.1 179.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -103.52 60.77 0.76 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.308 -0.87 . . . . 0.0 110.053 -179.578 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 16.5 tt -159.58 163.34 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.395 -0.816 . . . . 0.0 110.117 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -74.22 145.51 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.396 -0.815 . . . . 0.0 110.188 179.741 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' N ' HD13 ' A' ' 5' ' ' ILE . . . 117.34 -54.61 0.59 Allowed Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.26 57.41 8.45 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.808 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -130.08 14.16 5.71 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.545 -0.974 . . . . 0.0 111.053 -179.744 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 62.3 m -118.05 85.13 2.29 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.104 -0.998 . . . . 0.0 109.733 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -106.71 158.95 31.56 Favored Pre-proline 0 N--CA 1.497 1.876 0 O-C-N 121.707 -0.621 . . . . 0.0 110.097 179.855 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.401 ' HG2' HG11 ' A' ' 14' ' ' VAL . 44.6 Cg_endo -71.87 114.53 3.99 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.985 1.518 . . . . 0.0 110.751 -179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -77.03 -35.08 1.92 Allowed 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.828 1.436 . . . . 0.0 111.37 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 76.9 t -59.81 -51.47 72.45 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.175 0 O-C-N 121.283 -0.885 . . . . 0.0 110.867 -179.285 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.492 ' O ' HG23 ' A' ' 18' ' ' VAL . 9.9 p -61.49 -34.65 62.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.407 -0.808 . . . . 0.0 110.567 -179.822 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -70.02 -39.43 75.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.302 -0.874 . . . . 0.0 109.917 179.334 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.0 tt -62.46 -36.56 82.84 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.66 -0.65 . . . . 0.0 110.107 179.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 86.7 t -70.68 -41.06 77.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.962 179.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 14' ' ' VAL . 91.5 t -63.41 -29.5 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.043 0 O-C-N 121.38 -0.825 . . . . 0.0 110.152 179.578 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -60.61 -42.66 97.26 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.635 -0.665 . . . . 0.0 110.35 179.761 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 5.0 m -91.26 39.76 1.01 Allowed 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.405 -0.809 . . . . 0.0 110.258 179.37 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp85 -148.23 -42.58 0.16 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.393 -0.817 . . . . 0.0 110.709 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.61 -45.94 91.95 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.257 -0.902 . . . . 0.0 110.859 -179.583 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.39 -32.36 83.33 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.627 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.0 -30.64 70.81 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.334 -1.098 . . . . 0.0 110.772 179.711 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -97.06 -20.37 18.07 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.15 -0.968 . . . . 0.0 111.191 -179.564 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.65 -31.6 11.84 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.265 -0.897 . . . . 0.0 111.003 -179.667 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -97.39 -18.9 18.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.412 -0.805 . . . . 0.0 111.342 -179.664 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.38 49.24 0.82 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.95 -1.094 . . . . 0.0 110.409 -179.802 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.4 tp -130.54 133.92 25.43 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.146 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.02 102.54 1.35 Allowed 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.785 1.413 . . . . 0.0 110.2 179.608 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.974 0 CA-C-O 118.412 -0.804 . . . . 0.0 111.002 -179.546 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 23.5 t70 . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 120.986 0.422 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.2 p -127.75 38.42 4.04 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.477 -0.765 . . . . 0.0 110.078 179.722 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.17 113.44 7.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.466 -0.771 . . . . 0.0 109.939 179.679 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mp -125.79 159.42 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.88 -179.85 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 37.9 mm -69.71 119.38 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.481 -0.762 . . . . 0.0 110.208 -179.905 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.03 -97.27 0.34 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.877 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.13 -33.55 6.07 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 59.11 33.63 22.93 Favored 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.519 -0.989 . . . . 0.0 110.445 -179.467 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.1 p -138.0 73.99 1.46 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.436 -0.79 . . . . 0.0 109.823 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.9 pt -76.45 135.78 68.67 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.454 -0.779 . . . . 0.0 110.652 -179.842 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.62 155.83 44.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.88 1.463 . . . . 0.0 110.861 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.05 -9.42 23.47 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.979 1.515 . . . . 0.0 111.472 179.735 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 69.4 t -53.42 -36.18 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.067 0 O-C-N 121.319 -0.863 . . . . 0.0 110.73 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.2 m -57.15 -37.92 58.33 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.349 -0.845 . . . . 0.0 110.153 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.04 -37.87 57.85 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 178.836 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -60.32 -39.21 86.2 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.66 -0.65 . . . . 0.0 110.017 179.239 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 78.0 t -66.06 -42.67 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.599 -0.688 . . . . 0.0 109.912 179.393 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -60.25 -37.71 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.656 -0.653 . . . . 0.0 110.04 179.476 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tmm? -69.03 -44.79 72.0 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.014 179.489 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.8 m -59.97 -35.44 74.99 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.528 -0.732 . . . . 0.0 109.989 179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -58.95 -32.89 70.02 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.556 -0.715 . . . . 0.0 110.197 179.339 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -62.41 -48.99 77.27 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.421 -0.799 . . . . 0.0 109.362 179.238 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -67.36 -39.21 91.72 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.834 -1.706 . . . . 0.0 108.834 178.818 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -58.95 -44.23 91.4 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.63 -0.923 . . . . 0.0 109.745 179.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -58.02 -47.82 81.92 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.685 . . . . 0.0 109.768 179.219 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.449 ' HA ' ' HG3' ' A' ' 30' ' ' PRO . . . -64.71 -38.83 92.32 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 0.0 110.057 179.216 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -67.57 -29.27 68.59 Favored 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.676 -0.64 . . . . 0.0 110.564 179.502 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 16.7 mt -91.15 19.33 5.91 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.327 -0.858 . . . . 0.0 110.769 179.6 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 59.67 89.58 0.1 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.634 -0.666 . . . . 0.0 111.139 179.731 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.449 ' HG3' ' HA ' ' A' ' 26' ' ' ALA . 53.9 Cg_endo -81.1 48.05 2.77 Favored 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 123.933 1.491 . . . . 0.0 110.659 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 16.2 mtm-85 . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.111 -0.993 . . . . 0.0 110.349 -179.755 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.498 1.939 0 CA-C-O 120.871 0.367 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 45.4 p -94.23 19.4 9.43 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.102 -0.999 . . . . 0.0 110.791 179.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -92.63 121.55 34.16 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.167 -0.958 . . . . 0.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.3 mp -102.63 -55.9 5.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 110.1 -179.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 5' ' ' ILE . 30.3 mm -111.31 26.71 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.498 -0.752 . . . . 0.0 110.378 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.15 59.71 8.11 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.23 96.02 2.35 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -84.62 -46.11 11.85 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.537 -0.978 . . . . 0.0 110.557 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 18.2 p -116.15 92.43 3.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.58 -0.7 . . . . 0.0 110.348 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pt -91.97 133.92 29.66 Favored Pre-proline 0 N--CA 1.499 1.994 0 O-C-N 121.429 -0.794 . . . . 0.0 110.303 179.904 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.43 152.31 49.04 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.783 1.412 . . . . 0.0 110.799 -179.924 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.56 -23.04 27.62 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.925 1.487 . . . . 0.0 110.983 179.768 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.9 t -62.77 -44.05 99.21 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.283 -0.885 . . . . 0.0 110.001 179.71 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.419 ' O ' HG23 ' A' ' 18' ' ' VAL . 55.5 t -61.47 -43.46 96.86 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.478 -0.764 . . . . 0.0 109.872 179.572 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.62 91.41 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.555 -0.715 . . . . 0.0 110.279 179.628 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.9 tp -64.04 -42.1 97.17 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.492 -0.755 . . . . 0.0 110.052 179.564 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.2 t -62.26 -39.85 85.62 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.491 -0.756 . . . . 0.0 109.691 179.318 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 14' ' ' VAL . 96.4 t -64.66 -35.71 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.489 -0.757 . . . . 0.0 109.701 179.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 2.5 tpt -67.2 -39.9 86.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.53 -0.731 . . . . 0.0 109.82 179.275 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.3 m -63.95 -33.22 75.23 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.48 -0.762 . . . . 0.0 110.097 179.386 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.45 -23.32 66.83 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.501 -0.749 . . . . 0.0 110.59 179.519 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -56.47 -35.55 68.07 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.435 -0.791 . . . . 0.0 110.25 179.609 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -58.85 -37.31 90.37 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.13 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -64.29 -47.54 79.09 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.645 -0.915 . . . . 0.0 109.437 179.016 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -59.23 -38.8 80.87 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.69 -0.631 . . . . 0.0 110.132 179.389 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.44 -37.18 86.15 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.433 -0.792 . . . . 0.0 110.123 179.376 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -65.15 -33.74 76.74 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.438 -0.789 . . . . 0.0 110.028 179.449 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 mp -85.39 -40.3 16.62 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.498 -0.751 . . . . 0.0 110.257 179.591 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.463 HD23 ' HB3' ' A' ' 31' ' ' ARG . 0.5 OUTLIER -89.81 116.27 65.95 Favored Pre-proline 0 N--CA 1.495 1.789 0 O-C-N 121.531 -0.73 . . . . 0.0 110.276 -179.854 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -71.75 80.94 1.39 Allowed 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.919 1.484 . . . . 0.0 110.758 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.463 ' HB3' HD23 ' A' ' 29' ' ' LEU . 2.8 tpp180 . . . . . 0 N--CA 1.496 1.854 0 CA-C-O 118.222 -0.894 . . . . 0.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.043 0.449 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.8 t -166.44 152.25 8.51 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.519 -0.738 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -81.03 97.19 7.4 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.486 -0.759 . . . . 0.0 110.154 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.61 -42.97 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.47 -0.769 . . . . 0.0 110.119 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 20.9 mt -95.99 115.64 35.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.365 -0.835 . . . . 0.0 109.665 179.834 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 146.81 162.77 10.08 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.863 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -139.0 -90.64 0.21 Allowed Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.97 42.67 1.13 Allowed 'General case' 0 N--CA 1.499 1.975 0 O-C-N 121.442 -1.034 . . . . 0.0 110.571 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 19.6 m 62.44 106.87 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.185 0 CA-C-O 121.513 0.673 . . . . 0.0 111.065 179.639 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.456 ' N ' HD13 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -69.72 159.83 82.29 Favored Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 121.434 -0.791 . . . . 0.0 110.068 179.629 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 146.13 31.12 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.855 1.45 . . . . 0.0 110.631 179.755 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -76.29 61.87 6.74 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.814 1.428 . . . . 0.0 110.517 179.687 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.5 p -106.22 -33.57 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.287 179.808 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 40.1 t -77.13 -45.62 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.303 -0.873 . . . . 0.0 109.841 179.637 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -61.14 -40.48 94.0 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.592 -0.692 . . . . 0.0 110.427 179.696 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -64.44 -42.91 95.72 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.58 -0.7 . . . . 0.0 110.544 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -61.57 -36.39 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.305 -0.872 . . . . 0.0 109.927 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' VAL . 87.9 t -68.19 -46.51 81.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.403 -0.811 . . . . 0.0 109.706 179.546 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.58 -38.5 91.24 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.552 -0.717 . . . . 0.0 110.199 179.469 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.7 m -64.82 -39.88 94.29 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.475 -0.766 . . . . 0.0 110.372 179.768 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -59.28 -47.31 85.87 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.542 -0.724 . . . . 0.0 110.131 179.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -70.93 -39.58 72.57 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 110.103 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -45.33 95.41 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -66.09 -48.35 71.22 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.521 -0.988 . . . . 0.0 110.042 179.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.478 ' HA ' HD12 ' A' ' 28' ' ' LEU . 6.2 m-85 -61.88 -36.24 80.68 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.532 -0.73 . . . . 0.0 110.599 179.877 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.67 -43.04 73.36 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.273 -0.892 . . . . 0.0 110.175 179.627 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -104.23 38.57 1.83 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.449 -0.782 . . . . 0.0 110.297 179.548 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.478 HD12 ' HA ' ' A' ' 25' ' ' PHE . 0.5 OUTLIER -82.56 -35.04 27.55 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.297 -0.877 . . . . 0.0 110.373 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -62.04 151.19 81.35 Favored Pre-proline 0 N--CA 1.498 1.957 0 O-C-N 121.462 -0.774 . . . . 0.0 110.687 -179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.25 108.79 2.69 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.855 1.45 . . . . 0.0 110.712 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 117.808 -1.091 . . . . 0.0 110.522 -179.999 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.19 0.519 . . . . 0.0 110.502 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.4 t -87.5 177.73 7.0 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.41 -0.806 . . . . 0.0 110.466 179.834 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -86.56 79.35 8.96 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.495 -0.753 . . . . 0.0 110.165 179.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 18.5 tt -78.15 -26.39 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.304 -0.873 . . . . 0.0 111.218 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.0 pt -82.35 87.58 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.18 -0.95 . . . . 0.0 110.566 -179.747 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 155.3 165.96 14.89 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -115.8 -96.97 2.06 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.681 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 8.4 mt -125.43 41.03 3.61 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.552 -0.969 . . . . 0.0 110.07 179.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.1 m -122.63 39.68 3.87 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.453 -0.779 . . . . 0.0 110.132 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.1 pt -141.84 159.61 58.93 Favored Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -74.38 141.79 29.08 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 O-C-N 123.918 1.483 . . . . 0.0 110.244 179.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.534 ' HB2' ' HB3' ' A' ' 15' ' ' ALA . 52.1 Cg_endo -77.41 66.92 7.87 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.88 1.463 . . . . 0.0 110.695 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 14' ' ' VAL . 12.5 p -70.23 -40.96 78.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.408 -0.808 . . . . 0.0 110.664 -179.927 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' N ' HG13 ' A' ' 13' ' ' VAL . 34.5 m -70.51 -35.65 62.65 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.021 0 O-C-N 121.179 -0.95 . . . . 0.0 109.906 179.381 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.534 ' HB3' ' HB2' ' A' ' 12' ' ' PRO . . . -66.79 -39.14 87.68 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.473 -0.767 . . . . 0.0 109.832 179.189 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.6 tp -67.11 -36.12 81.24 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.512 -0.743 . . . . 0.0 110.223 179.456 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.1 t -67.23 -33.77 65.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 121.365 -0.834 . . . . 0.0 109.918 179.468 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.03 -36.76 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.193 -0.942 . . . . 0.0 109.75 179.384 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 24.3 mtt -68.63 -44.57 73.94 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.518 -0.739 . . . . 0.0 110.648 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 p -57.81 -39.94 78.75 Favored 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.413 -0.804 . . . . 0.0 110.526 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.7 mtm180 -59.96 -42.54 94.31 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.509 -0.744 . . . . 0.0 110.221 179.538 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 51.4 t80 -60.81 -48.08 83.44 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.532 -0.73 . . . . 0.0 109.958 179.609 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.64 -40.19 97.32 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -62.3 -44.56 96.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.555 -0.968 . . . . 0.0 110.037 179.55 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -63.5 -33.56 75.84 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.56 -0.712 . . . . 0.0 110.625 179.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -56.71 -39.82 74.55 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.472 -0.768 . . . . 0.0 110.782 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -108.79 19.87 19.15 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.31 -0.869 . . . . 0.0 110.677 179.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -156.52 44.54 0.41 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.227 -0.92 . . . . 0.0 110.283 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.59 141.28 28.5 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.283 -0.886 . . . . 0.0 110.238 179.856 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.33 160.38 42.13 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 O-C-N 123.883 1.465 . . . . 0.0 110.889 -179.784 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.5 tpp85 . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.554 179.88 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.074 0.464 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.3 m -131.33 151.16 51.77 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.524 -0.735 . . . . 0.0 110.185 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -99.66 62.55 1.19 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.675 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.5 tp -154.81 149.61 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.383 -0.823 . . . . 0.0 110.43 -179.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 5' ' ' ILE . 0.1 OUTLIER -137.84 162.14 32.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.487 -0.758 . . . . 0.0 110.242 179.909 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.28 151.75 20.3 Favored Glycine 0 N--CA 1.494 2.546 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.11 -45.75 8.05 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.452 HD13 ' HA ' ' A' ' 8' ' ' LEU . 2.0 mm? -116.91 31.32 6.81 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.53 -0.982 . . . . 0.0 110.112 179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.3 m -114.36 64.78 0.67 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.267 -0.896 . . . . 0.0 109.927 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -75.38 154.38 85.96 Favored Pre-proline 0 N--CA 1.499 2.012 0 O-C-N 121.412 -0.805 . . . . 0.0 110.561 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.54 ' O ' HG12 ' A' ' 14' ' ' VAL . 48.7 Cg_endo -75.76 144.62 28.03 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.924 1.486 . . . . 0.0 110.67 179.957 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.78 -19.87 17.98 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 O-C-N 123.911 1.48 . . . . 0.0 111.077 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 95.7 t -58.92 -42.24 85.34 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 O-C-N 121.396 -0.815 . . . . 0.0 110.691 -179.709 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.54 HG12 ' O ' ' A' ' 11' ' ' PRO . 9.7 p -56.62 -36.9 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.014 0 O-C-N 121.291 -0.881 . . . . 0.0 110.117 179.795 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.0 -38.15 61.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.365 -0.834 . . . . 0.0 109.244 178.733 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.492 ' HA ' ' HG2' ' A' ' 19' ' ' MET . 0.6 OUTLIER -60.3 -29.7 69.01 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.779 -0.576 . . . . 0.0 110.353 179.18 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.1 t -80.82 -42.54 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.3 -0.875 . . . . 0.0 109.836 179.664 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.15 -42.47 84.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.443 -0.786 . . . . 0.0 110.455 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . 0.492 ' HG2' ' HA ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -61.95 -29.98 70.6 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.22 -0.925 . . . . 0.0 110.157 179.551 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 8.2 t -68.8 -42.5 77.24 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.304 -0.872 . . . . 0.0 109.118 178.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.45 -38.21 90.26 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.509 178.857 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -60.23 -44.09 95.49 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.591 -0.693 . . . . 0.0 110.006 179.34 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -61.78 -39.01 96.89 Favored Glycine 0 N--CA 1.496 2.688 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.334 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -64.62 -43.35 94.0 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.474 -1.015 . . . . 0.0 109.834 179.405 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -58.65 -42.15 87.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.469 -0.769 . . . . 0.0 110.103 179.456 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.06 -37.04 72.5 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.588 -0.695 . . . . 0.0 110.295 179.563 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -73.35 -27.29 61.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.407 -0.808 . . . . 0.0 110.707 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.5 47.51 0.89 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.315 -0.866 . . . . 0.0 110.269 179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.2 tp -94.27 119.17 66.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.355 -0.84 . . . . 0.0 110.316 179.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.43 62.91 7.11 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.871 1.459 . . . . 0.0 110.409 179.782 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.2 ttm180 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.338 -0.851 . . . . 0.0 110.648 -179.869 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.496 1.86 0 CA-C-O 120.835 0.35 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.425 HG22 ' H ' ' A' ' 3' ' ' GLU . 6.2 m 61.57 172.81 0.12 Allowed 'General case' 0 N--CA 1.505 2.313 0 CA-C-O 121.312 0.577 . . . . 0.0 110.812 179.894 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.425 ' H ' HG22 ' A' ' 2' ' ' THR . 16.0 mt-10 -81.37 89.57 6.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.072 -1.017 . . . . 0.0 109.846 179.813 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.634 ' O ' HD13 ' A' ' 4' ' ' ILE . 0.2 OUTLIER -116.25 -33.08 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.371 -0.831 . . . . 0.0 110.986 -179.416 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.632 HG13 HG23 ' A' ' 4' ' ' ILE . 7.3 mt -101.72 114.75 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 120.948 -1.095 . . . . 0.0 110.123 179.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 129.63 64.38 0.11 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.949 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.4 -96.06 0.11 Allowed Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.873 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.4 -81.39 0.06 Allowed 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.598 -0.942 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.504 ' O ' ' HB ' ' A' ' 10' ' ' ILE . 8.0 p -143.46 53.38 1.33 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.007 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 9' ' ' THR . 14.3 mt 66.84 139.96 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.311 0 O-C-N 122.052 -0.405 . . . . 0.0 110.756 -179.871 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -79.48 166.89 21.69 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.742 1.391 . . . . 0.0 110.671 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.04 -30.95 38.1 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.967 1.509 . . . . 0.0 110.837 179.955 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 98.2 t -65.93 -50.59 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.357 -0.839 . . . . 0.0 109.348 179.349 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.38 -42.65 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.517 -0.739 . . . . 0.0 109.438 179.062 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.18 -38.66 83.89 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.495 -0.753 . . . . 0.0 110.245 179.457 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 15.7 tp -65.41 -40.98 94.07 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.401 -0.812 . . . . 0.0 110.062 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.82 -40.68 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.423 -0.798 . . . . 0.0 109.699 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -65.36 -30.26 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.502 -0.749 . . . . 0.0 110.093 179.427 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 5.7 ttm -57.19 -42.28 80.92 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.455 -0.778 . . . . 0.0 110.046 179.469 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.6 t -62.79 -41.64 99.36 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 109.586 179.061 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.2 ttm-85 -62.13 -40.23 95.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.582 -0.699 . . . . 0.0 109.882 179.231 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -61.49 -44.79 96.45 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.615 -0.678 . . . . 0.0 110.172 179.589 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.46 -40.23 95.91 Favored Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -63.76 -42.73 97.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.672 -0.899 . . . . 0.0 109.7 179.131 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -57.49 -41.13 80.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.741 -0.599 . . . . 0.0 110.089 179.396 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.66 -36.18 75.82 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.596 -0.69 . . . . 0.0 109.941 179.384 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -76.06 -22.89 55.16 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.461 -0.774 . . . . 0.0 110.734 179.694 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.468 ' HA ' HD13 ' A' ' 28' ' ' LEU . 2.8 mm? -92.92 52.66 1.87 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.338 -0.851 . . . . 0.0 109.923 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.9 mt -63.55 140.59 97.79 Favored Pre-proline 0 N--CA 1.498 1.968 0 O-C-N 121.573 -0.705 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.77 160.31 43.87 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.95 1.5 . . . . 0.0 110.614 179.684 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.902 0 CA-C-O 117.86 -1.067 . . . . 0.0 110.751 -179.993 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.494 1.765 0 CA-C-O 121.041 0.448 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.5 t -152.22 135.16 15.62 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.462 -0.774 . . . . 0.0 110.355 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.72 105.57 5.4 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 -179.979 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.467 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 41.9 mm -68.0 -43.2 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.973 0 O-C-N 121.513 -0.742 . . . . 0.0 110.034 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.467 ' HB ' ' O ' ' A' ' 4' ' ' ILE . 47.1 mt 64.04 116.74 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.338 0 CA-C-O 121.5 0.667 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.17 -79.39 1.32 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.36 -51.71 2.5 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.196 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 9' ' ' THR . 0.8 OUTLIER -162.33 -61.13 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 109.595 179.458 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.403 HG23 ' O ' ' A' ' 8' ' ' LEU . 1.1 p -153.28 142.59 21.57 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.799 -0.563 . . . . 0.0 109.865 179.754 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.31 121.04 7.63 Favored Pre-proline 0 N--CA 1.495 1.813 0 O-C-N 121.463 -0.773 . . . . 0.0 110.092 179.838 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.601 ' O ' HG22 ' A' ' 14' ' ' VAL . 49.8 Cg_endo -82.44 157.66 16.86 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.734 1.386 . . . . 0.0 110.746 -179.622 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.56 -16.91 23.91 Favored 'Trans proline' 0 N--CA 1.49 1.288 0 O-C-N 123.947 1.498 . . . . 0.0 110.993 179.518 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 17' ' ' VAL . 90.9 t -57.93 -33.3 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.09 0 O-C-N 121.418 -0.801 . . . . 0.0 110.608 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 11' ' ' PRO . 32.6 m -56.99 -36.85 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.236 0 O-C-N 121.415 -0.803 . . . . 0.0 110.167 179.799 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -71.53 -39.54 70.66 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.522 -0.736 . . . . 0.0 109.539 179.086 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -37.39 86.42 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.627 -0.671 . . . . 0.0 109.921 179.149 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' VAL . 92.3 t -69.01 -39.28 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.491 -0.755 . . . . 0.0 109.633 179.229 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 14' ' ' VAL . 46.8 t -60.36 -40.28 83.52 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.006 0 O-C-N 121.482 -0.762 . . . . 0.0 109.815 179.513 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 6.1 ttt -63.67 -39.94 95.59 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.578 -0.701 . . . . 0.0 109.948 179.24 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 2.5 t -78.96 -27.4 43.53 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.522 -0.736 . . . . 0.0 110.173 179.304 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -57.92 -29.86 65.46 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.59 -0.694 . . . . 0.0 111.095 -179.931 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 44.4 t80 -51.41 -49.09 62.29 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.394 -0.816 . . . . 0.0 110.581 179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.43 -44.31 95.47 Favored Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 179.478 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -41.71 95.19 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.642 -0.916 . . . . 0.0 109.781 179.295 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 25.0 t80 -62.88 -38.31 90.35 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.631 -0.668 . . . . 0.0 110.05 179.335 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.55 -35.15 75.32 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.482 -0.761 . . . . 0.0 110.171 179.424 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 -84.27 -28.78 26.94 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.5 -0.75 . . . . 0.0 110.285 179.52 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 9.7 mt -94.0 50.79 1.44 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.437 -0.789 . . . . 0.0 110.117 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -79.16 148.42 71.22 Favored Pre-proline 0 N--CA 1.498 1.926 0 O-C-N 121.475 -0.766 . . . . 0.0 110.566 -179.999 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.7 -171.89 1.17 Allowed 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.98 1.516 . . . . 0.0 110.664 179.979 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 10.7 mtm105 . . . . . 0 N--CA 1.498 1.943 0 CA-C-O 118.247 -0.883 . . . . 0.0 110.26 179.804 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.019 0.438 . . . . 0.0 110.324 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.2 t -113.77 168.26 9.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.54 -0.725 . . . . 0.0 110.039 179.703 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 49.85 70.78 0.46 Allowed 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.709 -0.619 . . . . 0.0 110.532 -179.844 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.422 HG23 ' N ' ' A' ' 5' ' ' ILE . 13.6 tt -58.05 -39.67 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 O-C-N 121.379 -0.826 . . . . 0.0 111.002 -179.547 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.422 ' N ' HG23 ' A' ' 4' ' ' ILE . 45.0 mm 46.05 60.05 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.14 0 O-C-N 121.527 -0.733 . . . . 0.0 110.215 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 106.28 -67.59 0.24 Allowed Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.589 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.6 73.79 0.84 Allowed Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.864 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -158.88 45.49 0.28 Allowed 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.504 -0.998 . . . . 0.0 110.723 179.94 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.6 m -92.4 73.95 5.24 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.254 -0.904 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.0 pt -139.89 142.21 30.07 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.463 -0.773 . . . . 0.0 110.36 -179.912 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.564 ' HG2' ' HB ' ' A' ' 14' ' ' VAL . 46.3 Cg_endo -73.88 129.63 13.61 Favored 'Trans proline' 0 C--N 1.313 -1.291 0 O-C-N 123.918 1.483 . . . . 0.0 110.543 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.37 -43.29 0.71 Allowed 'Trans proline' 0 N--CA 1.489 1.215 0 O-C-N 123.888 1.467 . . . . 0.0 111.203 -179.641 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 88.3 t -62.63 -46.58 96.03 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.394 -0.816 . . . . 0.0 109.925 -179.948 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.564 ' HB ' ' HG2' ' A' ' 11' ' ' PRO . 53.1 t -61.84 -42.26 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.501 -0.75 . . . . 0.0 109.927 179.545 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.4 -41.43 98.67 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.421 -0.8 . . . . 0.0 110.272 179.671 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 8.4 tp -62.17 -30.59 71.16 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.554 -0.716 . . . . 0.0 110.394 179.552 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.9 t -80.3 -37.02 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.373 -0.829 . . . . 0.0 109.939 179.687 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 14' ' ' VAL . 55.3 t -61.1 -48.18 90.19 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 121.458 -0.777 . . . . 0.0 110.471 -179.969 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 25.1 ptm -63.82 -34.24 77.47 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.364 -0.835 . . . . 0.0 110.192 179.649 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.84 -39.32 87.58 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.353 -0.842 . . . . 0.0 109.692 179.167 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.25 -38.21 82.79 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.431 -0.793 . . . . 0.0 109.65 179.063 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -65.31 -43.9 89.6 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.495 -0.753 . . . . 0.0 109.56 179.095 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.63 -37.86 95.45 Favored Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.013 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.08 -43.26 99.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.694 -0.886 . . . . 0.0 109.812 179.187 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 36.3 t80 -62.56 -39.87 95.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.543 -0.723 . . . . 0.0 109.982 179.338 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.29 -33.81 75.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.632 -0.667 . . . . 0.0 110.197 179.467 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 14.6 m80 -80.46 -35.19 35.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.438 -0.789 . . . . 0.0 110.153 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 mp -59.74 -35.11 73.9 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.456 -0.778 . . . . 0.0 110.767 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.438 HD22 ' HA ' ' A' ' 29' ' ' LEU . 0.3 OUTLIER -69.0 114.15 21.26 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 121.383 -0.823 . . . . 0.0 109.919 179.784 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.77 159.8 49.74 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.963 1.507 . . . . 0.0 110.771 -179.703 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.8 mtt85 . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 118.195 -0.907 . . . . 0.0 110.087 179.863 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.086 0.47 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.428 HG22 HG23 ' A' ' 4' ' ' ILE . 8.6 m -100.74 105.82 17.18 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 0.0 109.966 179.94 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -82.24 91.81 6.81 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.522 -0.737 . . . . 0.0 110.23 -179.96 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.428 HG23 HG22 ' A' ' 2' ' ' THR . 2.4 pt -98.8 82.12 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.463 -0.773 . . . . 0.0 110.375 179.929 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.6 tt -120.23 18.92 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.325 -0.859 . . . . 0.0 110.733 -179.975 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -85.37 68.8 3.38 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.848 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.44 71.76 0.26 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 37.7 mt -105.0 14.59 29.12 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.521 -0.988 . . . . 0.0 110.97 -179.681 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.8 m -93.67 65.11 3.62 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.174 -0.954 . . . . 0.0 109.676 179.624 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.1 pp -109.98 159.75 30.7 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.394 -0.816 . . . . 0.0 110.166 -179.945 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.14 113.46 3.79 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.861 1.453 . . . . 0.0 110.894 -179.624 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.39 -39.32 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 O-C-N 123.784 1.413 . . . . 0.0 110.787 179.708 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.3 m -64.97 -36.48 77.9 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.744 -179.774 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 50.0 t -60.48 -50.17 81.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.234 -0.916 . . . . 0.0 109.745 179.661 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.06 -34.46 78.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.597 -0.689 . . . . 0.0 109.867 179.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 7.0 tp -65.5 -39.49 91.94 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.581 -0.699 . . . . 0.0 110.365 179.502 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 54.5 t -67.77 -35.05 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.373 -0.829 . . . . 0.0 110.061 179.784 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 54.7 t -65.29 -50.66 72.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.493 -0.754 . . . . 0.0 110.09 179.829 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 4.4 ptt? -70.69 -33.47 70.95 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.383 -0.823 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.8 m -63.91 -43.88 94.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.248 -0.907 . . . . 0.0 109.838 179.387 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -63.35 -36.67 84.48 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.598 -0.688 . . . . 0.0 109.938 179.32 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -59.91 -46.4 89.47 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.482 -0.761 . . . . 0.0 109.642 179.317 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.86 -40.79 74.48 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.026 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.33 -47.59 85.39 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.593 -0.945 . . . . 0.0 109.956 179.422 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -68.05 -39.97 82.91 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.531 -0.731 . . . . 0.0 110.221 179.729 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.67 -40.15 96.1 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.409 -0.807 . . . . 0.0 110.262 179.676 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -88.21 2.02 53.15 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.532 -0.73 . . . . 0.0 111.034 179.731 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -77.59 -58.29 3.35 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.059 -1.026 . . . . 0.0 110.245 179.872 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.2 mp 63.76 160.17 0.12 Allowed Pre-proline 0 N--CA 1.504 2.246 0 O-C-N 121.89 -0.506 . . . . 0.0 111.055 179.903 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.41 81.15 2.35 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.641 1.337 . . . . 0.0 110.671 -179.841 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 118.291 -0.861 . . . . 0.0 110.438 179.814 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 120.958 0.408 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 5.2 t -82.11 171.59 14.17 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.389 -0.82 . . . . 0.0 110.358 179.975 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mm-40 54.03 66.8 1.13 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.662 -0.649 . . . . 0.0 110.688 -179.912 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.413 ' O ' ' C ' ' A' ' 5' ' ' ILE . 6.4 mt -92.09 -41.38 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.405 -0.81 . . . . 0.0 110.086 179.789 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.416 HG23 ' O ' ' A' ' 5' ' ' ILE . 8.7 tt 31.39 73.73 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.384 0 CA-C-O 121.821 0.82 . . . . 0.0 111.847 179.902 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -126.24 127.21 6.0 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.944 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.13 67.41 0.04 OUTLIER Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.878 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -165.85 43.74 0.07 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.546 -0.973 . . . . 0.0 109.989 179.844 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.4 t -160.26 -148.5 0.17 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.322 -0.861 . . . . 0.0 110.156 -179.616 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.782 HG13 HG13 ' A' ' 13' ' ' VAL . 26.8 pt -131.14 148.43 70.19 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.277 -0.889 . . . . 0.0 110.089 179.853 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.646 ' N ' ' HD2' ' A' ' 12' ' ' PRO . 45.1 Cg_endo -70.93 -26.87 21.57 Favored 'Trans proline' 0 CA--C 1.556 1.624 0 O-C-N 123.932 1.491 . . . . 0.0 114.841 -179.156 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 11' ' ' PRO . 40.7 Cg_endo -65.8 -24.21 54.57 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 CA-C-N 119.166 0.738 . . . . 0.0 112.754 -178.437 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.782 HG13 HG13 ' A' ' 10' ' ' ILE . 35.9 m -60.24 -38.26 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 O-C-N 120.771 -1.206 . . . . 0.0 110.615 179.983 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.5 t -67.55 -43.97 86.77 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.98 0 O-C-N 121.344 -0.847 . . . . 0.0 109.492 179.336 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -35.58 79.96 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.7 -0.625 . . . . 0.0 110.22 179.33 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.1 tp -67.72 -40.82 84.2 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.424 -0.797 . . . . 0.0 110.259 179.608 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.7 t -62.9 -36.27 74.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.979 0 O-C-N 121.458 -0.776 . . . . 0.0 109.743 179.466 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.3 t -71.57 -38.68 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.378 -0.826 . . . . 0.0 109.32 179.193 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mtt -71.14 -42.22 69.44 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.617 -0.677 . . . . 0.0 110.286 179.671 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 87.4 p -61.05 -36.64 80.11 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.422 -0.799 . . . . 0.0 110.168 179.607 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.5 ttm180 -63.85 -42.24 97.61 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.516 -0.74 . . . . 0.0 109.76 179.248 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -65.65 -39.33 91.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.591 -0.693 . . . . 0.0 109.892 179.268 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -63.27 -41.72 99.48 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.521 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -63.26 -38.63 91.9 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.493 -1.004 . . . . 0.0 109.952 179.366 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -65.28 -37.54 87.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.39 -0.818 . . . . 0.0 110.109 179.426 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -77.86 -22.37 49.94 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.417 -0.802 . . . . 0.0 110.784 179.771 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -95.24 -33.02 12.74 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.334 -0.854 . . . . 0.0 110.731 -179.771 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.73 30.68 1.01 Allowed 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.271 -0.893 . . . . 0.0 110.764 -179.792 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.5 tp -132.8 125.95 19.58 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.26 -0.9 . . . . 0.0 109.945 179.743 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.79 74.99 4.2 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 O-C-N 123.929 1.489 . . . . 0.0 110.358 -179.872 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 2.7 ttm105 . . . . . 0 N--CA 1.501 2.105 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.844 -179.712 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 21.8 t70 . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 120.843 0.354 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 54.6 p 35.58 64.01 0.5 Allowed 'General case' 0 N--CA 1.507 2.393 0 CA-C-O 121.298 0.571 . . . . 0.0 111.451 179.932 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.81 -85.42 0.08 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.347 -0.846 . . . . 0.0 110.386 179.995 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 pt -124.45 42.97 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.297 -0.877 . . . . 0.0 110.422 179.987 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.616 ' C ' HD13 ' A' ' 5' ' ' ILE . 0.0 OUTLIER -69.5 117.62 12.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.375 -0.828 . . . . 0.0 109.44 179.691 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 81.98 -68.65 3.46 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.085 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.93 -63.44 0.61 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -118.75 32.26 6.22 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.618 -0.931 . . . . 0.0 110.212 179.857 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 p -130.6 59.74 1.65 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.381 -0.825 . . . . 0.0 109.981 179.985 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pt -131.24 99.12 17.87 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.921 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.743 ' O ' HG22 ' A' ' 14' ' ' VAL . 47.3 Cg_endo -81.21 157.9 20.06 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 O-C-N 123.841 1.442 . . . . 0.0 110.577 -179.799 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.96 -20.45 25.61 Favored 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.774 1.407 . . . . 0.0 111.115 179.757 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.6 p -60.12 -33.29 52.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 121.341 -0.849 . . . . 0.0 111.069 -179.762 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 11' ' ' PRO . 20.2 m -64.54 -36.29 76.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.114 0 O-C-N 121.102 -0.999 . . . . 0.0 110.238 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.58 -40.36 96.64 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.414 -0.804 . . . . 0.0 109.65 179.106 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.516 ' O ' HD13 ' A' ' 16' ' ' LEU . 2.8 tm? -68.05 -40.25 82.84 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.593 -0.692 . . . . 0.0 109.591 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.0 t -61.29 -41.34 89.31 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.464 -0.772 . . . . 0.0 109.842 179.339 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 14' ' ' VAL . 99.0 t -63.11 -42.38 96.36 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.474 -0.766 . . . . 0.0 109.548 179.337 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 38.0 mtp -67.29 -46.91 72.18 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.677 -0.64 . . . . 0.0 109.614 179.179 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 15.0 m -61.85 -42.05 98.57 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.606 -0.684 . . . . 0.0 109.931 179.203 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.3 tmm_? -59.75 -32.81 70.91 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.576 -0.702 . . . . 0.0 110.198 179.384 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 18.4 t80 -59.61 -41.71 90.98 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.464 -0.773 . . . . 0.0 109.846 179.396 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.23 -32.31 23.27 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.299 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.45 ' HA ' ' NE2' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -64.56 -48.33 75.45 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.422 -1.046 . . . . 0.0 110.407 179.892 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -57.48 -30.85 65.42 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.567 -0.708 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.47 -35.98 61.13 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.45 -0.781 . . . . 0.0 110.719 179.889 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.45 ' NE2' ' HA ' ' A' ' 24' ' ' PHE . 31.5 p80 -117.74 21.77 12.73 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.404 -0.81 . . . . 0.0 110.558 179.468 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -108.28 -40.13 5.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.288 -0.883 . . . . 0.0 110.474 179.942 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 8.6 tp -83.76 124.17 75.31 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.316 -0.865 . . . . 0.0 110.28 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -75.39 80.48 2.51 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 O-C-N 123.92 1.484 . . . . 0.0 110.263 179.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 30.8 mtp85 . . . . . 0 N--CA 1.502 2.148 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.837 -179.661 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.745 0 CA-C-O 121.115 0.483 . . . . 0.0 110.517 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.7 m -77.51 136.23 38.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.525 -0.735 . . . . 0.0 109.845 179.829 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -125.31 101.31 6.91 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.643 -0.661 . . . . 0.0 110.279 -179.867 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.655 ' O ' HD13 ' A' ' 4' ' ' ILE . 0.1 OUTLIER -80.42 -26.88 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.445 -0.784 . . . . 0.0 110.42 179.929 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG12 ' CG2' ' A' ' 4' ' ' ILE . 43.8 mm -105.17 55.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.264 -0.898 . . . . 0.0 109.655 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -102.49 -63.47 0.73 Allowed Glycine 0 N--CA 1.494 2.566 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.892 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.7 -40.3 2.73 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 179.97 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 65.87 16.47 10.49 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.644 -0.915 . . . . 0.0 110.999 -179.516 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.0 m -148.46 23.8 1.01 Allowed 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.239 -0.913 . . . . 0.0 110.198 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.563 ' HB ' HG11 ' A' ' 14' ' ' VAL . 2.9 pt -145.64 139.75 15.12 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.16 -0.963 . . . . 0.0 110.182 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.655 ' O ' HG12 ' A' ' 14' ' ' VAL . 43.9 Cg_endo -71.8 168.34 24.07 Favored 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.791 1.416 . . . . 0.0 110.704 -179.854 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.87 -30.24 17.42 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.668 1.352 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.64 -33.52 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.287 -0.883 . . . . 0.0 110.886 -179.853 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.655 HG12 ' O ' ' A' ' 11' ' ' PRO . 1.3 p -67.15 -31.38 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.07 -1.019 . . . . 0.0 110.235 179.859 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.7 91.9 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.472 -0.767 . . . . 0.0 109.518 178.998 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 10.3 tp -74.43 -37.5 63.3 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.649 -0.657 . . . . 0.0 109.74 179.051 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.1 t -66.16 -35.62 75.46 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.614 -0.679 . . . . 0.0 110.24 179.6 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.0 t -79.08 -35.49 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.281 -0.887 . . . . 0.0 109.849 179.555 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.3 ttt -60.0 -45.68 91.94 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.431 -0.793 . . . . 0.0 110.658 179.95 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 52.1 p -60.62 -44.02 96.8 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.369 -0.832 . . . . 0.0 109.927 179.709 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -70.31 -35.41 73.64 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.549 -0.719 . . . . 0.0 109.951 179.244 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -54.65 -45.88 73.87 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.378 -0.826 . . . . 0.0 110.058 179.519 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.64 -42.39 54.76 Favored Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.41 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -62.65 -47.53 83.31 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.43 -1.041 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -66.51 -33.38 75.56 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.507 179.919 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.14 89.99 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.339 -0.851 . . . . 0.0 110.216 179.744 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -84.07 -42.22 16.34 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.407 -0.808 . . . . 0.0 110.154 179.669 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.411 HD13 ' HA ' ' A' ' 28' ' ' LEU . 3.3 mm? -63.36 -38.68 92.08 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.532 -0.73 . . . . 0.0 110.419 179.807 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.9 tp -115.12 87.48 15.77 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.416 -0.802 . . . . 0.0 110.031 179.788 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.95 100.39 1.08 Allowed 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 124.048 1.552 . . . . 0.0 110.659 -179.998 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 117.821 -1.085 . . . . 0.0 110.425 -179.995 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 17.7 t70 . . . . . 0 N--CA 1.495 1.798 0 CA-C-O 121.159 0.504 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 35.3 m -124.75 157.37 35.87 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.51 -0.744 . . . . 0.0 110.098 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.45 89.28 7.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.434 -0.791 . . . . 0.0 110.302 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.457 ' O ' ' HB ' ' A' ' 5' ' ' ILE . 42.4 mt 51.31 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.749 -0.594 . . . . 0.0 110.513 179.674 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.46 HD11 ' HB3' ' A' ' 12' ' ' PRO . 34.3 mm 64.55 121.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.378 0 CA-C-O 121.48 0.657 . . . . 0.0 110.894 179.823 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -104.69 -52.96 0.83 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.827 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.92 -32.65 81.6 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 -179.806 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 57.96 29.83 18.25 Favored 'General case' 0 N--CA 1.503 2.191 0 O-C-N 121.502 -0.999 . . . . 0.0 111.279 -179.958 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 9' ' ' THR . 25.6 m -128.65 19.23 6.19 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.15 -0.969 . . . . 0.0 110.401 179.573 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -143.2 151.67 55.91 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.2 -0.938 . . . . 0.0 110.231 179.808 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -75.78 122.97 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.938 1.494 . . . . 0.0 110.362 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.46 ' HB3' HD11 ' A' ' 5' ' ' ILE . 44.6 Cg_endo -71.95 -43.05 1.33 Allowed 'Trans proline' 0 N--CA 1.489 1.223 0 O-C-N 123.868 1.457 . . . . 0.0 111.187 -179.659 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 86.2 t -65.83 -47.82 84.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.075 0 O-C-N 121.331 -0.856 . . . . 0.0 110.008 179.934 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.84 -41.19 91.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.523 -0.735 . . . . 0.0 109.891 179.598 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.35 96.45 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.454 -0.779 . . . . 0.0 110.478 179.715 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.6 tp -66.09 -39.16 89.78 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.374 -0.829 . . . . 0.0 110.603 179.897 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 76.5 t -64.07 -35.67 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.41 -0.807 . . . . 0.0 110.207 179.773 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.3 t -81.74 -31.52 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.43 -0.793 . . . . 0.0 110.474 179.906 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 19.8 mmm -56.48 -56.0 26.68 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.436 -179.773 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 14.8 m -63.87 -42.95 97.39 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.396 -0.815 . . . . 0.0 109.967 179.441 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -58.76 -39.55 81.3 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.612 -0.68 . . . . 0.0 110.08 179.5 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 35.2 t80 -61.12 -48.09 83.24 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.586 -0.696 . . . . 0.0 109.897 179.503 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -64.8 -42.67 96.96 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 179.326 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.11 -40.39 89.54 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.546 -0.973 . . . . 0.0 110.04 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 -41.28 93.2 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.502 -0.749 . . . . 0.0 110.326 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.21 -35.97 82.53 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.484 -0.76 . . . . 0.0 110.218 179.658 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 3.6 t-160 -71.94 -32.3 67.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.411 -0.806 . . . . 0.0 110.504 179.691 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.6 mt -87.16 -48.3 8.16 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 5.9 tp -93.44 114.74 63.72 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.403 -0.81 . . . . 0.0 110.122 179.97 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.78 83.87 1.52 Allowed 'Trans proline' 0 C--N 1.315 -1.227 0 O-C-N 123.969 1.51 . . . . 0.0 110.57 179.985 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.216 -179.817 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 121.048 0.452 . . . . 0.0 110.101 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.6 p -70.13 107.77 3.82 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 -179.918 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 4' ' ' ILE . 0.5 OUTLIER -121.64 100.83 7.23 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.561 -0.712 . . . . 0.0 109.941 -179.833 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.406 ' C ' ' O ' ' A' ' 3' ' ' GLU . 23.2 pt 32.87 58.6 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.511 2.576 0 CA-C-O 121.221 0.534 . . . . 0.0 111.887 -179.51 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 24.4 mt 56.74 50.43 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.216 0 CA-C-O 121.443 0.64 . . . . 0.0 110.304 179.891 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -96.19 114.91 5.05 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.982 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.1 -76.6 1.24 Allowed Glycine 0 N--CA 1.497 2.711 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.753 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 8' ' ' LEU . 0.2 OUTLIER -148.68 70.97 1.13 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.333 -1.098 . . . . 0.0 109.819 -179.758 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.1 p -79.97 95.48 6.14 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.39 -0.819 . . . . 0.0 110.461 -179.734 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.6 pt -130.7 152.64 80.82 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.519 -0.738 . . . . 0.0 110.137 179.705 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.08 114.89 4.01 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.94 1.495 . . . . 0.0 110.895 -179.745 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.02 -38.51 2.17 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.828 1.436 . . . . 0.0 110.852 179.774 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 73.8 t -64.35 -43.36 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.422 -0.799 . . . . 0.0 110.28 -179.991 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.3 t -56.41 -49.89 74.87 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.44 -0.787 . . . . 0.0 109.611 179.575 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -64.83 -35.07 79.94 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.548 -0.72 . . . . 0.0 109.798 179.074 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.57 -42.21 92.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.624 -0.673 . . . . 0.0 110.211 179.521 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.8 t -62.22 -39.66 84.84 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.398 -0.814 . . . . 0.0 109.952 179.727 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.9 t -66.2 -46.56 87.16 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.434 -0.791 . . . . 0.0 109.649 179.505 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 1.3 tpp -69.65 -38.26 77.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.512 -0.742 . . . . 0.0 110.35 179.606 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.9 t -67.73 -39.81 84.23 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.467 -0.77 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.6 ttp85 -57.49 -44.44 84.96 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.395 -0.816 . . . . 0.0 110.352 179.871 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -77.25 -39.58 47.85 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.433 -0.792 . . . . 0.0 109.843 179.31 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.94 -45.46 96.54 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.452 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -63.36 -41.79 98.85 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.477 -1.014 . . . . 0.0 110.068 179.331 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -61.23 -36.62 80.43 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.518 -0.739 . . . . 0.0 110.389 179.712 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.45 -30.8 71.87 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.498 -0.751 . . . . 0.0 110.461 179.626 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -99.52 -6.61 27.21 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.32 -0.862 . . . . 0.0 111.092 179.807 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.1 mt -104.19 -63.41 1.2 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.183 -0.948 . . . . 0.0 110.117 179.885 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.481 HD23 ' HD2' ' A' ' 30' ' ' PRO . 0.1 OUTLIER 61.44 171.06 0.08 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.839 -0.538 . . . . 0.0 111.022 179.926 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.481 ' HD2' HD23 ' A' ' 29' ' ' LEU . 44.7 Cg_endo -71.69 113.66 3.71 Favored 'Trans proline' 0 C--N 1.316 -1.175 0 O-C-N 123.597 1.314 . . . . 0.0 110.596 -179.813 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 1.9 mtt85 . . . . . 0 N--CA 1.496 1.873 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.348 -179.989 . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.148 0.499 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 30.0 m -132.88 139.87 47.62 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.385 -0.822 . . . . 0.0 110.497 -179.756 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 54.62 31.88 16.01 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.781 -0.574 . . . . 0.0 111.565 179.527 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 47.3 mt 56.62 96.87 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.581 -0.699 . . . . 0.0 110.815 179.675 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.9 tt -62.23 -24.17 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.45 -0.781 . . . . 0.0 110.779 179.599 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -90.83 69.73 2.16 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.591 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.95 -53.21 2.9 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.965 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 tp -163.95 78.27 0.39 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.525 -0.985 . . . . 0.0 109.895 179.902 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.8 p -74.46 110.68 8.94 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.306 -0.871 . . . . 0.0 109.813 179.967 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pt -52.42 112.22 3.2 Favored Pre-proline 0 N--CA 1.503 2.178 0 O-C-N 121.916 -0.49 . . . . 0.0 110.999 -179.536 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.449 ' HB2' HG23 ' A' ' 13' ' ' VAL . 50.4 Cg_endo -81.21 140.97 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.679 1.357 . . . . 0.0 110.787 -179.76 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.22 61.28 6.55 Favored 'Trans proline' 0 C--N 1.316 -1.174 0 O-C-N 123.911 1.48 . . . . 0.0 110.541 179.57 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.449 HG23 ' HB2' ' A' ' 11' ' ' PRO . 87.0 t -106.07 -45.83 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.415 -0.803 . . . . 0.0 109.757 179.848 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 18' ' ' VAL . 48.8 t -60.64 -44.68 97.47 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.022 0 O-C-N 121.647 -0.658 . . . . 0.0 110.068 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -62.32 -40.79 97.5 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.599 -0.688 . . . . 0.0 110.438 179.765 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.7 tp -65.06 -40.55 94.86 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.468 -0.77 . . . . 0.0 110.317 179.836 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.0 t -63.53 -39.94 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 179.623 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 14' ' ' VAL . 71.7 t -61.67 -47.87 91.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.435 -0.791 . . . . 0.0 109.327 179.263 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 7.3 ttt -64.55 -43.79 92.83 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.564 -0.71 . . . . 0.0 109.597 178.984 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 9.9 t -63.43 -39.06 93.48 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.609 -0.682 . . . . 0.0 109.959 179.359 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 37.8 mtt-85 -58.27 -43.11 87.8 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.457 -0.777 . . . . 0.0 109.991 179.525 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -61.76 -45.76 92.53 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.495 -0.753 . . . . 0.0 109.653 179.18 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.83 -38.99 93.39 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.254 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -61.28 -45.94 92.41 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.522 -0.987 . . . . 0.0 110.049 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.401 ' HA ' HD12 ' A' ' 28' ' ' LEU . 4.1 t80 -59.07 -41.07 87.07 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.601 -0.687 . . . . 0.0 110.092 179.512 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.7 -30.46 70.71 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.51 -0.744 . . . . 0.0 110.204 179.373 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 2.8 m80 -80.78 -7.27 59.34 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.476 -0.765 . . . . 0.0 110.854 179.634 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 25' ' ' PHE . 17.0 mt -91.79 47.55 1.37 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.149 179.772 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 1.1 pp -96.42 162.22 24.24 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.452 -0.78 . . . . 0.0 110.481 179.984 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.16 128.22 11.98 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.806 1.424 . . . . 0.0 110.549 179.811 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.853 0 CA-C-O 117.856 -1.069 . . . . 0.0 110.414 -179.98 . . . . . . . . 1 1 . 1 stop_ save_